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RECOGNITION OF
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IN  MULTIPLE  SCLEROSIS
Multiple sclerosis (MS) is a 
chronic inflammatory disease
of the central nervous system. 
Symptoms of MS include
cognitive, motoric, sensory and visual 
impairment, pain and fatigue. The genetic 
background of the host and infection with
the herpesvirus family member Epstein-Barr 
virus (EBV) are risk factors for developing MS 
but the pathogenic mechanisms are 
unknown. In this thesis we set out to
clarify the putative role of EBV in MS by 
analyzing the intrathecal viral prevalence,
breadth and magnitude of humoral and 
cellular EBV-specific immune responses
and autoimmune responses in MS patients.
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management
Multiple sclerosis (MS) is a very heterogeneous, often devastating neurological disease.1 
In the Netherlands, over 20.000 patients suffer from MS and the incidence is increasing, 
mainly among woman.2,3 Typical symptoms are fatigue, sensory and motoric disturbances, 
visual impairment and paralysis caused by inflammation of the central nervous system 
(CNS).1 Clinical presentation and disease progression varies greatly between MS patients 
and is highly unpredictable. Most patients initially present with a clinically isolated 
syndrome (CIS) between the age of 20 and 40 years, which is characterized by neurological 
complaints that last over 24 hours. Over 60% of CIS patients develop MS within one year.4 
A CIS patient that experiences a second clinical attack is classified as having a relapsing 
remitting (RRMS) disease course.5 Symptoms typically reside, yet part of the RRMS patients 
suffer from residual neurological deficit after a relapse.6 In most cases, RRMS is followed by 
a secondary progressive (SPMS) phase, characterized by a gradual increase in neurological 
deficit with a reduction or absence of relapses. 10-15% of MS patients experience a gradual 
progression from disease onset, termed primary progressive MS (PPMS) (Figure 1A).1
  Clinically definite MS is diagnosed when a patient presents with neurological 
complaints for a second time, or with the aid of magnetic resonance imaging (MRI) and 
occasionally, lumbar puncture to collect cerebrospinal fluid (CSF).5 MRI is of great added 
value for diagnosis and to some extend, can visualize MS pathology. Compromised 
integrity of the blood-brain barrier (BBB) that surrounds the vasculature of the brain 
characterizes active lesions. This is visualized by contrast enhancement using intravenous 
administration of gadolinium. The revised McDonalds diagnostic criteria for MS are met 
when more than one lesion in the brain or spinal cord are detected on MRI, that are 
disseminated in space and time.5 Active lesions surround blood vessels and expand radially 
over time. Early in disease lesions are typically located in periventricular, juxta-cortical, 
infratentorial or spinal cord white matter.5 MS lesions are observed in white (WM) and grey 
matter (GM), e.g. the cortex. Longitudinal imaging studies show GM damage is secondary 
to WM damage independent of clinical disease course.7,8 WM inflammation correlates with 
BBB leakage and is continuous throughout disease development, but is most prominent 
in the early phase disease.1,5 GM lesions are associated with meningeal inflammation 
which is most prominent in progressive forms and late stage MS.9,10 Gradually, irreversibly 
damaged areas increase in number and size as a result of the characteristic white matter 
scars formation, i.e. sclerosis. The resulting neurodegeneration and loss of brain volume, 
termed brain atrophy, is pronounced in advanced MS (Figure 1B and C).7
  CSF is analyzed for intrathecal antibody production which is marked by the presence 
of oligoclonal Ig gamma (IgG) populations.11 Clonality of IgG populations is shown by iso-
electric focusing of CSF IgG. The presence of oligoclonal IgG bands in CIS patients are 
associated with a near ten-fold increased risk of developing MS.12
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  Currently MS is treated with a variety of immune modulatory drugs that damped the 
overall immune system, deplete or inhibit specific immune cell subsets or block migration 
of immune cells to the CNS, with a variable level of success. Recent advances in drug 
development show great efficacy in the relapsing remitting disease course with lowered 
clinical relapse rates and reduced MRI activity.13 However, due to their broad effect they are 
associated with a wide variety of side effects including secondary autoimmune diseases 
and opportunistic infections.13,14 Early treatment initiation with immune-modulatory 
drugs delays the onset of disease progression. Unfortunately, disease-modifying drugs 
that specifically target the gradual progressive phase of MS have limited efficacy.1,13 
Several criteria for safe and effective treatment are therefore not met, which underlines 
the need for more specific targets. Novel insight into the pathogenic mechanism at play 
are therefore of fundamental importance.
Biomarkers and clinical specimen
Although MS can be diagnosed using clinical parameters alone, or aided by MRI and 
intrathecal IgG, additional biomarkers for early and reliable diagnosis of MS or the 
prognosis and monitoring of disease progression are called for. Primarily because early 
detection and treatment of MS ameliorates disease.15 Additionally, because biomarkers 
may help to identify possible therapeutic targets, monitor therapy response or identify 
factors that are involved in MS pathology.16,17
  Due to the limited accessibility to the site of inflammation, identifying etiological 
factors for MS lesions is challenging. Likely, initiating factors are most reliably detected 
in newly forming lesions, early in disease development. However, collecting brain 
biopsies of MS lesions during early MS is highly invasive and is therefore only considered 
in fulminant or atypical MS cases. To gain insight in etiological factors and pathological 
processes early in MS, most studies rely on more readily accessible clinical specimen 
including CSF, peripheral blood (PB) and urine. CSF is produced by the choroid plexus 
in the brain ventricles and flows throughout the subarachnoid space that surrounds the 
brain and spinal cord (Figure 1B).18 CSF drains soluble proteins in the interstitial fluid 
via the perivascular space to cervical draining lymph nodes.19 Furthermore, intrathecal 
lymphocytes including their effector molecules are located in these CSF-drained areas. 
CSF therefore is a good alternative for brain biopsies to study inflammatory mediators and 
damage-associated proteins, albeit with compromised anatomical localization.11
  More readily accessible clinical specimen for the identification of biomarkers are 
peripheral blood and urine. Blood serum or plasma and urine are used to discover CNS- 
or immune-related markers that associate with CNS pathology.16,20 PB mononuclear cells 
(PBMC) are frequently used to identify systemic immune aberrancies.
Thesis final.indd   11 05-12-17   09:35
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The hallmarks of MS pathogenesis are brain and spinal 
cord inflammation, demyelination, partial remyelination 
and neurodegeneration.1,21 In MS lesions oligodendrocytes 
supplying the protective myelin sheath surrounding the 
neuronal axons die, leading to demyelinated exposed axons. 
Bear axons are vulnerable to injury and are functionally 
impaired without this structural and nutritional support.22,23 
Limitations in remyelination potential of oligodendrocyte 
progenitor cells result in chronically demyelinated axons 
and may lead to neurodegeneration.21
  What instigates the inflammation, demyelination 
and neurodegeneration of MS, and whether the same 
process is shared between MS patients is unknown. Some 
regard MS primarily as a neurodegenerative disease with 
secondary inflammation and demyelination. Others 
assume oligodendrocytes or neurons are targeted by the 
adaptive immune system, which leads to demyelination 
and neurodegeneration, respectively.1,24,25
Histopathology of MS
The anatomy of neuropathology is meticulously studied 
by immunohistochemistry (IHC) on post-mortem collected 
brain and spinal cord tissues from MS patients and controls. 
These analyses are therefore mostly limited to progressed 
or end stage MS patients.
  In order to comprehensively compare different 
studies, several methods have been proposed to classify 
MS lesions using IHC. Classifiers can be the anatomical 
location, i.e. WM/GM involvement, or markers of 
the involved pathological mechanisms, i.e. immune 
activation, complement deposition, infiltrating leukocytes, 
demyelinating activity, sclerosis and other factors.26–28 
Furthermore, lesion can be classified based on the progressive developmental stages as 
they are observed in animal models for MS and MRI.29 The staging of MS lesions offers 
an histological timeline of lesion development and has been used to characterize early 
lesions in progressed MS patients.29–32 Recently, a unifying comprehensive classification 
method has been proposed based on the inflammatory and demyelinating activity 
of lesions.27 Although many aspects of earlier systems are incorporated in this new 
classification method, diffuse WM changes in absence of demyelination have not been 
recognized, as there is still much debate on their origin.27,29,31 These changes include an 
►Figure 1. Timeline of disease 
course and neuropathology of 
multiple sclerosis. (A) Disease 
progression of the clinically 
distinct forms of multiple sclerosis 
(MS) are presented in a schematic 
graph. Gadolinium enhancing 
active white matter lesions are 
shown during the pre-clinical 
phase of MS using magnetic 
resonance imaging (MRI activity, 
orange arrows). Clinically isolated 
syndrome (CIS, light blue), 
potentially the first attack of 
relapsing remitting MS, typically 
occurs between 20-40 years 
of age. 30-70% of CIS patients 
subsequently develop relapsing 
remitting MS (black line). After a 
period of 10-15 years secondary 
progressive MS follows (red line). 
A minority of patients present 
with progressive disease from 
onset, termed primary progressive 
MS (green line). The brain volume 
diminished during disease course 
due to atrophy (dark blue dashed 
line). (B) Disease progression 
in time (from left to right) is 
schematically depicted in a cross-
sectional view of a MS brain and 
(C) diagram. Early and relapsing 
remitting MS is associated with 
perivascular white matter lesions 
(orange color), which may 
progress to sclerotic plaques 
(yellow color). Grey matter lesions 
(red color) are formed secondary 
to white matter pathology and 
are associated with the presence 
of meningeal inflammation (green 
color). Grey and white matter 
pathology leads to atrophy, which 
is most pronounced surrounding 
the brain ventricles and in the 
cerebral cortex (dark blue color). 
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previously classified as active non-demyelinating or pre-active lesions. Potentially these 
changes relate to the cytokine milieu of distant inflammatory processes, neuronal stress 
by distant demyelination, Wallerian degeneration or pre-lesional changes.25,27,29,33,34
  MS lesions are characterized by focal (partial) demyelination shown by reduced/
absence of myelin oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP) and 
luxol fast blue staining. Active lesions are hypercellular and contain immune activated 
phagocytozing macrophages and microglia. Activated microglia have a ramified 
appearance, short processes and enlarged cytoplasm.27,29,32 Immune activated microglia 
and macrophages have increased expression of CD68 and HLA-DR. Demyelinating 
microglia and macrophages contain intracellular myelin proteins, stained by myelin 
oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP) or Oil-red-O.27,29 Active 
lesions also contain reactive astrocytes, termed hypertrophic gemistocytes, characterized 
by enlarged cytoplasm and increased expression of glial fibrillary acidic protein (GFAP).27 
Lesions where immune activated and phagocytosing microglia and macrophages cells 
are distributed throughout the lesion are classified as active and early demyelinating 
lesions.27,29 Lesions where HLA-DR+CD68+Myelin+ macrophages and microglia are only 
present at the border of the lesions, surrounding a demyelinated core are classified as 
mixed active/inactive lesions27 or chronically active lesions.29 Demyelinated areas with very 
little signs of immune activation or infiltrating macrophages and microglia are regarded 
as inactive post-demyelination lesions27 or chronic inactive lesions.29 These demyelinated 
areas show increased signs of scarification, as shown by the transition of astrocytes from 
hypertrophic gemistocytes to fibrous gliosis, characterized by elongated processes.
  Infiltrating immune cells forming perivascular cuffs are a prominent feature of active 
WM lesions. Also GM lesions show perivascular infiltrates, but these are less pronounced 
than in WM lesions.21,35 These aggregates primarily consist of T-cells and macrophages, 
with lower frequencies of B-cells and plasmacells.14,21,36 These leukocytes are thought 
to instigate the inflammatory process and activate CNS resident immune cells that 
subsequently drive inflammation in progressed lesions.21,37 
  In conjunction with inflammatory lesions, neurodegeration is shown by IHC in MS 
lesions. Transected partially demyelinated axons, stained by Tau or neurofillement, form 
terminal ovoids (a characteristic union shaped bulb) in MS lesions.38 Moreover, axonal 
swelling is observed with aggregated proteins and organelles. These accumulations are 
marked with amyloid precursor protein (APP) stainings39 are suggested to aggravate 
neurodegeneration.25 These aggregates may result from axonal transport deficits, and 
have also been shown in absence of demyelination in NAWM.40 Different views exist on 
the cause of neuron death. Chronic inflammation may leads to neurodegeneration due 
to the production of reactive oxygen and nitrogen species (ROS and RNS). ROS an RNS 
induce cumulative DNA damage in mitochondria, which is detrimental for their energy 
production function in the form of adenosine triphosphate.41,42 Combined with the 
increased energy consumption of neurons due to lowered transduction efficiency of bear 
axons this may result in neurodegeneration.14,42 Conversely, axonal damage facilitates 
chronic inflammation and demyelination.25
Thesis final.indd   14 05-12-17   09:35
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Immunopathology of MS: innate immune cells
Innate immunity, also known as non-specific or in-born immunity, is an important arm 
of the immune system that comprises specialized cells and mechanisms that provide 
an immediate host defense against pathogens. However, unlike the adaptive immune 
system, innate immunity neither provides a tailored, nor a long-lasting pathogens-specific 
memory response.
  The continuous activation of CNS immune cells and periphery-derived innate 
immune cells are thought to drive the chronic decline of PP- and SPMS patients.30,37,43 
Although many innate immune cell types may contribute to pathological changes in MS, 
including astrocytes, dendritic cells, mast cells, and natural killer cells, the most prominent 
are monocyte-derived macrophages and microglia.37,43,44 Activated macrophages and 
microglia phagocytose myelin and their frequency associates with axonal damage.40 
This process is likely a scavenging response to oligodendrocyte death and myelin 
debris.30,45 Alternatively, innate immune cells are activated due to neuropathology.25,42 
Although demyelination is detrimental for neuronal function, this process is required 
for remyelination of axons by oligodendrocyte progenitor cells.37,44 Pro-inflammatory 
cytokines that are well known to skew macrophages and microglia into a pro-inflammatory 
M1 phenotype, including interferon-γ (IFNγ), interleukin-1β (IL-1β), tumor necrosis factor 
α (TNFα) and monocyte colony stimulating factor (GM-CSF), are highly prevalent in PB 
of MS patients.46–48 Furthermore, in untreated MS patients, peripheral monocytes show 
increased expression of the pro-inflammatory mediators IL-6 and IL-12 and co-stimulatory 
molecules CD80 and CD86.49 Contrastingly, in progressing MS lesions, myelin laden foamy 
macrophages display an anti-inflammatory M2-like phenotype with the expression 
of IL-10, IL-4, transforming growth factor-β (TGFβ) and C-C motif Chemokine ligand 18 
(CCL18).47,50 Together these data suggests that systemic innate immune aberrancies result 
in an exaggerated damage response in the CNS of MS patients. This may hamper the local 
suppressive function of phagocytes in progressing lesions.50,51
Immunopathology of MS: adaptive immune cells
Adaptive immunity, also known as the acquired or specific immunity, is composed of 
highly specialized, systemic lymphocytes that eliminate pathogens in a tailored manner. 
Although upon primary exposure to a pathogen the onset of the adaptive is delayed 
compared to innate immune responses, it does provide pathogen-specific immunological 
memory. This memory response is highly enhanced upon recurrent exposure to the 
specific pathogen. The adaptive arm of the immune system includes both cell-mediated 
immunity (T-cells) and humoral immunity (B-cells and antibodies)
  Adaptive immune cells are considered pivotal in the initiation or perpetuation 
of MS lesions.21,52 Active lesions, particularly in WM but less pronounced in GM, 
contain characteristic perivascular infiltrates. These infiltrates consist of mostly T-cells, 
macrophages and lower frequencies of B-cells and plasma cells. Contrary to experimental 
autoimmune encephalomyelitis (EAE) animal models for MS and earlier reports on 
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IHC analysis of human tissues,53,54 CD8+ T-cells 
outnumber CD4+ T-cells in MS lesions.36,55 Perivascular 
lymphocytes partly express granzyme B and Ki67, 
indicating their cytotoxic potential and activation-
induced proliferation, respectively (Figure 2A).56
  Although classically regarded as an immune 
privileged site that is enclosed by the BBB, CNS 
immune surveillance by adaptive immune cells is 
now widely recognized.57,58 With the recent discovery 
of CNS lymphatics in the meninges that drains fluid 
and CSF-derived lymphocytes to the cervical lymph 
nodes, this classic view of immune privilege is further 
mitigated.19 Although perivascular lymphocytes were 
initially thought to traverse the BBB and enter the CNS 
locally in response to inflammation, they may in part 
be CNS immune surveilling lymphocytes. Therefore, 
lymphocytes are able to initiate inflammation beyond 
the BBB.
Immunopathology of MS: T-cells
The sequential steps needed for T-cells to enter the 
CNS for immune surveillance and in response to local 
inflammation are studied in great detail, as these 
are attractive targets for therapeutic intervention.59 
Blocking entry of lymphocytes to the CNS with specific 
monoclonal antibodies directed to the α4ß1-integrin 
(VLA-4) is clinically highly efficacious.14 The access 
of lymphocytes is tightly regulated by the barriers 
that surround the CNS vasculature.57,58 Endothelial 
cells form BBB and the blood-spinal cord-barriers. 
Epithelial cells form the blood-CSF-barrier (BCSFB) 
in the choroid plexus and blood-leptomeningeal 
barrier (BLMB).18 A common feature of these barriers 
is the formation of tight junctions and a α1- and α2-
laminin containing basement membranes that allow 
regulated permeability for immune cells and soluble 
molecules.18,57,59,60 Integrity of the BBB is maintained 
in continuous cross talk with astrocytes, microglia, 
pericytes and neurons, but also with circulating 
immune cells.18,57,58,61,62 Memory T-cells traverse the 
BSCFB to patrol the CNS in the choroid plexus, located 
in the brain ventricles.57,58 Here, BCSFB epithelial cells 
◄Figure 2. T-cells infiltrate the brain 
parenchyma in multiple sclerosis 
lesions. (A) Consecutive 6µm formalin 
fixed paraffin embedded tissue sections 
of an active white matter lesions are 
stained using monoclonal antibodies 
for specific CD3 (top left), CD8 (bottom 
left), granzyme B (top right) and Ki67 
(bottom right), visualized by 3-amino-
9-ethylcarbazole deposition (red color), 
and nuclear counterstaining with 
haematoxylin (blue color). Perivascular 
infiltrates contain mostly CD3+ T-cells, 
of which the majority are CD8+ T-cells 
that express granzyme B indicating their 
cytotoxic potential and in part express 
Ki67 demonstrating proliferation. 
CD8+ T-cells partially infiltrate the 
brain parenchyma in MS lesions. (B) 
8µm sections of snap-frozen MS brain 
lesions are stained for nuclei with 
4’,6-diamidino-2-phenylindole (DAPI, 
white color) and monoclonal antibodies 
specific for pan-laminin (green color, top 
panel), demonstrating the basement 
membranes of the glia limitans (outer 
layer) and blood-brain barrier (BBB, 
inner layer), and glial fibrillary acidic 
protein staining (GFAP, bleu color, 
bottom panel), demonstrating the 
astrocyte end-feet that form the glia 
limitans surrounding the perivascular 
space. (C) CXCR12 expressed by 
activated endothelial cells (yellow color) 
and astrocytes (blue color) recruits 
CXCR4+ memory T-cells (orange color) 
to area of inflammation. The specified 
interactions facilitate T-cell [I] capture 
from the blood stream, [II] rolling on 
the vessel wall, [III] crawling to the site 
of inflammation, [IV] extravasation by 
passing the BBB formed by endothelial 
cells and the basement membrane 
(dark green color) by openings in the 
endothelial cell junctions, or via a trans-
cellular pathway, leaving the integrity of 
tight junctions intact. [V] Perivascular 
T-cells release IFNγ, GM-CSF and IL-17. 
These cytokines activate astrocytes 
(blue color) that then release CCL2 
that recruits additional CCR2+ myeloid 
cells (brown color). [VI] Activated 
perivascular macrophages secrete 
matrix metalloproteinases (MMP)-2 
and -9 that cleave the extracellular 
basement membrane (light green color) 
and disrupt the glia limitans, enabling 
T-cells to enter the brain parenchyma.
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(CCR6) is mainly expressed by IL-17 and IL-22 producing T helper 17 cells (Th17), IFNγ, 
GM-CSF and IL-17 expressing alternative Th17 cells (Th17.1) and IFNγ, IL-17, IL-21 and IL-
22 producing cytotoxic CD8+ Tc17 cells.61–63 All three cell types, including their effector 
molecules have been described to be pivotal in the induction and effector phase of EAE 
and MS.64,65
  Upon secondary activation within the CNS perivascular T-cells release IFNγ, GM-CSF 
and IL-17.65,66 These pro-inflammatory cytokines activate astrocytes and endothelial cells 
that thereby express the chemokine C-X-C chemokine receptor type 12 (CXCR12).65,67 This 
recruits CXCR4+ memory T-cells to the site of inflammation.61,62,68 Activated epithelial cells 
express P-selectin that captures P-selectin glycoprotein ligand (PSGL-1) positive T-cells 
from the blood stream. Upon this interaction, T-cells slow down and roll across the vessel 
wall. T-cell rolling is halted by binding of vascular cell adhesion molecule 1 (VCAM-1) with 
VLA-4 and intercellular adhesion molecule 1 (ICAM-1) with leukocyte function antigen 1 
(LFA-1) on endothelial cells and T-cells, respectively. Next, T-cells crawl across the vessel 
wall, often opposite to blood flow by interaction of ICAM-1 and ICAM-2 with LFA-1 to 
the site of inflammation. T-cells may either extravasate by passing the BBB formed by 
endothelial cells and the basement membrane by openings in the endothelial cell 
junctions, or via a trans-cellular pathway. Here, T-cells move through BBB endothelial 
cell leaving the integrity of tight junctions intact. Reactive astrocytes express CCL2, 
which results in the influx of CCR2+ myeloid cells, like monocytes or dendritic cells, and 
additional lymphocytes (Figure 2C).
  A second barrier, the glia limitans, formed by astrocytes end-feet and supported 
by a second α4- and α5-laminin containing basement membrane, confounds entry of 
perivascular lymphocytes to the brain parenchyma during homeostatic conditions.18,61 
However, in MS lesions, parenchymal T-cells are detected (Figure 2A). Astrocyte end-
feet and the basement membrane of the glia limitans and BBB can be visualized by IHC 
using glial fibrillary acidic protein (GFAP) and pan-laminin staining, respectively (Figure 
2B). Secondary activation of perivascular T-cells activate perivascular macrophages that 
secrete matrix metalloproteinases 2 (MMP2) and -9. MMP2 and -9 cleave the extracellular 
basement membrane and disrupt the glia limitans, enabling T-cells to enter the brain 
parenchyma (Figure 2C).18,61 Parenchymal T-cells are likely not part of CNS immune 
surveilling lymphocytes, but are involved in the inflammatory process in MS lesions. This 
is supported by studies showing clinical symptoms only manifest in EAE if T-cells breach 
the glia limitans to enter the brain parenchyma.69,70
  Clonal enhancement of T-cells, particularly CD8+ T-cells, in lesions and CSF of MS 
patients implies T-cell proliferation is receptor (TCR)-mediated, i.e. antigen (Ag)-specific 
activation.55,71–74 Within the same patients, TCR sequences are shared between lesions, 
which strongly suggests a common Ag drives T-cell proliferation in distinct lesions.55,71 
Furthermore, increased sharing of TCR is detected in WM lesions, CSF and PB of MS 
patients.55 These shared clones are mostly differentiated effector memory T-cells in PB.55 
These data endorse CSF and PB as relevant clinical specimen for the analysis of MS-related 
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lymphocytes and show potentially pathogenic memory T-cells, partially reside in and may 
originate from the periphery. It is widely believed that T-cells, that are initially activated in 
the periphery by pathogens or bystander activation,75 reactivate within the CNS by cross-
reactive self Ag due to molecular mimicry,76,77 epitope spreading78 or co-expression of 
TCRs with different specificities.79 Upon secondary activation in the CNS, T-cells initiate an 
inflammatory response that is subsequently aggravated by the activation of local innate 
immune cells and recruitment of additional leukocytes. Perivascular antigen presenting 
cells (APC) in WM/GM lesions, meninges and draining lymph nodes are exposed to CNS 
proteins.80–83 Phagocytosed CNS proteins are processed and peptides may either be 
presented on human leukocyte antigen class II (HLA class II) to auto-reactive CD4+ T-cells 
or cross-presented via HLA class I to auto-reactive CD8+ T-cells. This model concurs with 
the induction of EAE, where peripheral pathogenic T-cells are induced by immunization 
with CNS-specific Ag that subsequently evoke CNS inflammation.54,64
  An alternative hypothesis is that an event intrinsic to the CNS triggers inflammation 
of local innate immune cells, with the subsequent influx of (autoreactive) lymphocytes 
as a secondary event. The trigger may be CNS infection with an undefined pathogen or 
be the result of neurodegeneration.14,25,33,42 In this view, infiltrating lymphocytes merely 
amplify the local inflammatory process.
Immunopathology of MS: humoral immunity
Apart from T-cells, clonally expanded B-cells are also observed in the CNS of MS 
patients.21,84,85 Intrathecal oligoclonal IgG production is strongly associated with an 
increased risk of developing MS and is associated with increased cortical lesion load.5,12,86 
Autoreactive antibodies potentially initiate tissue damage.87 B-cell clones migrate between 
the meninges, CSF, cervical draining lymph nodes and the periphery.84,88 Although limited 
B-cells numbers populate the CSF and parenchyma, large numbers are detected in 
perivascular infiltrates in inflamed leptomeninges.1,9,21 Meningeal inflammation is most 
frequent in rapidly progressing MS patients, with high lesion load and pronounced GM 
pathology.9,10
  Perivascular infiltrates in the meninges, containing T-cells, CD20+ B-cells, CD68+ 
macrophages, CD138+ plasma cells and CD35+ follicular dendritic cells may form 
tertiary lymphoid structures.9,10,89 Here, follicular dendritic cells express the B-cell chemo 
attractant CXCL13. Proliferating B-cells and the presence of Ig+CD138+ plasma cells and 
plasma blasts indicate that part of these structures form functional ectopic germinal 
centers.9,90 This indicates B-cells potentially undergo antigen driven maturation within 
the CNS environment. Abundant extracellular myelin-derived proteins are selectively 
detected in the meninges of MS patients.81 This supports the model that autoreactive 
B-cell responses are shaped in the meninges of MS patients. However, intracellular myelin 
in local APC is not increased compared to controls,81 arguing against increased activation 
of myelin-specific T-cells in the meninges. Alternatively, B-cells mature in the deep cervical 
lymph nodes (CLN).84 Soluble CNS proteins are drained through the cribriform plate to 
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antigens presented by macrophages.83 Neuronal proteins are detected mainly in pro-
inflammatory IL-12 and TNFα producing APC and myelin proteins are mainly detected 
in anti-inflammatory TGFβ and IL-1 receptor antagonist (IL-1ra) producing APC.82 This 
may reflect induction of different types of immune responses or be a consequence of the 
inflammatory state during drainage of CNS antigens. Surgical removal of superficial CLN 
prior to induction of EAE in mice ameliorates disease severity and illustrates the role of 
CLN in initiating autoaggressive immune responses.91
  Apart from their potential role in producing pathogenic IgG,87 B-cells are considered 
important APC for pathogenic T-cells. Several lines of research support that B- and T-cell 
interactions are key in MS including: i) a recent metagenomic study showing strong 
overlap between MS-associated genetic risk factors and expression profiles in B- and 
T-cells,92 ii) the ability of B-cells to take-up myelin proteins independent of B-cell receptor 
specificity and present peptides to CD4+ T-cells via human leukocyte allele class II (HLA-
II) in vitro,93 iii) the success of B-cell depletion therapies.94 Several anti-CD20 mAb rapidly 
lower annual relapse rates and MRI lesion load after treatment onset without affecting IgG 
levels and IgG producing plasma cells.95 The efficacy of B-cell depletion is likely unrelated 
to IgG production, but rather to the APC-function and cytokine production of B-cells.75,94,96 
This view is supported by the observed reduced intrathecal T-cell numbers and activation 
state due to B-cell depletion.97 
Target antigens of autoreactive B- and T-cells
The striking similarity in pathology between MS and EAE animal models strongly support 
a role of autoreactive B- and T-cell responses in MS.54,98 In EAE, MS-like immunopathology 
is induced by immunization with various CNS antigens in adjuvant. Alternatively, EAE is 
induced in an antibody independent manner by adoptive transfer of CD4+ T-cells. These 
studies reinforced the idea that MS is an autoimmune disease mediated by CNS-specific 
CD4+ Th1, Th17 and Th17.1 cells.54 However, the presence of clonally enhanced meningeal 
B-cell and intralesional CD8+ and, to a lesser extent, CD4+ T-cell populations in MS patients 
is widely considered to prove that Ag-specific B- and T-cell responses drive inflammation 
in the CNS.55,71,73,74,84 Also the intrathecally synthesized oligoclonal IgG populations in the 
CSF of MS patients12 are suggested to contribute to MS pathology. However, the majority 
of these IgG clones are directed towards ubiquitous intracellular self-antigens that are 
released due to tissue damage.99 Likely, these antigens represent secondary immune 
targets.
  In order to gain insight into the pathogenic mechanism at play and to develop 
personalized treatment, identification of the enigmatic antigenic targets of auto-
aggressive B- and T-cells is of fundamental importance.100,101 Numerous CNS-restricted 
autoantigens have been proposed, yet none are exclusively or broadly recognized by MS 
patients.37,100–102
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  The identification of putative autoantigens involved in MS immune pathogenesis 
is technically challenging, especially considering that benign autoreactive B- and T-cells 
are an integral part of a normal immune system.100,101 These autoreactive regulatory T- 
and B-cells are though to modulate the immune system by dampening the inflammatory 
response and restore homeostasis to retain self-tolerance. Strategies to identify candidate 
target antigens of pathogenic B- and T-cells have mainly relied on their encephalitogenicity 
in EAE.37,54,100,102 Oligodendrocyte-specific proteins have been widely studied as candidate 
auto-antigens in MS, because of the overt axonal demyelination and protein abundance 
in CSF and meninges of MS patients and because their potent encephalitogenicity in 
EAE.37,102,103 More recently, also encyphalogenic glia-, astrocyte-, and neuron-specific 
proteins were considered as putative autoantigens for B- and T-cells in MS.104–108 Inducing 
EAE with oligodendrocyte-specific proteins induces focal white matter lesions and lead 
to strong clinical relapses. Immunization with neuron-specific proteins predominantly 
leads to grey matter pathology and progressive disease progression. Immunization with 
glia-specific proteins induces more diffuse pathology, termed experimental autoimmune 
panencephalitis, with mild or no clinical symptoms.104,106 These data suggest different 
antigens drive the inflammatory process at distinct anatomical sites in the CNS of MS 
patients or during the relapsing remitting and progressive phase of MS.
  Alternative approaches to identify potential target Ag include studying tissue- or 
CNS protein-binding capacity of serum- and CSF-derived IgG108,109 and determining the 
T-cell responses towards lesion-specific proteins.110 Indeed, CD4+ T-cell and IgG responses 
to the majority of EAE-inducing CNS proteins and other candidate MS-associated antigens 
(cMSAg) have been identified in MS patients, but T-cell frequency or IgG levels were 
indifferent compared to controls, questioning their pathogenic potential.37,100,102,105,107,109,111 
The conflicting outcomes of these studies are likely due to caveats in the experimental 
design, lack of standardization of applied assays and commonly small sample sizes. An 
extensive list specifying the tested MS-associated autoantigens is available in an immune 
epitope database (www.iedb.org), and their relevance is discussed by Vaughan et al.102
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The amount of studies implicating specific factors in the etiology of MS pathogenesis since 
Jean-Martin Charcot first described it in 1868112 is vast. Currently, MS is considered to be a 
result of nature ánd nurture, as both hereditary and environmental factors are implicated 
in MS development. Although both factors may contribute independently, it is more likely 
that the interactions between genes and environment dictate MS susceptibility. 
Genetics
Concordance studies in monozygotic twins support a genetic component of approximately 
30% in the risk of developing MS.1 In contrast to classically inherited diseases, neither a 
necessary, nor a sufficient genetic factor to develop MS has been identified.1 
  The dominant genetic factor in MS is the HLA haplotype. In the seventies already, 
HLA-II alleles were strongly associated with MS. Initially identified by their DR2 and DQ6 
serotype, these associations were later refined to the corresponding genotypes, HLA-
DRB1*15:01, -DRB5*01:01, -DQA1*01:02, and -DQB2*06:02, respectively.113 Additional 
HLA-I and HLA-II alleles have been identified that associate with either elevated or 
decreased risk of developing MS. The odds risk for developing MS of the HLA haplotype 
on ranges from an approximate 8-fold increase for homozygous HLA-DRB1*15:01 carriers 
to a 2-fold decrease for HLA-B*38:01 or homozygous HLA-A*02:01 carriers.114,115 The role of 
HLA haplotype in MS is not fully known. Detailed analysis of disease-associated variants in 
HLA-DRB1 genotype revealed the alterations predominantly influence the conformation 
of the peptide-binding pocket and consequently, the range of presented peptides.116 
Likely, the MS HLA haplotype shapes the repertoire T-cell specificities and thus the 
likelihood of initiating pathogenic T-cells. Conversely, MS-associated variants in HLA that 
do not influence antigen presentation are also detected.116
  Apart from HLA, in genome wide association studies (GWAS) over 230 disease-
associated single nucleotide polymorphisms (SNP) were identified with moderate odds 
risk for developing MS, ranging from 1.07 to 1.32.117–119 Including the HLA associations, 
an estimated 28% of the recurrence rate in siblings is explained by the identified genetic 
factors. Due to the marginal increase in MS risk, there is limited diagnostic or prognostic 
potential for these genetic associations.120 Nevertheless, GWAS offers a valuable tool 
to reveal genes that are functionally involved in this complex disease and hint upon 
the involved mechanisms in a hypothesis free manner. However, due to the pervasive 
interconnection of gene regulatory networks in disease relevant cells, part of the heritable 
associations that are defined in MS may be explained by effects outside core pathways.121 
The functional contribution of individual genes and networks should therefore be carefully 
interpreted in the context of disease relevant cell types.
  The majority of MS-associated genetic variants are located in non-coding enhancer 
regions near adaptive immune related genes. Especially in binding sites near key regulators 
of immune differentiation and activation.92 There is a striking genetic communality 
between related autoimmune and chronic inflammatory diseases like rheumatoid arthritis, 
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systemic lupus erythematosus, celiac disease, Crohn’s disease, psoriasis, type 1 diabetes 
and MS.122,123 In contrast to neurological and neurodegenerative diseases like migraine, 
Alzheimer’s and progressive supranuclear palsy, epigenetic fine mapping showed the 
MS-associated risk SNP poorly overlap with transcriptionally active genes of cells in the 
central nervous system. Contrarily, there is a strong overlap with active genetic regions 
in T- and B-cells, supporting the hypothesis that adaptive immune responses are key in 
MS pathogenesis with a minor contribution of neurodegenerative processes.92,124 Still, 
three kinesin family member proteins (KIF) that are related to retrograde axonal transport 
along microtubules contribute to MS susceptibility.34,117,125 The KIF associations may relate 
to neuronal transport of active mitochondria to the site where ATP is required. Aged 
mitochondria, that produce ROS and RNS, are normally removed from the active sites. In 
MS, stationary organelles and proteins accumulate in axons and form aggregates. These 
aggregates correlate with disease duration and are not only detected in active lesions but 
also in normal appearing white matter, which some interpret as an initiating event.25,34,42 
Environmental factors
The intricate interplay of many environmental factors contribute to the risk of developing 
MS and influence disease severity. These factors include behavioral, ecological and 
physiological factors like hormone balance,126 comorbid diseases,123 traumatic events or 
surgery,127 diet,128,129 gut microbiome,130 smoking,131 vitamin D levels132,133 and infections.134 
Similar to the genetic traits of MS, these factors are intricately interlinked and therefore 
may partly reflect indirect associations that are not related to the core pathways involved.
  A recent umbrella review of systematic reviews and primary and meta-analysis 
studies that examined associations between the majority of the above-mentioned 
environmental factors and multiple sclerosis revealed several caveats.135 The majority 
of studies showed large between-study heterogeneity (discordant results), small-study 
effects (large population studies showing more conservative results compared to smaller 
population studies) and excess significance bias (more statistically significant results 
than expected due to reporting bias), casting doubt on their validity.135 However, using 
stringent inclusion criteria, two environmental factors stand out from the rest, namely; 
smoking and infections. Smoking is hypothesized to increase the risk of MS by chronic 
activation of Th1 and Th17 in the lung,136 and by altering post-translational modification 
of autoantigens making them more immunogenic or more prone to cross-reactivity.137
  The strong correlations of MS with infections is shown by seropositivity for the 
Epstein-Barr virus as measured by IgG specific for EBV nuclear antigen-1 (EBNA-1) and 
infectious mononucleosis (IM). Because smoking does not correlate with EBNA-1 IgG levels 
or IM, it can be regarded as an independent risk factor.131,138 IM, also known as glandular 
fever and Pfeiffer’s or kissing disease, is a self-limiting lymphoproliferative disease that 
typically occurs when primary infection with EBV is delayed until adolescence. Increased 
EBNA-1 IgG levels and IM are therefore closely interlinked and likely associate with MS due 
to a single core pathway.
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inflammation together with epidemiological migration2,139 and twin studies140 support an 
etiopathological role of viruses in MS.141–143 Also the observation that viruses can cause 
demyelinating disease in various rodents has fueled this long-held hypothesis.78,144 Viruses 
may induce MS immunopathology in different ways. CNS cell infection may induce tissue 
damage. The innate and adaptive immune responses towards infections may cause 
by-stander damage to CNS cells.145–147 Virus-specific immune cells may cross-react with 
CNS-specific auto-antigens by molecular mimicry.76,148 Systemic infection and immune 
activation may create a pro-inflammatory milieu that activates auto-aggressive T-cells 
in an antigen independent manner.147,149 Infections may activate self-/pathogen-specific 
dual TCR T-cells and evoke an auto-immune response.79
  The various infectious agents considered as potential cause for MS include 
endogenous retroviruses, measles virus, rubella, mumps, chlamydophyla pneumoniae 
and human herpesvirusses (HHV).150–153 Especially HHV are considered attractive candidate 
viruses for MS. They are highly prevalent worldwide and are able to establish life-long 
latency in the host. Intermittently, HHV reactivate from this dormant state and may 
cause recrudescent disease. All HHV can infect lymphocytes during primary infection, 
and EBV, cytomegalovirus (CMV, also known as HHV5) and HHV6A/B establish latency in 
specific subsets. During inflammatory conditions, but also during immune surveillance, 
lymphocytes can traverse the BBB and BCSFB to the CNS. Their high prevalence, potential 
to reactivate and tropism for migratory lymphocytes argue for their putative role in MS. 
Most of these pathogens have not withstood the scrutiny of research over time and many 
of these associations were contradicted in subsequent studies.147,154–157 As is concluded 
in the meta-analysis by Belbasis and collegues, the only universal microorganism that is 
identified is, arguably, the endemic EBV, as is discussed in detail below.158
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Biology of the Epstein-Barr virus
EBV, also known as HHV4 or human lymphocrypto virus, is one of eight known HHV. 
Together with Kaposi’s sarcoma herpes herpesvirus, also known as HHV8, EBV is classified 
as a γ-herpesvirus. This class undergoes lytic replication in epithelial cells or fibroblasts 
and latently persists in lymphoid cells from which the virus intermittently reactivates.
  Michael Anthony Epstein, Bert Achong and Yvonne Barr first discovered EBV 
using electron microscopy in 1964 in Burkitt’s lymphoma cell lines.159 EBV particles are 
approximately 122-180 nm in diameter and are composed an envelope containing 
lipids and projecting glycoproteins that mediate infection of host cells. The envelope 
contains tegument, which consists of specific viral and host proteins and viral RNAs. In the 
tegument, an icosahedron shaped nucleocapsid composed of core proteins contains the 
about 172,000 base pair linear double stranded DNA EBV genome (Figure 3A).
  The EBV genome was the first herpesvirus that was completely cloned and 
sequenced. The complex and counterintuitive nomenclature of EBV proteins is still based 
on the original cloned BamHI restriction fragments. Lytic cycle-associated open reading 
frames (ORF) were designated according to the size of BamHI fragments (alphabetically 
from large to small; A, B, C, ..., Z, a, b, c, etc.), orientation (leftward or rightward) and order of 
appearance of the ORF (from left to right ORF1, ORF2, etc.). For example, BZLF1 is located 
on BamHI number 26 (Z), Leftwards oriented ORF number 1. Contrastingly, latency-
associated ORFs are designated according to cellular location of proteins (nuclear or 
membrane), regulation of expression (latency expression programme I, II or III) and order 
of appearance on the genome. For example, EBNA-3B, also known as BERF2, is Epstein-
Barr virus Nuclear Antigen expressed during latency 3 located downstream of EBNA-3A 
(B).
Epstein-Barr virus infection and tropism
EBV is transmitted via saliva. Primary infection occurs in epithelial cells of the naso- and 
oropharynx (Figure 3B). Here, EBV either traverses the epithelial barrier by transcytosis,160 
or by lytic infection. The EBV glycoproteins gH/gL may bind to αVβ5-, αVβ6- or αVβ8-
integrins161,162 or EBV BMRF2 binds to α3β1- or α5β1-integrins expressed by polarized 
epithelial.163 Interaction of gH/gL with its receptors induces a conformational change 
that enables interaction with gB (gB/gH/gL), which in turn mediates fusion with the cell 
membrane followed by lytic infection (Figure 3C).164 Subsequently, submucosal B-cells are 
infected in the tonsilar crypt or cervical lymph nodes. The EBV 350 and 220 kD glycoproteins 
(gp350/220) bind with complement receptor 2 (CR2 or CD21)165 or complement receptor 1 
(CR1 or CD35) expressed by B-cells.166 EBV binding of B-cells improves infection efficiency 
but is not required. Interaction of gp42 with HLA-II on B-cells is essential for fusion of EBV 
with B-cells.167 HLA-II-bound gp42 interacts with gH/gL (gp42/gH/gL). Next, the gp42/gH/
gL complex induces a conformational change of the pre-fusion gB trimer that triggers 
fusion with the cell membrane surface or in endocytic vesicles (Figure 3D).168,169 The 
nucleocapsid is transported via microtubules to the cell nucleus, where the viral genome 
is released together with several tegument proteins to establish latency (see below).
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endoplasmatic reticulum and is thereby targeted for degradation. Lytic infection in B-cells 
thereby leads the production of virions with low gp42 content. In HLA-II negative epithelial 
cells this does not occur, thus epithelial cell-derived virions contain large amounts of gp42. 
The gp42/gH/gL complex impairs infection of epithelial cells. Consequently, EBV switches 
cell tropism between epithelial and B-cells.170
  Alternative pathways of infection are gp350-specific IgA-mediated infection,171 
in-cell infection (phagocytosis of whole EBV infected B-cells),172 and cell-to-cell contact-
mediated infection.173 These pathways do not rely on glycoprotein-mediated entry of 
EBV. Consequently, EBV tropism is not limited to epithelial cells and B-cells, which is an 
important consideration when studying viral presence of putatively EBV-infected clinical 
specimen.
Epstein-Barr virus latency
EBV selectively establishes life-long latency in B-cells.174,175 In healthy EBV carriers, 1-50 
per 1,000,000 peripheral blood B-cells are latently infected with EBV. After infection of a 
B-cell, the unmethylated EBV genome first undergoes an abortive lytic replication cycle. 
Second, viral gene expression is reduced to a growth program (Latency III) with controlled 
expression by Wp and Cp promoters of EBNA-2, -LP, -3A, -3B, -3C and latent membrane 
protein 1 (LMP1). Distinct promoters regulate expression of the non-coding RNAs EBER-1 
and -2, and approximately 44 miRNAs in the BART and BHRF1 regions.176,177 EBV induces 
B-cells to undergo an antigen-independent germinal center reaction that induces 
differentiation to memory B-cells. Subsequently, EBNA-1 expression by the Qp promoter 
induces the host DNA repair machinery to circularize the viral genome at the terminal 
repeats, forming the viral episome. This enables expression of LMP2A/B, the exon region 
of which are located at either end of the terminal repeat.178 After the germinal center 
reaction the mature B-cells enter circulation. The Cp promoter is methylated, limiting gene 
expression to EBNA-1, LMP1, 2A and 2B, non-coding RNAs and controlled expression of 
BHRF1 and BARF1 (Latency II). LMP1 functions as a constitutively activated CD40 receptor, 
and LMP2A mimics an activated B-cell receptor (BCR), enabling proliferation of infected 
B-cells. BFRH1 is a BCL-2 homologue, protecting cells from apoptosis.175,179–181
  Full latency is established by down regulation of all viral protein expression by Cp 
and Wp promoter methylation, and selective expression of non-coding RNA (Latency 0). 
Expression of viral proteins is fully down regulated to reduce immune-exposure. EBNA-1 
is essential for the maintenance of the EBV episome in dividing cells and is selectively 
induced by the Qp promoter upon B-cell proliferation. EBNA-1 binds the origin of plasmid 
replication (oriP) on the circular EBV genome and facilitates its replication by the cellular 
DNA replication machinery (Figure 4).182,183 
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Figure 3. Epstein-Barr virus infects epithelial cells and B-cells in the oro- and nasopharynx. (A) The Epstein-
Barr virus (EBV) particle is composed of a 170.000 bp dsDNA genome packaged in a nucleocapsid surrounded 
by tegument and a lipid bilayer envelope with projecting glycoproteins (gp). Epithelial cell-derived EBV particles 
are rich in gp42/gH/gL trimmers, while B-cell derived particles are rich in gH/gL dimers, which determine the 
B-cell and epithelial cell tropism, respectively. (B) EBV is transmitted via saliva. Primary infection occurs in the 
oropharynx or nasopharynx. Here, epithelial cells are (C) traversed by transcytosis (left), infected via interaction 
of the gH/gL dimer with αVβ5, αVβ6 or αVβ8 integrins or interaction of BMRF2 with α3β1 or α5β1 integrins (middle). 
This leads to fusion with the cell membrane and lytic infection of the epithelial cell (right). (D) EBV binds to 
B-cells via interaction of the gp350/220 with CD21 or CD35. Bound EBV may be internalized by endocytosis (left). 
Interaction of the gp42/gH/gL trimer with HLA class II in endocytic vesicles (middle) or on the cell surface (right) 
induces fusion with the membrane via gB/gH/gL.  The viral capsid is then transported to the nucleus where the 
viral genome is released. Here, the EBV genome is circularized and establishes latency as a viral episome. 
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Figure 4. Regulation of the Epstein-Barr virus transcriptome during the virus lifecycle. After initial 
infection of tonsillar epithelial cells, the Epstein-Barr virus (EBV) infects naïve B-cells in the marginal zone of 
lymph nodes in the oropharynx. After release of the viral genome in the nucleus the genome is circularized 
and virus expresses the latency III program, inducing a germinal center reaction in B-cells. The infected B-cell 
is antigen-independently differentiated to a mature B-cell blast. Latency III includes expression of BHRF1, all 
EBNA and LMP proteins, the noncoding EBERs and BARTs and optionally BARF1. After growth transformation, 
EBV expression of EBNAs is limited to EBNA-1 (latency II). When full latency is established in resting B-cells, viral 
protein expression is shut down by methylation of the viral polymerases and only non-coding EBER and BART 
transcripts are expressed. Upon cell division the latency I program is expressed, including EBNA-1 and non-
coding transcripts, that enables EBV genome replication. Upon differentiation to plasma cell or in response to 
cellular stress or damage response EBV can reactivate from its dormant state. This is initiated by expression of 
the immediate early transactivators BZLF1 and BRLF1, which induce expression of early antigens, mainly needed 
for EBV genome amplification. Subsequently late proteins encoding mainly structural proteins are expressed; 
viral genomes are encapsulated by budding from the nuclear membrane and enveloped in cellular membranes 
of the Golgi apparatus. Viral particles are released by exocytosis. Released progeny either infects naïve B-cells or 
tonsillar epithelial cells. Lytic infection of tonsillar epithelial cells results in virus shedding in the saliva and EBV 
may be transmitted to a new host.
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Epstein-Barr virus reactivation
Activation of memory B-cells via the B-cell receptor may result in differentiation to plasma 
cells. This process has been shown to switch on the EBV lytic cycle.184 Stress hormone levels, 
cellular stress responses and DNA damage have also been linked to EBV reactivation.185–187
  Reactivation is initiated by regulated expression of three kinetic classes of lytic 
viral antigens termed immediate early (IE), early (E) and late (L) antigens. Immediate 
early antigens are the transcriptional activators BZLF1 (also known as Zebra or Zta) and 
BRLF1. Multiple BZLF1 and BRLF1 responsive elements in early gene promoters induce the 
expression of 38 early proteins, which in turn induce the expression of 40 late proteins and 
ultimately result in global bidirectional expression of the viral episome.188,189 Early proteins 
are mainly involved in viral genome amplification, immune modulation and host-gene 
shutdown. Contrary to late genes, early genes are persistently transcribed in the presence 
of inhibitors of viral DNA synthesis. Late proteins are mainly structural proteins (Figure 
4).183
  The induction of lytic EBV results in several cytopathic effects that are characteristic 
for herpesvirusses. These include amplification of the viral genome in the center of 
the nucleus, host-gene shutdown, formation of nucleocapsid at the nuclear border, 
encapsulation of the viral genome by budding of the nuclear membrane and final 
envelopment in cytoplasmic membranes.
Epstein-Barr virus-specific immune responses in healthy carriers
Infection of EBV induces a strong innate and adaptive immune response in the host.190 
Most prominent for the innate immune response is the highly increased CD56+ natural 
killer (NK) cells numbers in peripheral blood and lymph nodes within two days after 
infection that may persist for several months.191 NK-cells limit lytic replication of EBV and 
the pathogenic expansion of CD8+ T-cells that is associated with infectious mononucleosis 
(IM), which is discussed in detail below.192 The gradual decrease of NK-cells upon aging is 
thought to increase risk of IM after primary infection.190,192
  Antibodies are initially mainly directed towards a wide range of structural lytic viral 
antigens.191 Primary EBV infection is diagnosed by the presence of IgM and absence of 
IgG, specific for the viral capsid antigen (VCA) encoded by the late gene BcLF1.193 The 
subsequent VCA-specific IgG response persists for life. Humoral responses towards non-
structural lytic cycle early antigens (EA) are delayed for several weeks and decline over 
time, yet are rapidly increased upon viral reactivation. The EA-D (also known as BMRF1) 
specific IgG titer is therefore used as a serological marker for EBV reactivation. Antibody 
responses towards the latent antigens like EBNA-1 are delayed for 3-6 months and 
gradually increase over time.191 
  Primary infection leads to a dramatic increase in general CD8+ T-cell numbers. 
Subsequently, a strong EBV-specific CD8+ T-cells response is mounted that limits the 
initial NK-cell and general CD8+ T-cell numbers. Up to 50% of PB CD8+ T-cells specific 
for individual EBV antigens have been shown after primary infection using HLA class I 
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immediate early (BZLF1 and BRLF1) and early viral antigens (usually BMRF1, BMLF1, BARF1 
and BALF2). Reactivity towards late antigens is rare due to a strong HLA class I down-
modulation that is associated with late gene expression.195,196 The magnitude of the lytic 
viral antigen response declines and is followed by a relative increase in reactivity towards 
latent antigens (usually EBNA-3A/B/C, EBNA-1 and LMP2).191,197 Approximately 1-2% EBV-
specific CD8+ T-cells persist in PB in healthy EBV carriers.191,197
  CD4+ T-cell numbers are not, or only mildly increased upon primary EBV 
infection.191,197,198 Using HLA class II tetramers, up to 1% CD4+ T-cells are shown to be EBV-
specific.198 All kinetic classes of lytic viral antigens are targeted by CD4+ T-cells but latent 
EBV antigens are marginally immunodominant and are mainly CD27+CD28+ throughout 
the course of infection.198
Epstein-Barr virus-associated lymphoproliferative diseases and carcinomas
EBV infection is associated with a wide variety of diseases. Most individuals are infected 
with EBV during childhood and present with no, or minor symptoms. However, if 
primary infection is delayed until adolescence or later, IM, also known as glandular 
fever, Pfeiffer’s or kissing disease, frequently occurs. IM patients generally present with 
fever, headache, sore throat, enlarged tonsils and cervical lymph nodes and fatigue. 
These symptoms mostly resolve within 2 to 4 weeks, yet fatigue may persist for months. 
During IM, the immune system responds strongly to EBV infected cells leading to a self-
limiting lymphoproliferative disease. Initially, the frequency of infected lymphocytes and 
lymphocytes specific for EBV infected cells is low. Also the effect of antiviral therapy to limit 
viral replication in IM is limited. This suggests that neither EBV replication, nor EBV-specific 
responses drive the proliferation of lymphocytes, but rather a strong pro-inflammatory 
milieu drives cytokine mediated bystander activation of lymphocytes. Most patients 
recover by mounting strong EBV-specific immune responses, but immune compromised 
patients such as transplant recipients, HIV patients and the elderly may suffer from severe 
lympholiferative disease.197,199
  EBV infection is associated with an estimated 200,000 cases of B-cell, epithelial cell, 
T- and NK-cell carcinomas including Burkitt’s, Hodgkin’s and non-Hodgkin’s lymphoma, 
gastric cancer, nasopharyngeal carcinoma, oral hairy leukoplakia and central nervous 
system lymphomas.159,183,200–202 These malignancies are associated with distinct EBV latency 
expression patterns or chronic active EBV infection and are related to ineffective immunity 
against EBV.186,203 Interestingly, possible associations between MS and EBV-related 
carcinomas are suggested based on epidemiological associations and co-morbidity.204,205
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Epstein-Barr virus-associated autoimmune diseases
The etiology of autoimmune diseases is generally complex and multifactorial, but there 
are some striking similarities between different autoimmune diseases. There is a high 
level of overlap in the involved genes and pathways as is shown by shared genetic risk 
alleles.92,123 Also EBV infection is associated with multiple autoimmune diseases. This 
suggests partially communal pathogenic mechanisms are involved. Systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA) and MS are most prominently associated 
with EBV infection.206
  Virtually all SLE and MS patients are show to be EBV seropositive, which despite the 
ubiquitous nature of EBV (±95% seropositive among healthy adults) is highly significant.207 
More specifically, alterations in systemic B- and T-cell responses against particular EBV 
antigens are associated with SLE, RA and MS. Possibly the shared genetic background leads 
defective regulation of EBV latency or EBV-specific immune aberrancies. We anticipate 
valuable lessons to elucidate the pathological mechanisms in MS can be learned from 
other immune diseases.
  SLE is a chronic inflammatory autoimmune disease affecting several organs; mostly 
skin, joints, kidneys and CNS. Severe SLE may lead to multi-organ failure. The prevalence 
of SLE is dependent on gender and race, with highest incidence among women of 
African descent.207 SLE is characterized by non-tissue specific mature B-cell responses 
directed towards nuclear antigens like chromatin, dsDNA, and various spliceosomal and 
ribonucleoproteins components. Structural mimicry between several of these nuclear 
antibodies, as well as epitope spreading, has been shown for EBNA-1 and EBNA-2 specific 
IgG in SLE patients and various animal models.208 In SLE, EBV viral load, EA-D specific IgG 
seroprevalence and titers are increased.208,209 Furthermore, the frequency of EBV-specific 
CD8+ T-cells is increased, yet the cytotoxic potential of these cells is reduced.179,207 Together, 
these findings indicate EBV infection is poorly controlled in SLE patients.
  RA is a widespread chronic inflammatory autoimmune disease, selectively affecting 
joints. Patients have painfull, stiff and swollen joints, due to inflammation of the synovial 
membrane. In contrast to MS and SLE, EBV seroprevalence in RA patients is indifferent 
from healthy controls indicating EBV infection is not a prerequisite of developing RA. 
Nevertheless, EBV-specific IgG and viral load are increased in blood and synovial fluid.210,211
  Citrullinated fibrinogen, filament aggregating protein and keratin proteins are 
detected in the RA synovia. Auto-antibodies specific for these citrullinated proteins arise 
years before disease onset. Cross-reactive IgG against the citrullinated glycine–arginine 
rich region in EBNA-1 and collagen and keratin filaments are shown in affected joints.212 
Furthermore, cross-reactive T- and B-cell responses against EBV glycoprotein 110 (BALF1) 
and peptides of the dominant RA-associated genetic risk allele HLA-DRB1-04:01 have been 
shown.213 Molecular mimicry may therefore result in autoreactive B- and T-cell responses 
in RA.
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compared to controls.214 Synovial fluid of RA patients is enriched for EBV-specific CD8+ 
T-cells targeting various immunodominant latent (EBNA-3A/B/C and LMP2) and lytic 
target antigens (BZLF1, BMLF1, BRLF1, BCRF1, BMRF1 and BALF4).215,216 However, EBV-
specific CD8+ T-cells expressed reduced amounts of IFNγ,217,218 which suggests impaired 
T-cell control of EBV. These results suggest chronic antigenic challenge of EBV-specific 
CD8+ T-cells in the joints of RA patients. A study by Scotet and colleagues showed similar 
enrichment of EBV-specific and, to a far lesser extent, CMV-specific CD8+ T-cells in lesions of 
psoriatic arthritis, ankylosing spondylitis, arthrosis, encephalitis, uveitis and MS patients.216 
Although, they conclude EBV-specific CD8+ T-cells are trapped in chronic lesions by an 
undefined non-disease-related mechanism, one may also argue these results hint upon a 
common pathogenic EBV-related pathway in these chronic inflammatory diseases, like is 
suggested based on the shared genetic risk factors.92,123
Epstein-Barr virus and multiple sclerosis
Epstein-Barr virus and multiple sclerosis: sero-epidemiology
Besides smoking, the strongest associated environmental risk factor for developing MS 
is EBV infection.135 The initial link between EBV and MS was the striking epidemiological 
similarity between IM and MS.219 Areas with high EBV seroconversion rates before 
adolescence and consequently a low incidence of IM (e.g. Africa, Orient and Polynesia), 
coincide with low incidence of MS. Conversely, areas with low, or delayed EBV 
seroconversion and consequently, a high incidence of IM (e.g. Northern Europe), coincide 
with high MS incidence. These data are supported by migration data that suggest that 
the place of residence before the age of 16 years, and therefore the risk of contracting 
EBV infection, determines the risk of developing MS.219 A high incidence of IM and MS 
coincide with regard to age, geographical distribution, socio-economical status, ethnicity 
and hygiene status.134,219 Individuals with a history of IM have a 2- to 3-fold higher risk of 
developing MS.220–223
  Several hypotheses exist on how a history of IM contributes to MS risk. The 
widespread EBV infection of B-cells during IM may include infection and differentiation 
of naive autoreactive B-cells populations without negative selection.224 The strong Ag-
independent bystander activation and proliferation of CD8+ T-cells in the initial phase of 
IM may include auto-reactive CD8+ T-cells, or skews regulatory auto-reactive regulatory 
T-cells to a pro-inflammatory phenotype. Primary EBV infection in a mature immune 
system with reduced plasticity may result in suboptimal immune control of EBV, making 
EBV more prone to reactivate and chronically stimulate the immune system. During IM, 
cross-reactive B- and T-cell responses may be initiated. Notably, IM patients temporarily 
have antibodies that recognize unique cross-reactive epitopes in EBNA-1 and several host 
proteins225,226 that have been implicated in systemic lupus erythematosus.208,209
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  MS patients are almost universally infected with EBV, compared to 90-95% of age 
and gender matched controls.149,158 The odds ratio of developing MS was found to be 
0.06 in EBV seronegative individuals.134 Moreover, recently the validity of the negative 
serostatus in these rare MS patients is questioned.158,227 Longitudinal studies among 
over 3 million military personnel showed EBV infection precedes the development of 
MS.228 The elevated EBNA-complex and EBNA-1 IgG levels occurred years before clinical 
manifestation of MS.229 EBNA IgG is therefore a robust prospective biomarker for MS risk. 
Together these data imply EBV infection is a prerequisite for developing MS.
  In MS patients increased serum IgG responses towards EBNA-1 are consistently 
shown, whereas responses towards other viral antigens such as EA-D and VCA are more 
variable.227 Whereas some show EBNA-1 IgG levels, but not VCA IgG, correlate with lesion 
load on MRI and disease severity,145,230 others show VCA IgG correlate with brain atrophy 
and lesion load.231,232
  The sero-epidemiological evidence of the association between EBNA-1 IgG levels and 
MS is compelling, but the biological relevance of these antibodies is uncertain. Potentially, 
the increased EBNA-1 IgG levels are a consequence of the MS-associated genetic factors. 
Serum EBNA-1 IgG titers are shown to contribute to MS-risk independent of the dominant 
MS-risk allele HLA-DRB1*1501.233 Still, HLA-DRB1*1501 carriership correlates with increased 
EBNA-1 titers in the general population,234,235 which points towards an independent 
additive effect. Potentially, other MS-associated genetic factors associate with EBNA-1 IgG 
levels. Alternatively, IgG specific for epitopes in EBNA-1 cross-react with yet undefined 
CNS autoantigens like described for SLE and RA.208,209 If cross-reactive EBNA-1 IgG are 
involved in MS pathogenesis, their intrathecal synthesis is anticipated. Oligoclonal bands 
of MS patients have been reported to bind EBV antigens.236 However these are low affinity 
poly-specific antibodies that are a consequence of the chronic inflammatory response in 
MS patients.237,238 What portion of these are functionally relevant high-affinity antibodies 
and if they are produced intrathecally remains to be determined.
Epstein-Barr virus and multiple sclerosis: intrathecal prevalence
Aberrancies in the humoral response against EBV suggest the control of EBV in MS patients 
is compromised which suggests EBV is more prone to reactivate which may be reflected in 
the viral load. Although in some MS patients an increased EBV load is detected in PBMC, 
these results were not significant compared to healthy EBV carriers.239
  Alternatively, EBV may induce MS pathology by infection or CNS resident cells or 
by reactivation of infected intrathecal B-cells. In some studies EBV genomes are detected 
by PCR in the CSF of a minority of MS patients,157,240–242 this suggests ongoing lytic EBV 
infection is not a common CNS feature of MS. Furthermore, some report these findings 
were indifferent from other neurological diseases which refutes disease association.241 
Even though, the highly cell-associated nature of latent EBV may lead to misdiagnosis in 
cell-poor CSF, these findings argue against fulminant lytic intrathecal infection in MS. In 
sharp contrast with these findings, several studies by the group Aloisi and collaborators 
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and perivascular cuffs of active WM lesions in the majority of MS patients.85,243–246 They 
showed most EBV infection in B-cells expressed the latency III growth program with the 
expression of EBNA-2 and LMP1.243 Part of EBV-infected B-cells expressed the IE and E lytic 
viral antigens BZLF1 and BFRF1 which indicates of intrathecal reactivation of EBV.243,245 
These data implicate a key role for active EBV in WM and GM pathology of MS patients. 
However, these results could not be confirmed by others.247,248 In these studies EBER 
expressing B-cells were detected in a single MS but not in 105 other MS cases including 
12 that were documented as EBV-positive by Aloisi and colleagues. They conclude EBV 
infection is not a characteristic feature of the MS brain. This discrepancy may either be 
methodological or relate to selective presence of EBV in ectopic follicles near early MS 
lesions, which are rarely sampled.223,246,249 Conclusive evidence of intrathecal EBV infection 
in MS patients is of fundamental importance to decipher the role of EBV in the etiology 
and pathology of MS. Despite this ongoing debate, even in absence of virus within the 
CNS, EBV may also evoke pathogenic immune responses elsewhere. 
Epstein-Barr virus and multiple sclerosis: T-cell responses
Systemic elevated EBV-specific humoral responses suggest also the cellular immunity 
against EBV is altered. The overall peripheral T-cell responses, mainly of CD8+ T-cells, to 
EBV infected B-cells are decreased in MS patients, as determined by IFNγ secretion of PB-
derived CD4+ and CD8+ T-cells stimulated by EBV-infected autologous B-cells (BLCL).250 
Notably, these results may reflect reduced numbers of BLCL-specific CD8+ T-cells, or 
reduced functionality analogous to findings in SLE and RA patients.179,207,217,218 Other 
studies that document increased frequencies of CD8+ T-cell frequencies specific for 
immunodominant latent peptides (EBNA-3A and LMP2A)146 and antigen-HLA pentamers 
(EBNA3C and LM2A)224 or lytic viral antigens-HLA pentamers (BZLF1 and BMLF1)224,245 in MS 
patients support the latter. Peripheral CD8+ T-cell frequencies specific for lytic antigens 
correlate with disease activity,224,245 but show decreased polyfunctionality224 possibly 
due to exhaustion. These data support the hypothesis that viral reactivation due to an 
impaired CD8+ T-cell control induces MS pathology. It is also hypothesized that a defective 
peripheral CD8+ T-cell control of EBV reactivation leads to an expanded population of 
EBV-infected B-cells. Because EBV is able to differentiate B-cells in an Ag-independent 
manner without negative selection, these may include autoreactive B-cells.224
  To a lesser extent peripheral CD4+ T-cell responses are altered in MS patients. EBNA-
1 specific CD4+ Th1 (but not Th17) effector memory frequencies are selectively increased 
and show broadened specificity against EBNA-1 peptides.148,239 Part of EBNA-1 specific 
CD4+ T-cells cross-react with myelin-derived peptides.239 Also BALF5-specific CD4+ T-cells 
cross-react with myelin basic protein (MBP).76 This suggests EBV can induce virus/host 
cross-reactive CD4+ T-cell responses due to molecular mimicry.
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  EBV infection also induces expression of αB-crystallin in B-cells, an antigen that is 
normally restricted to the CNS and is strongly upregulated in MS lesions.46,251 αB-crystallin 
peptides are selectively presented via HLA-DR to pro-inflammatory IFNγ producing CD4+ 
T-cells.251,252 EBV may therefore induce autoreactive T-cells.
  Another possible implication of EBV in inducing auto-aggressive T-cells is suggested 
by the altered autoantigen processing and presentation as is shown in a rhesus monkey 
EAE model. Here, B-cells infected with an EBV-related lymphocryptovirus are selectively 
capable of presenting a MOG core epitope that is normally degraded. Lymphocryptovirus 
infected B-cells may therefore selectively be capable of inducing autoaggressive T-cell 
responses.253 It is currently unknown if this also holds true for human B-cells and EBV.
  If EBV-specific or EBV-induced autoaggressive T-cells are involved in the 
immunopathogenesis of MS, intrathecal enrichment of specific clones is anticipated. 
Several studies have consistently shown intrathecal EBV-specific T-cell responses using 
various methods. Increased CD4+ T-cell responses towards EBV-infected B-cell lines (BLCL) 
were reported in MS patients but in this study the cognate Ag was not defined.254 Early 
in disease increased CD8+ T-cells frequencies specific for latent (EBNA-3A) and lytic viral 
antigens (BMLF1) were shown using HLA-peptide tetramers in CSF.255 Intrathecal CD4+ 
and CD8+ T-cells responses towards autologous dendritic cells laden with total EBV and 
EBNA-1 lysates (but not CMV or myelin lysates) were increased in MS patients.256 In one 
patients a cross-reactive BALF5 and myelin basic protein specific CD8+ T-cell clone was 
identified using synthetic peptides.257 T-cell receptor (TCR) sequencing of intrathecal 
T-cells showed sequences that overlap with previously described EBV-specific CD8+ 
TCRs, including the immunodominant lytic antigen BMLF-1.258 In one study by the 
group of Aloisi and colleagues, CD8+ T-cells were shown to closely interact with BFRF-1 
expressing B-cell in a GM lesion and express granzyme B and membrane bound CD107a, 
indicative of recent degranulation and cytotoxicity.244 These data strongly suggest a pro-
inflammatory T-cell response in the CNS that is fueled by reactivation of EBV. However, in 
light of the current debate on EBV infected B-cells in the CNS of MS patients, these data 
need independent confirmation. Detailed characterization of T-cells specific for EBV or 
candidate autoantigens is therefore warranted.
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T-cells are widely considered pivotal in the initiation or perpetuation of MS lesions and are 
thought to recognize CNS-specific antigens. Reactivity towards candidate MS-associated 
autoantigens (cMSAg) is mostly assessed in PB of MS patients and controls. While some show 
elevated cMSAg-specific T-cell responses in MS patients, others find similar frequencies in 
healthy controls and contradict disease association. These conflicting outcomes that may 
be due to caveats in the experimental design, lack of standardization of applied assays, HLA 
mismatched patients and controls and the commonly small sample sizes. Likely, disease-
initiating auto-aggressive T-cells are enriched in the CNS of MS patients, early in disease 
development. In Chapter 2, we setup a platform to simultaneously determine CD4+ 
and CD8+ T-cell responses towards endogenously synthesized candidate antigens and 
determined intrathecal T-cell responses towards 7 putative MS-associated autoantigens 
in CIS and early stage MS patients.
  Human herpesvirus (HHV) infections are associated with several non-infectious 
neurological diseases, including MS. However, due to the highly cell-associated nature 
of HHVs, intrathecal presence of herpesvirusses may often be misdiagnosed in cell-poor 
CSF samples. The prevalence of EBV in the CNS of MS patients is debated. Evidence of 
intrathecal HHV infection is of fundamental importance to decipher the etiological role 
in MS pathogenesis and other neurological diseases. In Chapter 3 we determined the 
prevalence of all known HHV infections in CSF cell pellets of a large cohort of MS patients 
and other neurological disease patients lacking typical clinical signs of infection, sampled 
early after onset of disease symptoms.
  Systemic EBV-specific humoral immune responses, particularly EBNA-1, are elevated 
in MS patients. Serum EBNA-1 IgG levels are elevated before onset of MS and subsequently 
correlate with disease activity and prognosis. However, the biological relevance of these 
antibodies is uncertain. Intrathecal synthesis of high affinity EBV-specific IgG is anticipated 
if they are involved in the immune pathogenesis of MS. In Chapter 4 we determined the 
spectrum of EBV antigens recognized in serum and CSF, and defined highly specific B-cell 
epitopes in the immunodominant EBNA-1. Next, we determined whether the highly 
EBNA-1-specific IgG are produced intrathecally in MS and non-infectious neurological 
disease patients.
  Alternatively, the increased peripheral EBNA-1 specific IgG in MS patients is a 
consequence of a shared genetic background. MS-associated genetic factors may either 
influence EBV latency in B-cells, or affect EBV-specific humoral response. The contribution 
of MS-associated genetic risk variants in EBNA-1 and EA-D specific IgG responses was 
determined in Chapter 5.
  EBV-specific T-cell responses may be involved in MS immunopathology. Intrathecal 
virus-specific T-cells may recognize EBV-infected cells in the brain or cross-react with 
CNS antigens. Auto-aggressive T-cells may recognize autoantigens induced in, or 
selectively presented by EBV infected B-cells. In Chapter 6 we determined reactivity 
of intrathecal T-cells towards autologous EBV-infected B-cells in early MS patients and 
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controls. Subsequently, we assayed the specific EBV-antigens recognized by these CSF-
derived CD8+ T-cells, including EBV-induced αB-crystallin. In Chapter 7, we determined 
the phenotype and function of T-cells at the site of immunopathology; the MS lesion. In 
paired post-mortem blood, CSF, NAWM and white matter lesion tissue biopsies of a large 
cohort of end-stage MS patients we characterized the phenotype, clonal repertoire and 
reactivity towards a panel of candidate MS-associated autoantigens and autologous EBV-
infected B-cells antigen specificity of T-cells. 
  Key findings are summarized, their merits discussed in context of current literature 
and future directions for further research are proposed in Chapter 8.
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Abstract
Multiple sclerosis (MS) pathology is potentially orchestrated by autoreactive T-cells, but 
the antigens recognized remain unknown. A novel antigen presenting cells (APC)/T-
cell platform was developed to determine intrathecal CD4+ and CD8+ T-cell responses 
to candidate MS-associated autoantigens (cMSAg) in clinically isolated syndrome (CIS, 
n=7) and MS (n=6) patients. Human cMSAg encoding open reading frames (n=8) were 
cloned into an Epstein–Barr virus (EBV)-based vector to express cMSAg at high levels in 
EBV-transformed B-cells (BLCLs). Human cMSAg cloned were myelin-associated MAG) and 
-oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), proteolipid protein 
(PLP), ATP-dependent potassium channel ATP-dependent inwards rectifying potassium 
channel 4.1 (KIR4.1), S100 calcium-binding protein B (S100B), contactin-2 (CNTN2), and 
neurofascin (NFASC). Transduced BLCLs were used as autologous APC in functional T-cell 
assays to determine cMSAg-specific T-cell frequencies in cerebrospinal fluid derived T-cell 
lines (CSF-TCLs) by intracellular IFNγ flow cytometry. Whereas all CSF-TCL responded 
strongly to mitogenic stimulation, no substantial T-cell reactivity to cMSAg was observed. 
Contrastingly, measles virus fusion protein-specific CD4+ and CD8+ T-cell clones, used 
as control of the APC/T-cell platform, efficiently recognized transduced BLCL expressing 
their cognate antigen. The inability to detect substantial T-cell reactivity to eight human 
endogenously synthesized cMSAg in autologous APC do not support their role as 
prominent intrathecal T-cell target antigens in CIS and MS patients early after onset of 
disease.
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Introduction
MS is a chronic neurological disorder characterized by inflammation, demyelination, and 
axonal loss leading to accumulative disability.1 MS immunopathology has been widely 
studied in EAE models.2 EAE is induced by immunization of animals using various, mainly 
myelin-derived CNS proteins, or by adoptive transfer of autoreactive T-cells. Autoreactive 
CD4+ and CD8+ T-cells are analogously assumed to orchestrate MS pathology, but 
candidate MS autoantigen (cMSAg) targets remain enigmatic.1,2
  Several cMSAgs have been proposed including oligodendrocyte-specific 
proteins like myelin-associated glycoprotein (MAG), myelin basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), glia-specific proteins 
like inwards rectifying potassium channel (KIR4.1, ATP-dependent inwards rectifying 
potassium channel 4.1) and S100 calcium-binding protein (S100B) and neuron-specific 
proteins like contactin-2 (CNTN2) and neurofascin 155kD isoform (NFASC).1,2 The majority 
of studies detailing cMSAg-specific T-cells in MS patients assayed peripheral blood with 
conflicting outcome.1,2 Some observed increased auto-reactive T-cell frequencies in MS, 
while others described equivalent numbers in patients and controls questioning their role 
in MS.3 The poor correlation between blood and intrathecal T-cell phenotypes, and TCR 
repertoires4 dispute extrapolation of systemic T-cell data to MS immunopathology.
  Most studies assayed intrathecal cMSAg-specific T-cell responses using autologous 
PBMC, pulsed with synthetic peptides or recombinant (animal) cMSAg, as APC.2 This 
strategy has several limitations.2,3 First, cMSAg of different species and bacterial-produced 
antigens have a different amino acid composition and conformation compared with 
native human cMSAg, respectively, which potentially affect processing and presentation 
of the cognate epitope.5 Second, peptide binding is highly HLA allele-specific. Distinct 
HLA alleles are dominant MS risk or even protective factors.1 Thus, differences in cMSAg 
T-cell responses in MS patients and controls may be due to intercohort HLA genotype 
disparity1 ensuing mandatory HLA matching of patients and controls. Third, CD8+ 
T-cells preferentially recognize endogenously synthesized proteins. This is only partially 
overcome using cMSAg-spanning synthetic peptides as corresponding epitopes may not 
be presented when processed intracellularly and might need length optimization.5 Finally, 
previous studies commonly used superphysiological peptide concentrations, typically in 
the 10–250 μM range, which may lead to activation of disease-irrelevant T-cells expressing 
low-avidity TCR.6
  To overcome the aforementioned limitations we developed a novel APC/T-cell 
platform that facilitates high and stable expression of individual cMSAgs in Epstein–Barr 
virus (EBV)-transformed B-cells (BLCL), an easy to generate and efficient APC system to 
assay CD4+ and CD8+ T-cell responses simultaneously by flow cytometry. This APC system 
was used to determine the frequency of CD4 and CD8 T-cells directed to eight different 
human cMSAgs in short-term cerebrospinal fluid (CSF)-derived T-cell lines (CSF-TCLs) 
obtained from MS (n=6) and clinically isolated syndrome (CIS; n=7) patients.
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Results and discussion
BLCL express and present recombinant proteins to CD4 and CD8 T-cells efficiently
The advantage of using immortalized BLCL as APC is their high expression of HLA class I 
and II (HLA-I/II) and costimulatory molecules crucial for T-cell activation. Ectopic expression 
of EBV nuclear antigen 1 facilitates episomal replication of the origin of latent replication 
(oriP) containing EBV genomes. We optimized an eukaryotic EBV-based vector, containing 
the EBV OriP and a geneticin transferase expression cassette, facilitating stable plasmid 
maintenance in BLCL.7 The original pNS vector was modified to clone and express human 
cMSAg proteins more efficiently (Figure 1A).
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Figure 1. EBV-based episomal pNS vector enables stable expression and efficient presentation 
of a cloned gene in BLCL to CD4+ and CD8+ T-cells. (A) Schematic representation of the pNS 
expression vector containing EBV origin of latent replication P (EBV oriP) for episomal replication in 
EBV-transformed B-cell lines (BLCLs). Combined kanamycin/neomycin transferase under control of the 
prokaryotic transposon Tn5 and eukaryotic herpes simplex type 1 (HSV-1) promoter enabled positive geneticin 
selection of transduced BLCL. Antigens of interest were cloned in BamHI site and expressed under control of SRα 
promoter and SV40 polyadenylation signal (poly A). (B) Histograms of flow cytometry analyses of cells gated for 
lymphocytes, based on forward and side scatter and viability using fluorescent viability staining of representative 
BLCL transduced with pNS encoding measles virus fusion protein (MVF) and seven individual candidate human 
MS-associated autoantigens (cMSAg) cultured under gentamycin selection for >2 weeks. Dark area represents 
antigen-specific staining and the dotted line represents the respective isotype control staining. Vertical axis shows 
cell counts normalized to mode. Histograms are representative of two independent experiments. (C) HLA-matched 
BLCL pulsed with increasing synthetic peptide concentrations encompassing epitopes of MVF-specific CD4+ (4-
F99) and CD8+ (2-F40) T-cell clones (TCCs) and stably pNS.MVF-transduced BLCL expressingMVFprotein were 
cocultured for 24 h with respective TCC. IFNγ levelswere determined by ELISA. As controls, TCC were nonstimulated 
(TCC), stimulated with phorbolmyristate-acetate and ionomycin (P/I) or cocultured with untransfected 
BLCL (mock) and BLCL transducedwith empty pNS vector (pNS.empty). Data are shown as mean±SD (n=4) and 
are pooled from two independent in-duplo experiments.
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  To validate that stable transduction of BLCL leads to efficient processing and 
presentation of endogenously expressed antigen by both HLA-I and II, we cloned measles 
virus fusion protein (MVF) into the pNS vector (pNS.MVF). The pNS.MVF-transduced 
BLCL grown for several weeks under geneticin selection showed uniform MVF surface 
expression (Figure 1B; left panel) (Supplementary Figure 1A). Next, we assayed recognition 
of transduced HLA-matched BLCL (GR-BLCL) by well-defined MVF-specific CD4+ (4-F99) 
and CD8+ T-cell clones (2-F40; TCCs).8,9 Both TCC showed a dose-dependent response to 
BLCL pulsed with their cognate peptides (Figure 1C). TCCs cultured alone or cocultured 
with mock-transduced GR-BLCL secreted negligible IFNγ amounts, whereas both TCCs 
stimulated with phorbolmyristate-acetate and ionomycin (P/I) secreted high IFNγ levels. 
Notably, both TCCs efficiently recognized pNS.MVF-tranduced GR-BLCL, but not empty 
vector (pNS.empty)-transduced BLCL (Figure 1C). Thus, the pNS/BLCL-system facilitates 
high expression and efficient presentation of CD4+ and CD8+ T-cell epitopes of an 
endogenously expressed antigen.
No evidence for intrathecal T-cell responses to cMSAg in CIS and MS patients
No consensus exists on autoantigens specifically recognized by systemic and intrathecal 
T-cells in MS. Limited studies have addressed cMSAg-specificity of CSF-derived T-cells in 
MS.10–12 Ideally, antigen specificity of CSF-derived T-cells is determined ex vivo. However, 
limited cell numbers in surplus CSF samples, particularly in CIS cases, prohibited functional 
T-cell assays for multiple cMSAgs directly (Table 1). Therefore, we generated short-term 
CSF-TCLs by stimulating CSF-derived cells from CIS and MS patients in a single round of 
mitogenic stimulation to characterize intrathecal human cMSAg-specific CD4+ and CD8+ 
T-cell responses simultaneously and to perform repetitive analysis to determine interassay 
variability.
Table 1. Patient demographics and diagnosis   
Patient 
ID 
Age; 
Sexa 
Disease 
entityb 
Disease 
durationc 
CSF WBC 
(x103/mL)d 
CSF 
OCBe 
IgG 
indexf 
Follow-up 
(months) 
Progression 
to MSg 
  1 37; F CIS   10   5 no 0.5 50 no 
  2 34; F CIS   22   5 no 0.5   3 no 
  3 21; F CIS     8   5 multiple 0.7 46 yes, to RRMS 
  4 25; M CIS     1 12 multiple 0.9 42 yes, to RRMS 
  5 37; M CIS     4   3 no 0.5 25 no 
  6 37; M CIS     2   2 no 0.5 24 no 
  7 42; M CIS     4   3 multiple 0.7 30 no 
  8 51; F PPMS   54 11 multiple 0.9   2 n.a. 
  9 36; F RRMS 102   4 multiple 1.4 29 n.a. 
10 34; F RRMS     9 14 multiple 1.0 26 n.a. 
11 29; F RRMS   30 25 multiple 1.0 32 n.a. 
12 41; F RRMS   36   7 multiple 2.1 51 n.a. 
13 38; F RRMS   18   5 n.d. 0.5 51 n.a. 
aAge in years; F, female; M, male. 
bCIS, clinical isolated syndrome and PP, primary progressive MS; RRMS, relapsing remitting MS. 
cDisease duration in months at time of lumbar puncture. 
dWhite blood cell count (WBC) per mL cerebrospinal fluid (CSF). 
ePresence and number of oligoclonal bands (OCB) in CSF only; n.d. not determined 
fIgG index was determined by the following formula: (CSF [IgG] ⁄ CSF [albumin])  ⁄ (serum [IgG] ⁄ serum 
[albumin]). 
gNo, no progression to MS during follow-up; n.a. not applicable 
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  The coding sequences of human cMSAg for oligodendrocyte (i.e. MAG, MBP1, 
MOG, and PLP), glia (i.e. KIR4.1 and S100B) and neuronal origin (i.e. CNTN2 and NFASC) 
were cloned in the pNS vector and subsequently used to nucleofect autologous 
BLCL (autoBLCL). Flow cytometry showed that all viable transduced BLCLs uniformly 
expressed the respective cMSAg intracellularly after 2–3 weeks of geneticin selection 
(Figure 1B). Whereas all assayed cMSAg, except MBP1 and S100B, are transmembrane 
proteins only MOG- and CNTN2-specific mAb target extracellular domains of the protein. 
Transmembrane localization of MOG and CNTN2 was confirmed by extracellular staining. 
Unfortunately, no MBP1-specific mAb was available.
γ
γ
+
+ +
+
γ
γ
+ +
Figure 2. CD4+ and CD8+ T-cell reactivity to candidate MS-associated human autoantigens in CSF-
derived T-cell lines from CIS and MS patients. (A) CSF-derived T-cell lines (CSF-TCLs) generated from patients 
diagnosed for clinically isolated syndrome (CIS; n=7) and MS (n=6) were stimulated with phorbolmyristate-
acetate and ionomycin (P/I). Phenotype and frequency of responding T-cells was determined by flow cytometry. 
Cells were gated on viable lymphocytes using fluorescent viability staining, expression of CD3, 
subdivided on CD4 and CD8 and subsequently intracellular IFNγ expression. Colored dots and 
vertical bars represent median reactivity and range of individual CSF-TCL. (B) Autologous BLCL 
(autoBLCL) were nucleofected with pNS vector encoding candidate MS-associated antigens (cMSAgs; n=8) and 
positively selected in culture for >2 weeks with geneticin to generate stable cMSAg expressing BLCLs. CSF-TCLs 
were cocultured with cMSAg-transduced autologous BLCLs. The netto frequency of cMSAg-specific T-cells, 
corrected for reactivity toward pNS.empty-transduced BLCL, is shown as percentage of IFNγ+ CD4 (left panels) 
or CD8 T-cells (right panels). Threshold for positive cMSAg T-cell reactivity, indicated by a horizontal dashed line, 
was calculated as 3.09-times SD of all mean netto cMSAg-specific CD4+ and CD8+ T-cell responses, allowing 
a 0.1% one-tailed false discovery rate. Significance of variation in T-cell reactivity per cMSAg was determined 
by one-way analysis of variance for CD4+ and CD8+ T-cells independently. CSF-TCL T-cell reactivity to cMSAg-
transduced autoBLCLs was determined at least twice, except for RRMS patient #9  (red color) and #12 (black 
color), which were measured only once.
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  To determine the lower level of detection of antigen-specific CD4 and CD8 T-cells in 
T-cell lines using the APC/T-cell platform developed, we spiked a T-cell mixture consisting 
of two irrelevant varicella zoster virus-specific CD4+ (TCC 146) and CD8+ (TCC 38) with 
increasing numbers of the MVF-specific CD4+ and CD8+ TCCs and measured the response 
to pNS.MVF-transduced GR-BLCL by intracellular IFNγ flow cytometry.8,9 The estimated 
detection limit of CD4+ and CD8+ T-cells directed to endogenously expressed protein, here 
represented by MVF, in transduced GR-BLCL was 1 and 3%, respectively (Supplementary 
Figures 1B and 2). Next, the frequency of cMSAg-specific CSF-derived CD4+ and CD8+ 
T-cells was determined by coculturing CSF-TCL with human cMSAg-transduced autoBLCL. 
P/I stimulation of all CSF-TCL showed that the majority of CD4 and CD8 T-cells produced 
high levels of IFNγ indicating that the CSF-derived T-cells cultured were immunecompetent 
and not exhausted (Figure 2A). To correct for background T-cell reactivity (e.g. intrathecal 
EBV-specific T-cells recognizing BLCL),13 cMSAg-specific CD4+ and CD8+ T-cell responses 
were normalized for reactivity toward pNS.empty-transduced autoBLCL (Supplementary 
Figure 3). Interassay variation for CD4+ and CD8+ T-cell responses was determined by 
calculating the SD of all mean netto cMSAg-specific responses. The variation was lower for 
CD4+ T-cells (0.33%) as compared with CD8+ T-cells (0.86%). Consequently, the threshold 
for positive calls was set at 1.2% for CD4+ T-cells and 2.9% for CD8+ T-cells allowing a 
one-tailed 0.1% false discovery rate, respectively.14 This closely resembles the detection 
limit determined using titrated MVF-specific TCCs and MVF-transduced GR-BLCL as APC 
(Supplementary Figure 2). Notably, the only positive call for cMSAg reactivity was the 
CSF-TCL of patient #13 containing a median 1.4% (range 0.3–2.5%) frequency of NFASC-
specific CD4 T-cells. However, no significant variation was observed between pMSAg for 
CD4+ (p=0.74) and CD8+ T-cells (p=0.30, one-way analysis of variance) (Figure 2B).
Concluding remarks
Intrathecal autoreactive T-cells are anticipated to be involved in MS pathology, but we 
were unable to detect substantial CD4+ and CD8+ T-cell reactivity to a broad panel of 
cMSAgs (n=8) in short-term cultures of CSF-derived T-cells of seven MS and six CIS patients. 
Few studies enumerated intrathecal antigen-specific CD4+ and CD8+ T-cells responses 
simultaneously using endogenously processed antigen.2,3 Whereas antigen processing 
and presentation may differ between BLCL and the currently undefined local APC in MS 
lesions, the use of cMSAg-transduced autoBLCL as artificial APC represents a reasonable 
compromise to detect intrathecal cMSAg-specific T-cells. Congruent to our findings, Wuest 
and colleagues also did not observe significant reactivity of CSF-derived T-cells toward 
self-antigens using cell-, myelin-, and brain-derived lysate pulsed autologous dendritic 
cells used as APC.12
  Still, a cautious interpretation of our data is warranted, as there are a few limitations. 
First, the assay format is not well equipped to detect low frequencies of cMSAg-specific 
T-cells, as the overall background was 1.1±0.3% and 2.6±0.9% (mean±SD) reactive CD4+ 
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and CD8+ T-cells, respectively. Nevertheless, local frequencies of Ag-specific T-cells 
observed by others typically exceeded our detection limit in compartmentalized T-cell 
mediated diseases like Chronic Chagas’ Cardiomyopathy15 and autoimmune thyroiditis.16,17 
Moreover, using BLCL as APC we have previously detected profound frequencies (>5%) 
of intralesional T-cells. T-cells directed to the triggering herpes virus in patients with 
herpetic ocular diseases.18,19 Second, a limited number of 13 patients were included in this 
study, which warrants further studies on larger cohorts of patients and disease controls. 
However, we included patients early in disease development, particularly seven CIS 
patients. Notably, two of them progressed to RRMS during clinical follow-up, suggesting 
that intrathecal reactivity against the explored antigens did not contribute to their disease 
evolution.
  In conclusion, the inability to detect substantial intrathecal T-cell reactivity to eight 
human cMSAgs in CIS and MS patients do not support their role as prominent target 
antigen for intrathecal T-cell responses in CIS and MS patients.
Materials and methods
Patients and clinical specimens
Paired blood and CSF samples from CIS (n=7) and MS (n=6) patients were obtained as 
part of diagnostic workup at the Erasmus MC (Rotterdam, the Netherlands) (Table 1). No 
patient received immunomodulatory therapy at time of lumbar puncture, except one 
CIS patient (patient #2) who received Avonex treatment. CSF was always obtained >1 
month after start of clinical symptoms. The study was performed according to the tenets 
of the Helsinki declaration, approved by the local medical ethical committee and written 
informed consent was obtained from all participants.
Generation of BLCL and CSF-TCL
Isolation of PBMC and generation of autoBLCL were performed as described 
previously.8,13 CSF-TCL were generated from surplus CSF cells by stimulation with 1 μg/
mL phytohemagglutinin-L (Roche, Branfort, CT) in the presence of 30 Gray γ-irradiated 
allogeneic PBMC used as feeder cells.13 Cells were grown in RPMI-1640 supplemented 
with antibiotics and 10% heat-inactivated bovine (B-cells) or pooled human (T-cells) 
serum. T-cells received recombinant human IL-2 (25 U/mL) and IL-15 (25 ng/mL; Myltenyi 
biotec, Bergisch Gladbach, Germany) every 3–4 days and were harvested around day 14, 
aliquoted and stored frozen.13 Generation, characterization, and maintenance of MVF-
specific CD4+ and CD8+ TCC was described.8
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Cloning of human cMSAg in the EBV-based episomal pNS vector
The eukaryotic expression vector pNS.CD8α described by Mazda et al.7 was modified to 
the current pNS vector by removing murine CD8α by PvuII/HindIII digestion, generation of 
blunt ends using T4 DNA polymerase and subsequent self-ligation (all from New England 
Biolabs, Ipswich, MA) (Figure 1A). ORFs encoding human MAG, MBP1, MOG, PLP1, S100B, 
CNTN2, and NFASC were PCR amplified from cDNA clones obtained from Darmacon 
(Lafayette, CO) and cloned in pCR4.1-TOPO (Invitrogen). Restriction endonuclease target 
sequences engineered into amplification primers were used to shuttle ORFs to pNS vector’s 
BamHI site (Supplementary Table 1). ORFs encoding MVF were cloned from pEC12.MVF20 
and human KIR4.1 (Damacon) from a cDNA clone by SacI or SacII/SmaI digestion into pNS 
vectors’s BamHI site after generating blunt ends using T4 DNA polymerase, respectively. 
DNA sequences of all cloned vectors were verified by Sanger sequencing using an ABI 
prism 3130XL genetic Analyzer (Applied Biosystems, Foster City, CA) with pNS vector 
specific 5´- and 3´-end cMSAg flanking primers and if no overlapping sequences were 
obtained internal cMSAg-specific primers (data not shown).
Generation of BLCL expressing MVF and candidate MS-associated neuroantigens
BLCL were nucleofected using Amaxa Cell line nucleofection kit V (Lonza; Bazel, 
Switzerland) per manufacturer’s instructions and transduced cells positively selected 
using 500 μg/mL geneticin (Life Technologies; Carlsbad, CA) for >2 weeks. Expression 
of cMSAgs and MVF were determined by extracellular and intracellular flow cytometry 
on a FACSCanto II (BD Biosciences; San Jose, CA) using specific antibodies. Intracellular 
staining was performed using Cytofix/Cytoperm Kit (BD Biosciences) per manufacturer’s 
instructions. The following mAbs were used at predefined concentrations: Mouse-anti-
MVF (clone F3-5), mouse-anti-MAG (clone 513; Millipore; Darmstadt, Germany), mouse-
anti-MOG (clone 8–18C5; Millipore), mouse-anti-PLP1 (clone sc-73336; Santa Cruz; Dallas, 
TX), mouse-anti-KIR4.1 (clone 1C11; Sigma-Aldrich; St. Louis, MO), mouse-anti-S100B 
(clone 19/S100B; BD Biosciences), mouse-anti-CNTN2 (clone 372913; R&D systems; 
Minneapolis, MN), and rabbit-anti-NFASC (clone ab31457; AbCAM; Cambridge, UK). 
Secondary fluorescein-conjugated goat-anti-mouse IgG (BD Pharmingen; San Diego, CA) 
or swine-anti-rabbit IgG (Dako; Glostrup, Denmark) were used. Respective mouse IgG1, 
IgG2a, IgG2b, or Rabbit IgG isotypes were used as negative controls. Data analysis on 
viable stained cells was performed using FlowJo software version 10 (Ashland, OR). Gating 
strategy for BLCL is shown in Supplementary Figure 1A.
T-cell reactivity to endogenously expressed MVF in BLCL
CD4+ and CD8+ MVF-specific TCCs were incubated with pNS.MVF-transduced HLA-
matched BLCL (GR-BLCL). Negative controls included TCC alone, TCC cocultured with 
BLCL or BLCL nucleofected with the pNS vector without insert. Positive control for 
T-cell stimulation included stimulation with phorbolmyristate-acetate (50 ng/mL) and 
ionomycin (500 ng/mL) (Sigma-Aldrich). Additionally, TCC were incubated with GR-BLCL 
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pulsed overnight with increasing concentrations of synthetic peptide, range 0.01–10 μM, 
representing minimal T-cell epitopes.8 In all assays, 5 × 104 BLCL were cocultured with 
either TCC at a 1:1 ratio for 24 h. Secreted IFNγ was quantified by ELISA in conditioned 
culture medium (eBioscience; San Diego, CA). Experiments were performed twice.
  The detection limit of T-cell responses toward endogenously expressed antigen 
was determined by titrating the MVF-specific CD4+ (4-F99) and CD8+ TCC (2-F40) into a 
T-cell mixture, consisting of VZV-specific CD4+ (TCC 146; patient 4) and CD8+ TCC (TCC 
38; patient 3),9 ranging from 0.1 to 10% of either MVF-specific TCC in the T-cell mixture. 
T-cell mixtures (total 105 cells) were cocultured with pNS.MVF -transduced GR-BLCL in 
a 1:1 ratio for 6–8 h in the presence of Golgistop per manufacturer’s instructions (BD 
Biosciences). GR-BLCL transduced with pNS.empty and GR-BLCL pulsed overnight with 
3 μM of aforementioned synthetic peptides were used as negative and positive control 
APC, respectively. T-cells were phenotyped with fluorochrome-conjugated mAbs 
directed to CD3 (clone SP34-2) (BD Pharmingen; San Diego, CA), CD4 (clone SK3; BD 
Biosciences), and CD8α (clone RPA-T8; eBioscience) stained for viability (violet live/dead 
stain; Invitrogen), fixed, permeabilized, and subsequently stained for intracellular IFNγ 
(clone B27; BD Pharmingen) followed by flow cytometry. Lymphocytes were first gated 
based on forward and side scatter characteristics and viability using violet live/dead 
staining and subsequently on differential expression of surface markers CD3, CD4, and 
CD8 (Supplementary Figure 1B). Finally, intracellular IFNγ expression was defined for both 
gated T-cell subsets (Supplementary Figure 2). Experiment was performed twice.
Intrathecal T-cell reactivity to endogenously expressed human cMSAg expressed in 
autologous BLCL
CSF-TCL (105 cells) were cocultured with autoBLCL stably transduced with aforementioned 
cMSAg (n=8) in a 1:1 ratio for 6–8 h in the presence of Golgistop per manufacturer’s 
instructions (BD Biosciences). Negative and positive controls included CSF-TCL 
incubated with pNS.empty-transduced autoBLCL and CSF-TCL solely stimulated with P/I, 
respectively. T-cells were stained and analyzed using flow cytometry as described above 
(Supplementary n Figure 3). Experiments were performed at least twice, except for RRMS 
patient #9 and #12 where limited numbers of CSF-TCL cells were available.
Statistical analysis
Netto T-cell reactivity toward cMSAg-transduced BLCL was calculated by subtracting 
reactivity toward pNS.empty-transduced BLCL. Threshold for positive cMSAg T-cell 
reactivity was calculated as 3.09-times SD of all mean netto cMSAg-specific CD4+ and 
CD8+T-cell responses, allowing a 0.1% one-tailed false discovery rate.14 Significance of 
variation in T-cell reactivity per cMSAg was determined by one-way analysis of variance 
for CD4+ and CD8+ T-cells independently.
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Supplementary Figure 1. Gating strategy for EBV-transformed B-cells and T-cell subsets. (A) Cultures of 
EBV-transformed B-cells (BLCL) were stained for viability with the violet live/dead buffer and subsequently for 
intra-cellular or surface expression of candidate multiple sclerosis-associated antigens as depicted in Figure 1B. 
Viable BLCL were identified based on lymphocyte forward and side scatter characteristics and cell viability. (B) 
Cell cultures, consisting of T-cells and BLCL, were stained for surface markers CD3, CD4 and CD8 and viability 
using violet live/dead buffer. Viable T-cells were identified based on lymphocyte forward and side scatter 
characteristics, live cells and subsequently CD3 expression. Finally, viable CD3+ cells were separated into CD4+ 
and CD8+ viable T-cells.
Supplementary Figure 2. Estimation of CD4+ and CD8+ T-cell detection limit recognizing recombinant 
protein expressing EBV- transformed B-cells used as antigen presenting cells. EBV-transformed B-cells 
(BLCL) were nucleofected with a eukaryotic expression vector (pNS) encoding measles virus F (MVF) protein to 
generate stable high MVF protein expressing BLCL. Indicated percentages of two different MVF- specific T-cell 
clones (TCC), one CD4+ (clone 4-F99) and one CD8+ (clone 2-F40) TCC, were spiked into a T-cell population 
consisting of two irrelevant varicella zoster virus-specific CD4+ and CD8+ TCC. T-cell mixtures were co-cultured 
with MVF-expressing BLCL in a 1:1 ratio for 6 to 8 hrs at 37˚C in the presence of Golgistop and subsequently 
stained for intracellular IFNγ and surface CD4 and CD8 followed by flow cytometry analysis (black bars). Cells were 
gated for viable lymphocytes, based on forward and side scatter and cell viability using violet live/dead buffer, 
expressing CD3 and subsequently subgated for viable CD4+ and CD8+ T-cells expressing IFNγ. Frequencies of 
reactive T-cells are shown as percentage of IFNγ+ CD4+ or CD8+ T-cells. T-cell reactivity towards non-transduced 
BLCL pulsed overnight with 3 μM synthetic peptide encompassing the MVF-specific TCC cognate MVF epitopes 
were included as positive control (white bars). BLCL transduced with the empty pNS vector were used as 
negative control (grey bars). Data of an experiment, performed in monoplo, are shown. The experiment was 
performed twice.
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Supplementary Figure 3. T-cell reactivity towards endogenously synthesised cMSAg of a cerebrospinal 
fluid-derived T-cell line (CSF-TCL) of multiple sclerosis (MS) patient #11. Autologous EBV-transformed 
B-cells (BLCL) were nucleofected with the eukaryotic expression vector pNS encoding candidate human MS-
associated antigens (cMSAg; n=8) and positively selected in vitro with geneticin for >2 weeks at 37˚C to generate 
stable cMSAg expressing autologous BLCL. CSF-TCL generated from surplus CSF of patient #11 were co-cultured 
with cMSAg-transduced autologous BLCL in a 1:1 ratio for 6 to 8 hrs at at 37˚C in the presence of Golgistop 
and subsequently stained for intracellular IFNγ and surface CD3, CD4 and CD8 followed by flow cytometry 
analysis. Cells were gated for lymphocytes forward and side scatter characteristics, viability using violet live/
dead buffer and subsequently CD3 expression. Finally, viable CD3+ cells were subgated for CD4+ (pink) and 
CD8+ (blue) T-cells and subsequently intracelIular IFNγ expression. Frequency of reactive T-cells are shown as 
percentage of IFNγ+ CD4+ (pink) or CD8+ (blue) T-cells. The normalized frequency of cMSAg-specific T-cells, 
corrected for reactivity towards autologous BLCL transduced with the empty pNS vector (pNS.empty, is shown 
as netto percentage of IFNγ+ CD4+ or CD8+ T-cells (bold). CSF-TCL alone and co-cultured with non- transduced 
autologous BLCL served as negative controls. CSF-TCL stimulated solely with phorbolmyristate-acetate and 
ionomycin (P/I) served as positive control for T-cell activation. Data of an experiment, performed in monoplo, are 
shown. The experiment was performed twice.
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Abstract
Prevalence of eight human herpesviruses (HHV1–8) was determined by real-time PCR in 
cell-rich cerebrospinal fluid (CSF) samples, obtained early after disease symptoms, of Dutch 
patients with multiple sclerosis (MS) and other noninfectious central nervous system 
diseases (NIND). Whereas HHV1–8 DNA was undetectable in CSF samples of MS patients, 
HHV6 DNA was detected in a plexus neuritis case and HHV7 DNA in an ependymoma 
and a Behçets’ disease patient. However, intrathecal HHV infection was not detected. 
Data indicate that HHV1–8 are rarely detected in CSF of Dutch NIND patients and do not 
support the role of intrathecal HHV infection early after onset of disease symptoms in MS.
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Introduction
Human herpesviruses (HHV) are endemic worldwide. The HHV family includes eight 
members: herpes simplex types 1 (HSV-1; HHV1) and 2 (HSV-2; HHV2), varicella zoster 
virus (VZV; HHV3), Epstein-Barr virus (EBV; HHV4), cytomegalovirus (CMV; HHV5), human 
herpesviruses 6 (HHV6) and 7 (HHV7), and Kaposi’s sarcoma-associated herpesvirus (KSHV; 
HHV8). A hallmark of HHV is their ability to establish a lifelong latency of the host and 
reactivate intermittently to shed virus or cause recrudescent disease.1
  All HHV can infect lymphocytes during primary infection but also establish latency 
in specific lymphocyte subsets (e.g., HHV4, HHV6, and HHV7). Predominantly in central 
nervous system (CNS) disease, but also during normal immune surveillance, lymphocyte 
can pass the blood–cerebrospinal fluid barrier or the blood–brain barrier to enter the 
cerebrospinal fluid (CSF).2 The high prevalence of HHV infections worldwide and their 
ability to infect migratory lymphocytes argue for their potential etiopathogenic role in 
CNS diseases.3,4
  Multiple sclerosis (MS) is an inflammatory CNS disease leading to demyelination and 
neurodegeneration. Environmental risk factors, including infectious agents like viruses 
and bacteria, determine whether MS develops in genetically predisposed individuals.5–7 
Various herpesviruses including HHV3, HHV6, and, more recently, HHV4 have been 
suggested to be involved in MS pathology.6 In addition to MS, herpesvirus infections 
have also been advocated to trigger other neurological diseases without clinical evidence 
of an infectious origin.3 Current data on the potential role of HHVs in MS and other 
noninfectious neurological diseases are inconclusive.3,4,6  Contradictory studies have been 
reported on the association with MS and HHV3,8–13 HHV4,4,9–17 and HHV6 (Supplementary 
Tables 1 and 2).9–12,14,17–23 Discordant data on the etiologic role of HHV and CNS diseases 
may in part be due to the sampling interval after disease onset, content of the CSF 
samples analyzed, and methodology used to detect HHV DNA. The time window in which 
cell-free HHV is detectable in clinical samples like CSF after infection is usually short due 
to enzymatic degradation of the virus. Furthermore, HHVs are commonly highly cell-
associated and may often be misdiagnosed in cell-poor CSF samples.24,25
  The aim of the current study was to determine the prevalence of HHV infection in 
the Netherlands in a large cohort of patients with MS (n=53) and patients lacking typical 
clinical signs of infectious neurological disease (n=135) by analyzing cell-rich CSF samples 
obtained early after onset of disease symptoms.
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Materials and Methods
Patients and clinical specimens
At the Department of Neurology (Erasmus University Medical Center, Rotterdam, the 
Netherlands), between years 2004 and 2008, CSF samples from MS patients (n=53) and 
patients with clinical noninfectious neurological disease (NIND; n=135) were obtained by 
lumbar puncture. The CSF studied were surplus samples collected as part of the diagnostic 
workup within 2  weeks after onset of disease symptoms. The patient characteristics 
are summarized in Table 1. The MS patient cohort consisted of 28 cases with relapsing–
remitting (RRMS), 12 primary progressive (PPMS), and 13 patients with clinically isolated 
syndrome (CIS).26,27 The NIND patient cohort consisted of 135 cases suffering from a variety 
of clinical symptoms including cancer (e.g., leukemia and lymphoma;  n=25), headache 
(n=19), subarachnoid hemorrhage (n=8), Behçet’s disease (n=4), and epilepsy (n=4) (data 
not shown). A patient with clinically diagnosed herpetic encephalitis was included as 
positive control for the combined detection of HHV-specific DNA and RNA. Each enrolled 
patient had consented in future testing of archived clinical samples. The study was 
approved by the local ethical committee and performed according to the tenets of the 
Helsinki Declaration.
Isolation of DNA and RNA from CSF samples
CSF aliquots (2–5 mL) were centrifuged at 3,000×g for 10 min, and CSF cell pellets (CSFpel) 
and supernatant (CSFsup) were stored at −80˚C. Total nucleic acid was isolated using 
MagNA Pure LC total nucleic acid isolation kit combined with the MagNA Pure LC isolation 
station (Roche Diagnostics, Mannheim, Germany) from the CSFpel or 200 μL CSFsup per 
manufacturer’s instructions.
Table 1. General characteristics of the study population 
Neurological disease entity Number  Gender male: female 
Mean age 
(years ±  SD)  
Multiple sclerosis   53 21 : 32 39 ± 12 
Relapsing remitting   29 10 : 19 39 ± 11 
Primary progressive   11 5 : 6 47 ±  9 
Clinically isolated syndrome   13 6 : 7 32 ± 10 
    Non-infectious neurological diseases  135 63 : 72 50 ±18 
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Quantification of cells and HHV1–8 DNA in CSF samples
Real-time quantitative PCR (qPCR) was used to determine both the total amount of cells 
and HHV1–8 genome equivalent copies (gec) in CSF-derived nucleic acid preparations 
using an ABI Prism 7500 and Taqman Universal Master Mix (both from Applied Biosystems, 
Nieuwerkerk, the Netherlands) as described previously.28,29 The qPCR assay used to 
determine the number of cells was based on the human single-copy housekeeping 
gene Homo sapiens hydroxymethylbilane synthase (HMBS).29 The HHV-specific sequences 
and target genes of the primers/probe pairs used are described elsewhere: HHV1 
gene US4 (glycoprotein G),28 HHV2 gene US6 (glycoprotein D),28 HHV3 gene ORF38 
(thymidine kinase),28 HHV4 gene BNRF1 (tegument protein p143),30 HHV5 gene UL75 (DNA 
polymerase),28 HHV6 gene U38 (DNA polymerase),31 HHV7 gene U57 (DNA polymerase),31 
and HHV8 gene ORF25 (major capsid protein).32 For standardization of the HHV-
specific qPCR assays, commercially available quantified DNA control panels (Advanced 
Biotechnologies, Columbia, MD) and high-titer virus preparations derived from culture 
supernatants were used.28 The sensitivity of the HHV-specific qPCR assays, as defined by 
the 95 % hit rate on the electron microscopy-counted virus stocks, was ~100 HHV gec/
mL. For HMBS standardization, an HHV4-transformed B-cell line was used as reference.29
Quantification of HHV transcripts in CSF samples
Nucleic acid preparations of HHV DNA-positive CSF samples were treated with recombinant 
DNase (Roche Diagnostics) followed by complementary DNA (cDNA) synthesis using 
random hexamer primers and subsequently subjected to qPCR analysis with the same 
HHV-specific primer/probe pairs used to detect the respective late HHV transcripts.29–31 
Reverse transcribed qPCR (RT-qPCR) analysis of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Applied Biosystems) was always run in parallel to calculate the 
relative HHV transcript levels, calculated by the following formula: ΔCt(GAPDH) = Ct(viral 
transcript) − Ct(GAPDH). In case of HHV6 U38 transcript detection, cDNA was synthesized 
using primers that cross-react between HHV6A and HHV6B in a well-defined splice 
junction in the HHV6 U100 gene region.33 HHV6 transcripts were amplified by a nested PCR 
and detected using ethidium bromide staining and agarose gel electrophoresis. Omission 
of reverse transcriptase in cDNA synthesis resulted in no detectable HMBS, GAPDH, and 
HHV qPCR signals demonstrating that the RT-qPCR signals obtained represent transcript 
levels (data not shown).
Statistical analysis
Statistical differences between CSF cell numbers were determined by the Mann–Whitney 
U test. p<0.05 was considered significant.
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Results
Estimation of cell numbers in CSF samples
Discordant data on the role of HHV in the etiology of noninfectious neurological diseases, 
particularly the association of MS and HHV3,8–13 HHV4,4,9–17 and HHV6,9–12,14,17–23 may be due 
to the CSF format assayed.24,25 Because most HHVs are lymphotropic and cell-free viral 
DNA is more vulnerable to enzymatic destruction, we postulated that qPCR analysis on 
DNA isolated from CSF-derived cells is more appropriate to assay the role of intrathecal 
HHV1–8 infections in relation to MS and other noninfectious neurological diseases.
  To estimate the cell content in the pelleted CSF samples of our study cohort, 
consisting of 53 MS and 135 NIND patients, we performed qPCR analysis specific for the 
single-copy human gene HMBS on nucleic acids extracted from the CSF cell pellets of all 
patients.29 The median estimated number of cells ± interquartile range in all CSF samples 
was 551±2,248 cells/CSF (range, 0–1.18×106). HMBS qPCR signal was undetectable in the 
CSF of six (4%) NIND, two (15%) CIS, six (55%) PPMS, and eight (28%) RRMS patients. The 
median estimated cell numbers in NIND patients (618±2,159; range 0–1.18×106 cells/CSF) 
was significantly higher compared to those in MS patients (166±3,019; range 0–217,432 
cells/CSF; p=0.04) (Figure 1A). Within the MS patient group, the median CSF cell numbers 
in PPMS patients (0±122; range 0–7,598) was significantly lower compared to both RRMS 
patients (654±2,172; range 0–27,196; p=0.037) and CIS patients (1,394±217,431; range 
0–217,431; p=0.013) (Figure 1B). In neither patient group, CSF cell numbers correlated 
with the patients’ age and gender (data not shown).
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Figure 1. Comparison of estimated cell numbers in cerebrospinal fluid (CSF) samples between patients 
with multiple sclerosis (MS) and noninfectious central nervous system disease (NIND). (A) Comparison 
betweenMS and NIND patients. (B) Comparison betweenMS patients with clinically isolated syndrome (CIS), 
primary progressive MS (PPMS), and relapsing–remitting MS (RRMS). Statistical differences between CSF cell 
numbers were determined by the Mann–Whitney U test.
Thesis final.indd   66 05-12-17   09:35
3Ch
ap
te
r 3
Intrathecal prevalence of human herpesviruses in MS patients and controls
67
Prevalence and state of intrathecal HHV1–8 infection in MS and NIND patients
We determined the presence of HHV1–8 DNA in CSF samples of all MS (n=53) and NIND 
patients (n=56) with suspected mononuclear pleocytosis, arbitrarily set at >1,500 HMBS 
gec/CSF (n=49) (Figure 1A). Whereas HHV1–8 DNA was undetectable in CSF samples of MS 
patients, HHV6 DNA was detected in one plexus neuritis case (patient #2) and HHV7 DNA 
in both an ependymoma (patient #3) and a Behçet’s disease patient (patient #4, Table 2). 
In comparison, CSF cell pellet of the plexus neuritis case contained a relatively high HHV6 
DNA load (4.3 HHV6 gec/CSF cell).
  Detection of HHV-specific DNA implicates a disease-relevant lytic HHV infection 
or the presence of latently infected cells that may have entered the subarachnoid space 
nonspecifically upon inflammation-induced disruption of the blood–brain barrier.24,25 To 
differentiate between both options, HHV DNA-positive CSFpel samples were analyzed for 
lytic transcripts of the respective HHVs. To validate our assays, we included a CSF sample of 
a herpetic encephalitis case (patient #1). We confirmed the clinical diagnosis by identifying 
HHV2 as causative agent but also detected HHV4 DNA in the same CSFpel sample. 
Consistent with the pathology of herpetic encephalitis, which is predominantly mediated 
by the cytopathic effect of the virus,34 we detected the HHV2 US6 transcript encoding the 
glycoprotein D and the presence of HHV2 in the patient’s CSFsup sample. Moreover, the 
HHV2 DNA load in CSFsup was lower compared to the paired CSFpel sample (Table 2). 
Notably, no viral transcripts and DNA of the respective HHVs were detected in both the 
CSFpel and paired CSFsup samples of the other HHV DNA-positive patients, respectively 
(Table 2; data not shown).
Table 2. Characteristics of patients with human herpesvirus DNA positive cerebrospinal fluid (CSF) samplesa 
    Estimated cell number and quantity of HHV-specific DNA and RNA in CSF 
Patient 
No. 
Gender; 
Age (yrs) 
Clinical 
diagnosis  
Cell number/      
CSF pellet 
HHV 
 type 
CSF pellet 
HHV gec/cell 
CSF supernatant 
HHV gec/mL 
HHV RNA level 
ΔCt (HHV-GAPDH) 
1 Male; 60 HHV2 encephalitis 
 
1.8X106 
HHV2 4.6x10-2 8.5x104 -3.95 
 HHV4 2.8x10-2 UND UND 
2 Female; 59 Plexus neuritis  3.2X103 HHV6 4.3 UND UND 
3 Male; 32 Ependymoma  1.17X106 HHV7 4.4x10-4 UND UND 
4 Female; 27 Behcet’s disease  1.9X103 HHV7 2.2x10-2 UND UND 
aHHV, human herpesvirus; gec/cell, genome equivalent copies per cell; ΔCt (HHV-GAPDH), delta Ct value of respective HHV and 
the hous-keeping gene GAPDH; UND, undetectable and ND, not determined. 
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Discussion
Central nervous system infections are predominantly caused by viruses, commonly 
HHVs and enteroviruses.25,35 However, the etiology of the vast majority of neurological 
diseases has not been defined.3 Epidemiological data and clinical presentation of specific 
sterile CNS diseases, particularly MS, hint at the etiopathological role of viruses.4,6 Human 
herpesviruses are potential candidates as they are endemic worldwide and establish 
a lifelong persistent infection with intermittent reactivation.1 The aim of the current 
retrospective study was to determine the prevalence and state of HHV1–8 infection in 
surplus CSF samples of MS patients (n=53) and individuals with neurological disease 
lacking typical clinical signs of CNS infection (n=135), who underwent a diagnostic lumbar 
puncture at early onset of disease symptoms in the Netherlands.
  Real-time PCR is considered the gold standard to detect and quantify viruses 
in clinical specimens. However, viral loads in CSF samples are commonly presented as 
genome equivalent copies per milliliter, potentially leading to misinterpretation or even 
false-negative results as most viruses, including HHVs, are cell-associated, and cell-free 
virus is more vulnerable to degradation.24,25 We postulate that diagnostic analysis aimed to 
unravel both the viral etiology and the burden of virus infection in CSF of patients with CNS 
diseases should preferably be performed on CSF cell pellets. The estimated cell content 
of the CSFpel samples, determined by HMBS-specific qPCR, varied extensively within 
and between CSF samples of MS and NIND patients (Figure 1A). Sterile CSF pleocytosis, 
arbitrarily set at >1,500 HMBS copies/sample, was found in 16 of 53 (30%) MS patients and 
correlated with the clinical MS subtype. Pleocytosis was detected in CSF samples of 6 of 13 
(46%) CIS and 9 of 28 (32%) RRMS patients compared to only 1 of 12 (8%) PPMS patients 
who had no signs of clinical relapse. The HMBS copy numbers were significantly higher 
in both CIS and RRMS patients compared to those in PPMS patients (Figure 1B). The data 
are in line with the reported association between CSF pleocytosis and clinical activity in 
MS.27 Moreover, 49 of 135 (36%) NIND patients showed signs of pleocytosis, which was not 
restricted to a specific CNS disease, and significantly more cells were detected in the CSF 
of NIND compared to MS patients (Figure 1A).
  The presence of HHV1–8 DNA in CSFpel samples was assayed by qPCR in all MS 
patients and 49 NIND cases with suspected pleocytosis. We did not detect HHV1–8 DNA 
in CSF samples of the MS patients, which concur with previous reports that did not found 
an association with HHV1, HHV2, HHV5, HHV7, and HHV8 and MS (Supplementary Tables 
1 and 2).9–12,14,36,37 However, our data contrast previous reports that documented a strong 
disease association between HHV3,10,12,13 HHV4,12,16,17 and HHV6 DNA10,11,14,17–22 in CSF. For 
all three HHVs, however, analogous studies on CSF samples of MS patients by multiple 
labs in different countries were also unable to confirm these findings.4,8,9,11,12,18,23,36 These 
discordant data are puzzling and may be related to various methodological variables that 
influence the sensitivity of detecting HHV DNA in CSF, including patient selection (i.e., 
country and MS entity) and sampling date of CSF in relation to disease symptoms, the 
CSF format analyzed (i.e., whole CSF, CSFsup, or CSFpel), and the PCR assays (i.e., qPCR, 
conventional and nested conventional PCR) used.24,25,38 However, detailed analyses of the 
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design and data of analogous studies did not identify a specific variable that explains the 
conflicting PCR data on the presence of HHV3, HHV4, and HHV6 DNA in the CSF of MS 
patients (Supplementary Tables 1 and 2).
  HHV-specific DNA was detected in 3 of 49 (6%) CSFpel samples of NIND cases with 
suspected pleocytosis. A similar low prevalence of HHV DNA-positive CSF samples of NIND 
patients have been reported in Sweden.39 We detected HHV7 DNA in an ependymoma 
and a Behçet’s disease patient and HHV6 DNA in a plexus neuritis case (Table 2). Because 
the HHV7 DNA load/CSF cell was very low and no viral DNA was detected in the paired 
CSFsup sample, an intrathecal HHV7 infection at time of sampling was excluded.24,25 
Moreover, as two and three additional ependymoma patients and a Behçet’s disease 
patient tested were HHV7 negative, the etiopathogenic role of HHV7 infection in both 
diseases is unlikely. Based on the same arguments, we conclude that the plexus neuritis 
case did not have an intrathecal HHV6 infection and that HHV6 was not associated with 
the disease. Moreover, the relatively high HHV6 DNA load (4.3 HHV6 gec/CSF cell) does 
not imply an active infection but most likely represents chromosomal integrated HHV6 
(ciHHV6).1,40 HHV6 is the only HHV that is integrated into the host germ line genome and 
can be detected in lymphocytes and hair follicle cells, at ~1–4 HHV6 gec/cell, in about 
1% of the US and UK population.41 Recent studies have shown that detection of HHV6 
DNA in CSF is commonly due to infiltrating ciHHV6 lymphocytes and does not indicate 
an active HHV6 CNS infection.41 Surplus blood sample of the plexus neuritis case was not 
available to determine the patient’s ciHHV6 status. Consequently, we postulate that both 
lymphotropic HHVs did not originate from the CNS itself but have most likely entered the 
subarachnoid space nonspecifically within migratory lymphocytes upon inflammation-
induced disruption of the blood–brain barrier.2
  In conclusion, our data do not support the role of intrathecal HHV infection in MS 
early after disease onset and demonstrate that incidental detection of HHV1–8 DNA in 
CSF samples of NIND patients does not indicate viral infection. Paired analysis of the 
CSFpel and CSFsup sample, supplemented with RT-qPCR to detect viral transcripts as 
shown for the HHV2 encephalitis case, can differentiate between virus-induced disease 
and nonspecific presence of HHVs in CSF samples. Future collaborative studies between 
MS centers are recommended to share clinical specimens and use standardized molecular 
assays to validate the postulated etiopathogenic role of HHVs in MS.15,38
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Abstract
Background: Recent studies suggest an intrathecal IgG response against Epstein-Barr virus 
(EBV) in multiple sclerosis (MS), implicating a pathogenic role for the virus in MS.
Objectives: To determine the spectrum of anti-EBV antibodies and B-cell epitopes within 
EBV nuclear antigen-1 (EBNA-1). Furthermore, to determine whether EBNA-1-specific IgG 
is produced intrathecally.
Study design: Immunoblot analysis was used to study the anti-EBV IgG response in serum 
and cerebral spinal fluid (CSF) in MS and controls. EBNA-1 B-cell epitopes were identified 
by immunoscreening of 12 residue long peptides, with 11 residue overlap, spanning 
EBNA-1. Thirteen peptides containing all immunoreactive regions were constructed and 
used in paired serum and CSF of MS patients (n=17) and controls (n=18). Subsequently, 
reactivity to the identified immunodominant peptide was analyzed in a large cohort of 
serum and CSF of MS patients (n=114) and disease controls (n=62).
Results: No difference was observed in the overall anti-EBV antibody diversity, but EBNA-
1 reactivity was increased in MS patients versus controls for immunoblot and ELISA 
(p<0.0001). Epitope analysis on EBNA-1 revealed one immunodominant region covering 
residues 394–451: EBNA-1394–451. Anti-EBNA-1394–451 IgG levels in serum and CSF were 
significantly higher in MS patients compared to controls. However, normalization for total 
IgG content of paired serum and CSF samples abrogated this disease association.
Conclusions: MS patients have normal overall anti-EBV antibody responses with increased 
reactivity to EBNA-1394-451. No evidence was found for intrathecal EBNA-1-specific IgG 
synthesis in MS.
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Background
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) resulting in demyelination and neurodegeneration. The disease develops in 
genetically predisposed individuals in response to environmental factors, most likely 
viral infections.1 Although many viruses have been postulated to be implicated in MS 
pathology, including varicella zoster virus,2 human herpesvirus 63 and measles virus,4 
none of these were irrefutably linked. However, recent studies advocate the role of 
Epstein-Barr virus (EBV) in MS.5 EBV seroprevalence is higher in MS patients compared to 
controls (99% versus 90–95%) and MS is shown to have a clear and reproducible clinical 
relation with infectious mononucleosis.6 Serum and intrathecal IgG levels to the latency-
associated EBV nuclear antigen-1 (EBNA-1) are elevated before onset of MS and correlates 
with disease activity and prognosis.5–10 Contrastingly, IgG to lytic EBV proteins including 
the viral capsid antigen (VCA) are not changed or only marginally increased, suggesting 
that EBV abnormalities in MS are associated with B-cell responses to latent EBV antigens.5,8 
Recently, Serafini et al. reported the presence of EBV-infected B-cells in meninges and 
perivascular regions of MS lesions.11 However, this observation as well as the involvement 
of a local EBV-specific B- and T-cell response is still under debate.5,12–14
Objectives
The aim of our study was twofold. To substantiate the postulated EBV-MS association, we 
first identified the overall anti-EBV antibody reactivity and defined EBNA-1 B-cell epitopes 
recognized by serum and CSF IgG of MS patients and controls. Second, we determined 
whether EBNA-1-specific IgG is produced intrathecally.
Study design
Study population
The study group included 114 MS patients and 62 patients with non-inflammatory 
neurological diseases (NIND) recruited at the Erasmus Medical Centre (Rotterdam, 
Netherlands) and the diagnosis were controlled by an experienced neurologist (RQH) 
based on diagnostic McDonald criteria for MS.15 As for the controls, the patient files and 
follow-up have been thoroughly checked to exclude possible MS in the NIND cohort. 
Serum and CSF samples were obtained for diagnostic purposes. For detailed EBNA-1 
epitope analyses we obtained sera from 18 healthy EBV seropositive individuals from the 
USA (n=7), The Netherlands (n=6) and Hong Kong (n=5). Sera from 4 EBV seronegative 
individuals were used for background measurements. Informed consent was obtained 
from all patients and the study was approved by the local ethical committee.
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Routine serology
Overall IgG antibody responses to EBV proteins and defined EBNA and VCA markers 
were determined by standardized immunoblot and ELISA assays as described before.16–18 
Before analysis, all serum samples were diluted one-hundred times and all CSF ten times. 
Antibody responses to human cytomegalo virus (HCMV) antigens were determined by 
ELISA using a purified glycine-extracted antigen preparation.19,20
Epitope mapping of EBNA-1
To specify EBNA-1 B-cell epitopes from healthy EBV seropositive individuals, the IgG 
reactivity was determined to 12-mer synthetic peptides (n=630), with 11 residue overlap, 
spanning the entire 641 residue long EBNA-1 sequence of the B95-8 EBV strain.21 Peptide 
synthesis and immunoscreening were performed as described elsewhere from 18 EBV 
seropositive healthy individuals from globally distinct regions.21,22 Mean OD450 values of 
four healthy EBV seronegative individuals was used to determine individual background 
value for each peptide.
EBNA-1 combipeptide reactivity
EBNA-1 peptide-specific IgG for the thirteen high affinity epitopes (Table 1) were 
determined by ELISA and validated by Western blotting using recombinant full-length 
EBNA-1 as described previously.16–18 Sera from peptide-immunized and pre-immune 
rabbits were used as positive and negative controls, respectively. Monoclonal antibodies 
OT1x and 2B4, reacting with an alpha-helical epitope located at residues 430–442 and a 
linear epitope at 446–451, respectively were used as positive controls.23,24 Additionally, 
sera from healthy EBV seropositive and seronegative donors were included in each ELISA 
assay for further standardization. Background levels of the serum ELISAs were determined 
using four EBV seronegative controls. Serum cut-off values (COV) were defined as the 
mean OD450 values plus 2-times standard deviation (SD) of these EBV seronegative 
controls. CSF ELISA COV was defined as the mean of all NIND CSF plus 2-times the SD. CSF 
ELISA OD450 values were standardized by dividing the mean of duplicate measurements 
for the clinical sample by the COV. Total IgG was determined with the PeliClass human IgG 
kit (Sanquin Reagents, Amsterdam, The Netherlands). EBNA-1-specific IgG was normalized 
for total IgG levels according to the following formula:
 OD450 EBNA-1 IgG CSF/OD450 EBNA-1 IgG serum
 IgGtotal CSF/IgGtotal serum
  Results were statistically analyzed with Mann–Whitney U and Spearman correlation 
test. P values <0.05 were considered statistically significant.
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Results
Clinical characteristics
Patients analysed included 114 MS and 62 NIND cases. The mean (±SD) age of MS and 
NIND patients was 38 (±11.5) and 44 (±18.6) years, respectively. Among MS patients, 
clinical definite MS was confirmed in 61 of 114 (54%) and clinically isolated syndrome (CIS) 
in 53 of 114 patients (46%). The mean (±SD) age at MS onset was 34.2 (±10.1) years. Within 
definitive MS group, 35 and 26 patients had a relapsing remitting (RR-MS) and primary 
progressive (PP-MS) course, respectively. The control group consisted of 62 NIND patients.
Similar repertoire of anti-EBV IgG response in serum and CSF of MS and NIND patients
Immunoblot analysis revealed a normal diversity pattern for anti-EBV IgG response in 
serum and CSF from both MS and NIND patients. Serum and CSF showed the characteristic 
limited diversity of anti-EBV IgG, involving antibodies directed to the recombinant 
antigens EBNA-1 (BKRF1), VCA-p18 (BFRF3), VCA-p40 (BDRF1) and the EBV transactivator 
protein Zebra (BZLF1), as observed for healthy EBV carriers (data not shown).16,18,22 MS 
cases frequently showed more intense EBNA-1 IgG reactivity compared to NIND (data not 
shown),25,26 which led us to investigate the anti-EBNA-1 response in more detail.
  Relevance of EBNA-1 for intrathecal anti-EBV response in MS patients was 
substantiated by testing all samples for VCA-p18 IgG using ELISA. Only serum, not CSF, 
showed significantly elevated VCA reactivity for MS compared to NIND. Parallel analysis of 
anti-HCMV IgG responses, revealed no differences between any of the study groups (data 
not shown).
 
Table 1. Epstein-Barr Nuclear Antigen 1 (EBNA-1) synthetic peptides used in ELISA 
Antigen aa Position aa sequence 
EBNA-1 1-44 MSDEGPGTGPGNGLGEKGDTSGPEGSGGSGPQRRGGDNHGRGRG 
Gly-Ala 
147-168 
174-195 
268-289 
AGAGGGAGGAGAGGGAGGAGG 
Gly-Arg 348-369 GGSGGRRGRGRERARGGSRERA 
EBNA-1 368-387 RERARGGSRERARGRGRGRG 
EBNA-1 394-420 PPRRPPPGRRPFFHPVGEADYFEYHQE 
EBNA-1 424-451 DGEPDVPPGAIEQGPADDPGEGPSTGPR 
EBNA-1 436-461 QGPADDPGEGPSTGPRGQGDGGRRKK 
EBNA-1 450-477 PRGQGDGGRRKKGGWFGKHRGQGGSNPK 
EBNA-1 460-486 KKGGWFGKHRGQGGSNPKFENIAEGLR 
EBNA-1 477-502 KFENIAEGLRALLARSHVERTTDEGT 
EBNA-1 506-531 GVFVYGGSKTSLYNLRRGTALAIPQC 
EBNA-1 459-607 
RKKGGWFGKHRGQGGSNPKFENIAEGLRALLARSHVERTTD
EGTWVAGVFVYGGSKTSLYNLRRGTALAIPQCRLTPLSRLPF
GMAPGPGPQPGPLRESIVCYFMVFLQTHIFAEVLKDAIKDLVM
TKPAPTCNIRVTVCSFDDGVDLP 
EBNA-1 614-641 VEGAAAEGDDGDDGDEGGDGDEGEEGQE 
EBNA-1 Epstein Barr Nuclear Antigen 1; aa amino acid; Gly-Ala Glycine-Alanine repeat; 
Gly-Arg Glycine-Arginine rich domain 
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Identifying EBNA-1 B-cell epitopes
Epitope mapping by immunoscreening of 630 twelve residue long peptides spanning 
the entire EBNA-1 antigen showed that the B-cell epitopes are largely confined to the 
N-terminal part of the protein (Figure 1). Here, mostly the glycine–alanine repeat 
consisting of residue 90–325 (Gly–Ala, EBNA-190–325) and to a lesser extent, the glycine–
arginine rich domain (Gly–Arg, EBNA-1348–369) contained many B-cell epitopes. However, 
numerous proteins contain similar repeat sequences gainsaying that the IgG responses 
measured for these Gly–Ala and Gly–Arg repeats are EBNA-1-specific.27,28 Thus, EBNA-1-
specific IgG responses in healthy EBV seropositive individuals are predominantly directed 
to EBNA-1394–451.
1 51 101 151 201 251 301 351 401 451 501 551 601
0
500
1000
1 51 101 151 201 251 301 351 401 451 501 551 601
OD450 values of EBV seropositive healthy individuals
US
NL
HK
A
B
Figure 1. Epstein-Barr virus nuclear antigen 1 peptidescan of serum IgG of heatlhy EBV carriers. Plot of 
enzyme-linked immunosorbent assay OD450 values of 18 Epstein Barr virus (EBV) seropositive healthy individuals 
from United States (US), The Netherlands (NL) and Hong Kong (HK) for 12-mer peptides with an 11 residue 
overlap spanning the entire EBV nuclear antigen-1 (EBNA-1) protein (A). Horizontal axis shows peptide number: 
peptide 1–630. Average of all sera (B) shows that high reactive B-cell epitopes are confined to the glycine–
alanine repeat (EBNA-190–325) and EBNA-1395–451.
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Increased IgG levels to EBNA-1394–451 in serum and CSF of MS patients
Elevated levels of EBNA-1 IgG have been reported in serum and CSF of MS patients.7–10 
To confirm this finding and to delineate recognized EBNA-1 B-cell epitopes, 13 partly 
overlapping immunoreactive EBNA-1-specific peptides (Table 1) were synthesized based 
on the preceding EBNA-1 B-cell epitope mapping (Figure 1). By computer aided minimal 
energy calculations, these longer peptides are predicted to acquire their normal structural 
conformation, as proven for EBNA-1394–451 by OT1x and 2B4 monoclonal antibody reactivity, 
and thereby include epitopes having secondary structures (data not shown).24
  IgG reactivity to these larger EBNA-1 peptides was determined in paired serum 
and CSF samples of 17 MS and 22 NIND patients. The overall pattern in serum and CSF 
was comparable between both patient groups (Figure 2). In contrast to CSF, serum IgG 
responses were mainly directed to Gly–Ala and Gly–Arg repeat domains of EBNA-1 (Figure 
2). Interestingly, in serum and particularly CSF of MS patients significantly increased IgG 
responses to EBNA-1394–461 and EBNA-1614–641 were detected (Figure 2). Low reactivity to 
EBNA-1450–477 advocates EBNA-1394–451 as the immunodominant region.
  Subsequent analyses of EBNA-1394–451 in a larger set of MS patients (n=114) and 
controls (n=62) substantiated the significantly elevated IgG levels to EBNA-1394–451 in MS 
patients (Figure 3A). Western blotting using recombinant EBNA-1394–451 confirmed ELISA 
data, showing that 95% of the MS sera and only 82% of NIND were EBNA-1394–451 positive.
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Figure 2. Epstein-Barr nuclear 
antigen-1 (EBNA-1)-specific 
IgG responses in serum and 
cerebrospinal fluid (CSF) 
samples towards EBNA-
1 peptides. Enzyme linked 
immunosorbent assay  of serum 
and CSF samples towards 
synthetic peptides covering the 
indicated residues of EBNA-1 
of multiple sclerosis patients 
(MS; n=17; white bars) and 
non-inflammatory neurological 
disease controls (NIND; n=22; 
grey bars). EBNA-1 peptide 
responses are presented as the 
relative IgG levels, calculated as 
described in the study design 
section. Median values (centre 
line), interquartile ranges (boxes) 
and minimal and maximum 
values (whiskers) are indicated. 
Results were statistically 
analysed with the Mann–
Whitney U test.
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Blood-brain barrier dysfunction attributes to increased anti-EBNA-1394–451 IgG levels in 
CSF of MS patients
The elevated CSF EBNA-1394–451 IgG levels may be due to intrathecal synthesis or leakage 
of serum IgG into the CSF compartment. To differentiate between both options, anti-
EBNA-1394–451 IgG levels in paired serum and CSF of 85 MS and 46 NIND patients were 
normalized for total IgG of the respective samples. Total IgG in serum of MS patients were 
significantly lower compared to controls (Figure 3C) and were significantly elevated in 
CSF of MS patients (Figure 3D). Contradictory, normalized anti-EBNA-1394–451 responses 
were similar between MS and NIND (Figure 3E) and anti-EBNA-1394–451 IgG levels in paired 
serum and CSF samples correlated significantly (Figure 3F). Thus, the data suggest that 
elevated anti-EBNA-1394–451 IgG responses in CSF of MS patients is not due to intrathecal IgG 
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Figure 3. Elevated IgG levels 
towards Epstein Barr nuclear 
antigen-1 protein residues 
394–451 (EBNA-1394–451) in 
cerebrospinal fluid (CSF) of 
multiple sclerosis (MS) patients 
is not attributable to intrathecal 
IgG synthesis. EBNA-1394–451-
specific IgG levels in serum(n=114) 
(A) and CSF samples (n=85) (B) 
of MS patients are significantly 
higher compared to patients with 
non-inflammatory neurological 
diseases (NIND; serum (n=62) 
and CSF (n=49)). Total IgG levels 
in serum (C) and CSF samples 
(D) of MS (n=102) and NIND 
patients (n=43) differ significantly. 
Normalized EBNA-1394–451 IgG 
levels (E), calculated as described 
in the study design section and 
the correlation of EBNA-1394–451 
IgG levels (F) in paired serum and 
CSF samples of MS (n=85) and 
NIND (n=32inE; n=49 in F) argues 
against intrathecal synthesis. (A–E) 
Horizontal lines represent median 
IgG levels. Results were statistically 
analysed with the Mann–Whitney 
U (A–E) and Spearman correlation 
test (F).
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synthesis, but more likely associated with blood-brain barrier dysfunction. This conclusion 
is also supported by correlation of the Q albumin (albumin CSF/albumin serum) with Q 
EBNA-1 (EBNA-1394–451 CSF/EBNA-1394–451 serum). Albumin was tested by routine diagnostic 
assays and the data were available for 77 MS cases and 31 NIND patients. Spearman 
correlation was statistical significant for the Q albumin and Q EBNA-1394–451 with r2=0.35 
(95% CI 0.17–0.51; p=0.0002).
Discussion
During the past three decades, several viruses including measles virus and human 
herpesviruses have been suggested to play a role in initiation and perpetuation of MS 
pathology.1,8 Whereas most MS-associated viruses have not withstood scrutiny in time, the 
long-held assumption of EBV as causative agent in MS has recently been reinforced by the 
demonstration of latently EBV-infected B-cells in MS lesions and increased IgG responses 
to latency-associated EBV protein EBNA-1 in both serum and CSF of MS patients.5,9–11 
Confirming previous findings, we observed that all MS patients were EBV seropositive, 
either by IgG immunoblot or ELISA. Immunoblot analysis revealed that the recognized 
spectrum of EBV proteins was similar in serum and CSF from MS and NIND patients. 
Moreover, both patient groups showed similar patterns of limited EBV antigen diversity as 
observed in healthy EBV carriers. This indicates that aberrant lytic replication is unlikely to 
play a role in MS and is in agreement with the non-elevated EBV–DNA levels in both CSF 
and circulation of MS patients.11,12
  The EBNA-1 immunoblot analyses confirmed increased aberrant EBNA-1 IgG 
reactivity in MS serum and CSF, suggestive of a role for latent EBV antigens in MS. 
Therefore, the main aim of our study was to delineate the EBNA-1 B-cell epitopes and 
to determine whether anti-EBNA-1 IgG is produced intrathecally in MS patients. We first 
identified EBNA-1 B-cell epitopes recognized by serum IgG in healthy EBV carriers and 
then compared it to the response in serum and CSF of MS and NIND patients. We identified 
one immunodominant EBNA-1 protein region (EBNA-1394–451) in serum and CSF samples of 
MS (Figure 2). The data are in line with a recent study by Sundström et al.,25 describing 
significantly elevated serum IgG titers to EBNA-1385–420 in MS patients. Notably, our data 
extend this association by also demonstrating significantly increased anti-EBNA-1394–451 
IgG levels in CSF next to serum (Figure 3). Sundström et al. also suggests that antibodies 
to EBNA-1-specific domains and HLA DRB1*1501 interact as risk factors.25 Although this 
has not been tested in our study, we do not expect this would influence the message of 
our study since the higher prevalence of HLA DRB found in MS would only contribute to a 
positive result.
  To compare distinct disease courses of MS (RRMS, PPMS and CIS), we included 
a relatively high number of PPMS cases (43% of MS samples; normal 10–15% of MS 
population). However, no significant differences between these subgroups were observed 
(data not shown).
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  We demonstrated that EBNA-1-specific IgG responses are elevated both in serum 
and CSF of MS patients compared to controls. Confirming earlier studies,8–10,12 this was 
not shown for other EBV proteins, including the VCA-p18 marker (data not shown). To 
determine whether increased EBNA-1-specific IgG levels in MS were due to intrathecal 
synthesis, we corrected for the possible dysfunction of the blood-brain barrier by 
normalizing for total IgG (Figure 3C and D). This revealed comparable normalized anti-
EBNA-1394–451 IgG levels in MS and NIND patients, arguing against intrathecal IgG synthesis 
(Figure 3E). Significant correlation between EBNA-1394–451 IgG levels in paired serum and 
CSF samples in both MS patients and controls strengthens this conclusion (Figure 3F).
  In conclusion, our data showed no evidence for intrathecal anti-EBV IgG synthesis, 
as also supported by others.29 Whether peripheral infection or immune responses play 
a pathogenic role remains to be determined. Notably, the MS-associated EBNA-1394–451 
region identified encompasses several immunodominant HLA DR-, including potential 
HLA DRB1*1501-restricted CD4+ T-cell epitopes.30,31 Moreover, MS patients have elevated 
frequencies and broader epitope reactivity of EBNA-1-specific CD4+ T-cells,31 including 
specific T-cells that cross-reacted with MS-associated myelin proteins.24,26–32 We hypothesize 
that in genetically predisposed individuals,1,33 EBNA-1 expression evokes a neuroantigen 
cross-reactive anti-EBNA-1 T-cell response, that upon entry into the CNS recognizes and 
targets cells expressing the cognate neuroantigen.
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Abstract
Objective: To assess whether multiple sclerosis (MS) genetic risk polymorphisms (SNP) 
contribute to the enhanced humoral immune response against Epstein Barr virus infection 
(EBV) in MS patients.
Methods: Serum anti-EBV nuclear antigen-1 (EBNA-1) and early antigen-D (EA-D) IgG 
levels were quantitatively determined in 668 genotyped MS patients and 147 healthy 
controls. Anti-varicella zoster virus (VZV) IgG levels were used as a highly prevalent, non-
MS associated control herpesvirus. Associations between virus-specific IgG levels and MS 
risk SNP were analyzed. 
Results: IgG levels of EBNA-1, but not EA-D and VZV, were increased in MS patients 
compared to HC. Increased EBNA-1 IgG levels were significantly associated with risk 
alleles of SNP rs2744148 (SOX8), rs11154801 (MYB), rs1843938 (CARD11) and rs7200786 
(CLEC16A/CIITA) in an interaction model and a trend towards significance for rs3135388 
(HLA-DRB1*1501). Additionally, risk alleles of rs694739 (PRDX5/BAD) and rs11581062 
(VCAM1) were independently associated and interacted with normal EBNA-1 IgG levels. 
None of these interactions were associated with EA-D and VZV IgG titers. 
Conclusions: Several MS-associated SNPs significantly correlated with differential IgG levels 
directed to a latent, but not a lytic EBV protein. The data suggest that the aforementioned 
immune related genes orchestrate the aberrant EBNA-1 IgG levels.
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Introduction
The etiology of multiple sclerosis (MS) involves genetic and exposure to environmental 
factors, including Epstein-Barr virus (EBV) infection.1–3 Genetic risk factors for MS include 
specific human leucocyte antigen (HLA) alleles and currently approximately 100 mainly 
adaptive immune related single nucleotide polymorphisms (SNP) with modest odds 
ratios (OR) compared to the major HLA-DRB1*1501 association4–6 and EBV exposure.7
  Almost all MS patients are infected with EBV, compared to 90-95% in healthy 
controls.7,8 A history of EBV-related infectious mononucleosis (IM) and elevated EBV nuclear 
antigen-1 IgG levels increases the risk to develop MS later in life.9–11 Recently, a meta-
analysis showed that antibodies against the latency associated EBNA-1 are consistently 
increased in MS patients compared to healthy EBV carriers, whereas results for the lytic 
viral capsid antigen (VCA) and early antigen D (EA-D), are more heterogeneous.7
  Epidemiological and genetic studies support interactions between EBV and HLA-
DRB1*15 on an additive scale.12–14 Whether the MS risk SNP are associated with enhanced 
IgG levels against EBV is currently unclear.13,14
We hypothesized that certain MS risk SNP are involved in the increased humoral immune 
response against EBV. Serum IgG levels against the EBV antigen EBNA-1 were measured 
and associations with MS risk SNPs were assessed. 
 
Table 1. Clinical and demographic characteristics of patients and controls 
 HC (n=147) MS (n=668) p-value 
Age at sampling (SD) in years 41 (12) 42 (13) 0.46 
Age at onset (SD) in years n.a. 34 (11) n.a. 
Number of female: male 78:60 477:190 5x10-4 
Disease duration in months (IQR) n.a. 98 (13-152) n.a. 
CSF abnormal 
IgG index raised 
Oligoclonal bands: 
Multiple 
1 additional 
 
 
n.a. 
82% 
72% 
 
61% 
12% 
 
 
n.a. 
Treated patients (%) n.a. 17 n.a. 
HC; healthy controls, MS; multiple sclerosis, SD; standard deviation, IQR; 
interquartile range, CSF; cerebrospinal fluid, n.a.; not applicable, CSF abnormal
defined as: either oligoclonal bands specific in CSF or a raised IgG-index >0.67 
or both.  
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Materials and methods
Patients and controls
Consecutive MS patients (n=668) seen at the MS center ErasMS between 2003 and 2013 
were included. A diagnosis of MS was made based on the 2005 McDonald criteria for MS15 
and sub classified as clinically isolated syndrome (CIS), primary progressive (PP), relapsing 
remitting (RR) or secondary progressive (SP) MS based on the clinical course of disease. 
Unrelated healthy controls (HC, n=147) were persons accompanying MS patients to our 
outpatient clinic. HC were age matched to the MS patients. Exclusion criteria for HC to 
participate in this study were prior neurological symptoms suggestive for MS or the use of 
immunomodulatory drugs for other autoimmune diseases. 
Standard Protocol Approvals, Registrations, and Patient Consents
This study was performed according to the guidelines specified in the declaration of 
Helsinki, approved by the medical ethical committee of the Erasmus MC and all participants 
gave written informed consent. 
Determination of IgG levels against viral proteins
Plasma from blood collection tubes containing EDTA (BD) was used to measure IgG levels 
against EBNA-1, EA-D and VZV as a control. Subsequently in samples negative for EBNA-1 
and EA-D, we measured anti-VCA IgG to ascertain anti-EBV serostatus. All samples were 
determined using well validated chemoluminescent assays and IgG levels measured on a 
Liaison XL (all Diasorin) according to the manufacturers’ guidelines at the national referral 
center for virus diagnostics at the Erasmus MC. All samples were automatically diluted by 
a factor 20 by the Liaison XL. If antibody levels were below or above the threshold, these 
samples reanalyzed undiluted or manually pre-diluted by factor 10 and subsequently 
diluted by the Liaison XL, respectively. Using this protocol, all samples were in the linear 
range of the assays. Patients negative for EBNA-1, EA-D and VCA IgG were omitted from 
further study to prevent bias between MS patients and HC due to differences in EBV 
seroprevalence.
DNA isolation and genotyping.
Genomic DNA was isolated from peripheral blood cell pellets using standard laboratory 
techniques. Isolated DNA was resuspended in TE-buffer and stored at -20˚C. Genotyping 
was performed using Illumina 610K Quad array (Illumina) or Sequenom platform (on both 
platforms, genotyping was performed in 1 run according to good laboratory practice 
following the manufacturers’ protocol) for 78 MS-associated risk SNP at the Erasmus MC 
(Supplementary Table 1).4,5 All SNP were in Hardy-Weinberg equilibrium (all p>0.30).
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Statistical analysis
IgG levels for EBNA-1, EA-D and VZV were 10log transformed to normalize titers. T-tests 
were used to compare groups and ANOVA was used to compare more than two groups 
(clinical parameters: use of immunomodulatory drugs, age, gender, disease form). For 
logistic regression, IgG levels were dichotomized as above or below the 75th percentile 
and the odds ratio (OR) for MS risk SNP were determined. In the first phase of this study, 
330 MS patients were included and all MS risk SNP included in this study (Table e-1) were 
assessed. All SNP (in interaction) that associated with EBNA-1 IgG with a p-value <0.10 (i.e. 
VCAM-1, PRDX5, SOX8, MYB, CARD11, CLEC16A and HLA-DRB1*1501), EBNA-1, EA-D, VZV, 
and optionally VCA IgG levels were subsequently determined in a validation cohort of 336 
MS patients and 147 healthy controls. All associations were confirmed in the validation 
cohort. Subsequently, both datasets were pooled for further analysis. Lastly, interaction 
models between MS risk SNP associated with IgG levels were constructed using forward 
conditional logistic regression. Initially, in a univariate model SNP associated with 
increased EBV IgG were identified. Subsequently, the most significant SNP was assessed 
in an interaction term with all remaining SNP. Significant interactions were subsequently 
taken into the next model with an additional SNP in the interaction term, until no 
more significant interactions were found. Lastly, using this interaction term, remaining 
interactions between the other SNP were assessed using the same method. Logistic 
regression models were determined both uncorrected and corrected for aforementioned 
clinical parameters. If the number of homozygous SNP carriers was smaller than 40 
persons, this group was pooled with heterozygous allele carriers. 
  95% confidence interval (CI) were calculated using bootstrapping analysis with 
10.000 random samples from the assessed population with a Bias corrected accelerated 
method (BCa, unless indicated otherwise). All analyses were performed using SPSS version 
20 (IBM).
  P-values <0.05 were considered statistically different and significance is indicated in 
the figures as * p<0.05, ** p<0.01, *** p<0.001. Graphs were constructed using GraphPad 
Prism version 5.04 (GraphPad Software Inc.).
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Results
Patients and controls
MS patients and HC were age matched, however the gender distribution was significant 
different. Demographic characteristics and clinical information are shown in Table 1.
EBV seroprevalence and EBNA-1 IgG levels are increased in MS patients compared to 
controls.
More MS patients (665 of 668; 99.6%) compared to HC (131 of 147; 89.1%) were EBV 
seropositive based on EBNA-1, EA-D and VCA IgG levels (OR 29.0, 95% CI 8.4-100.5; 
p=1x10-7, Figure 1). This difference in EBV seroprevalence was irrespective of HLA-
DRB1*1501 carriership (HLA-DRB1*1501 adjusted OR 43.6, 95% CI 9.7-196.7; p=9x10-7). 
Study participants
n=815
Healthy individuals
n=147
EBNA-1
VZV p=0.53
OR: 0.53 (95%CI 0.12-2.31)
p=1x10-9
OR: 9.6 (95%CI 4.7-20.0)
p=0.07
OR: 1.4 (95%CI 0.97-2.0)
p=1x10-7
OR: 29.0 (95%CI 8.4-100.5)
IgG+
n=145/147 (98.6%)
IgG+
n=125/147
(85.0%)
IgG+
53/147
(36.1%)
IgG-
94/147
(63.9%)
MS patients
n=668
IgG+
n=650/666 (97.5%)
IgG+
294/667
(44.1%)
IgG+
n=656/668
(98.2%)
IgG-
372/667
(55.9%)
IgG-
12/668
(1.8%)
EA-D
VCA
IgG+
5/21
(23.8%)
IgG-
16/21
(76.2%)
IgG+
9/12
(75%)
IgG-
3/12
(25%)
IgG-
22/147
(15.0%)
IgG+
131/147
(89.1%)
EBV
IgG-
16/147
(10.9%)
IgG+
665/668
(99.4%)
IgG-
3/668
(0.6%)
EBNA-1/EA-D/VCA triple 
negative subjects were 
excluded from further analysis
Figure 1 Flowchart of the study and virus seroprevalence. Immunoglobulin G (IgG) levels against varicella-
zoster virus (VZV) and the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) and early antigen D (EA-D) 
peptides were determined. For EBNA-1 and EA-D IgG double-negative patients, viral capsid antigen (VCA) IgG 
was assessed to ensure EBV serostatus. IgG levels against VZV was used as a highly prevalent herpes control virus 
to assure the specificity of the outcomes. EBNA-1, EA-D, and VCA triple negative patients were excluded from 
further study. CI=confidence interval; OR=odds ratio.
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No difference in VZV seropositivity between MS and HC was observed (p=0.40, Figure 1). 
Additionally, EBNA-1 IgG levels were higher in MS patients compared with healthy EBV 
carriers (HEC) (p=9x10-7, Figure 2A). Differences in EBNA-1 IgG levels were not related 
to gender differences (p=0.36, Figure 2D), clinical disease course (p=0.16, Figure 2E) or 
immunomodulatory drug treatment (p=0.62, Figure 2F). Contrastingly, no differences 
were observed for EA-D (p=0.55, Figure 2B) and VZV IgG levels between MS and HC 
(p=0.08, Figure 2C). 
HLA-DRB1*1501 is associated with enhanced serum EA-D IgG levels
EBNA-1, EA-D and VZV IgG levels were dichotomized as above or below the 75th percentile 
of MS patients. Subsequently, OR of HLA-DRB1*1501 carriers for high IgG levels was 
determined. Previous associations of HLA-DRB1*1501 with elevated EBNA-1 IgG titers12 
showed a trend for significance (OR: 1.43; 95%CI 0.96-2.13; p=0.08) using a multivariate 
logistic regression model (Figure 3A). Moreover, we observed an association of HLA-
DRB1*1501 with EA-D IgG levels (OR: 2.08, 95% 1.19-3.64; p=0.01), but not VZV (data not 
shown).
A B
C D
E F
EBNA-1 EA-D
VZV EBNA-1
EBNA-1 EBNA-1
Figure 2. EBNA-1, but not 
EA-D nor VZV IgG, are 
increased in patients with 
MS. (A) Epstein-Barr virus 
(EBV) nuclear antigen 1 
(EBNA-1) immunoglobulin g 
(IgG) titers are significantly 
increased in patients with 
MS (grey bars) compared 
with healthy EBV carriers (HC; 
white bars). No significant 
differences in IgG levels 
between MS and healthy 
controls (HCs) were observed 
for (B) early antigen D (EA-
D) and (C) varicella-zoster 
virus (VZV). (D) IgG levels 
against EBV are similar in 
(D) women and men, (E) 
relapsing-remitting (RR) MS, 
secondary progressive (SP) 
MS, primary progressive 
(PP) MS, or clinically isolated 
syndrome (CIS) patients, and 
(F) patients treated with 
immunomodulatory drugs 
or untreated.
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PRDX5 and VCAM1 protective alleles are associated with elevated EBNA-1 IgG levels
Next, we assessed the OR of 78 MS-associated risk SNP (Table e-1) for high serum EBNA-1, 
EA-D and VZV levels. The non-MS-risk alleles of PRDX5 (OR: 0.63; 95%CI 0.42-0.95; p=0.028) 
and VCAM1 (OR: 0.54; 95%CI 0.36-0.81; p=0.003) were correlated with high EBNA-1 IgG 
levels. Conversely, MS-risk alleles of MYB, SOX8, CARD11, CLEC16A and HLA-DR showed a 
trend towards significance for high EBNA-1 IgG levels (p<0.10, Figure 3A). No significant 
differences were found for the remaining 71 MS risk SNP. No association between these 
MS risk SNP and EA-D IgG and VZV IgG was found (all p>0.52).
Complex interaction between VCAM1-PRDX5 and SOX8-MYB-CARD11-CLEC16A 
associated with EBNA-1 IgG
Next, we assessed whether interactions between MS risk SNP are associated with the 
enhanced anti-EBNA-1 humoral response observed in MS patients. All associated SNP with 
p<0.10 and HLA-DRB1*1501 (Figure 3A) were included in logistic regression models with 
interaction terms. Interaction was observed between the non-MS-risk polymorphisms 
in VCAM1 and PRDX5 (p=0.01, Figure 3B) in association with high EBNA-1 IgG levels. A 
EBNA-1 IgG
EA-D IgG
VZV IgG
Figure 3. VCAM1-PRDX5 and 
SOX8-MYB-CARD11-CLEC16A 
interactions are associated with 
EBNA-1 and EA-D IgG levels. 
Epstein-Barr nuclear antigen 
1 (EBNA-1; filled circle), early 
antigen D (EA-D; filled square), and 
varicella-zoster virus (VZV) (open 
diamond) immunoglobulin G (IgG) 
levels were dichotomized, and 
logistic regression was performed 
to assess which MS risk SNPs are 
associated with EBNA-1, EA-D, 
and VZV IgG levels. (A) Univariate 
logistic regression in patients with 
MS showed significance for EBNA-
1 IgG above the 75th percentile 
for VCAM1 (odds ratio [OR] 0.54, 
95% confidence interval [CI] 0.36–
0.81; p=0.003) and PRDX5 (OR 
0.63, 95% CI 0.42–0.95; p=0.028). 
Multivariate logistic regression 
with interaction terms between 
MS risk SNPs showed significant 
interactions of VCAM1*PRDX5 (OR 
0.54, 95% CI 0.32–0.89; p=0.01) and 
SOX8*MYB*CARD11*CLEC16A 
(OR 2.1, 95% CI 1.23–3.66; 
p=0.004) for EBNA-1 IgG, but 
not HLA-DRB1*1501 (p=0.1), in 
patients with MS (B) and in healthy 
Epstein-Barr virus carriers (C). HLA 
5 human leukocyte antigen.
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second interaction term between the risk alleles of SOX8-MYB-CARD11-CLEC16A was 
associated with high EBNA-1 IgG (p=0.004). In a combined model, HLA-DRB1*1501 was 
not associated with increased EBNA-1 IgG titers (p=0.1, Figure 3B). Adjustment for gender, 
clinical disease course and immunomodulatory treatment did not affect the results 
(p>0.20, data not shown). Age at sampling was significantly associated with EBNA-1 
IgG, adjusting our model did not alter the conclusions (data not shown). No associations 
between these interacting genes and EA-D or VZV IgG were found (Figure 3B). Similar, 
though less robust trends in HEC were observed (Figure 3C). Lastly, the 95% CI of these 
interactions were assessed using a bootstrapping approach with 10.000 random samples 
to non-parametrically fit the model. Only very minor differences after bootstrapping were 
observed (approximate bias between the actual data and the bootstrapped dataset was 
0.019 or less), indicating that the OR on EBNA-1 IgG levels are accurate. In conclusion, 
gene-gene interaction between VCAM1-PRDX5 and SOX8-MYB-CARD11-CLEC16A is 
specifically associated with EBNA-1 IgG and not with EA-D and VZV. 
Latent
EBV episome
EBV
HLA class II
LMP1
Mitochondria
ROSPRDX5
rs694739
ApoptosismiR-BART20-5p
CD21
BCR
CARD11
rs1843938
miR-155 NF-κB
EBV reactivation
Late endosome
HLA-DRB*1501
rs3135388
BZLF1
VLA-4
VCAM-1
rs11581062
Activated BBB endothelial cell
B-cell
NucleusCytoplasm
LMP2A
EA-D
VCA
EBNA-1
BAD
rs694739
CIITA
rs7200786
CLEC16A
rs7200786
+
+
+
–
–
A B C D
MYB
rs11154801+ +
IgG
Late viral proteins
+
E
Figure 4. Model proposing interaction between EBV latency proteins with here described MS risk genes. 
(A) Epstein-Barr virus (EBV) infection of B-cells induces very late antigen 4 (VLA-4) expression, the ligand of 
VCAM-1 expressed by activated brain epithelial cells. (B) Latency-associated membrane protein 1 (LMP1) of 
EBV induces expression of the peroxiredoxin family of antioxidant enzymes (PRDX5), thereby reducing reactive 
oxygen species (ROS) and preventing caspase-mediated apoptosis. EBV-expressed micro RNA (miR)-BART20-5p 
targets B-cell chronic lymphocytic leukemia/BAD transcripts, reduces BAD protein levels, and inhibits apoptosis. 
(C) Analogous to B-cell receptor signaling, EBV LMP2A activates miR-155 and NF-kB expression via CARD11 
and thereby inhibits apoptosis and promotes proliferation. (D) Immediate early lytic EBV protein BZLF1 blocks 
loading of peptides to HLA class II in late endosomes by inhibiting CIITA and induced expression of early antigen 
D (EA-D) and viral capsid antigen (VCA). (E) CLEC16A is involved in HLA-II antigen presentation via regulation 
of the endosomal compartment and is important for the production of Ig. Plus and minus indicate increased 
and reduced expression, respectively. EBNA-1=Epstein-Barr nuclear antigen 1; HLA=human leukocyte antigen; 
IgG=immunoglobulin G; NF-kB=nuclear factor kappa B.
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Gene-gene interaction associated with EBNA-1 IgG is not secondary to MS
Next, we assessed whether the different gene-gene interactions are related to the MS 
risk SNP or secondary to MS disease activity. Therefore, we used logistic regression with 
abundant EBNA-1 IgG as the dependent variable and MS patients as a covariate. Correcting 
for MS as a covariate did not alter the previously described interactions, indicating that 
the gene-gene interactions itself are important for the increased EBNA-1 IgG and that the 
associations are not secondary to MS alone. Additionally, correcting for HLA-DR did not 
affect our results (data not shown).
Discussion
Increased EBV seroprevalence and more specifically, enhanced immunoglobulin γ (IgG) 
specific for EBNA-1 immune response in MS patients have been widely reported2,8,10,11 and 
confirmed in this study. Longitudinal studies demonstrating EBV infection in the years 
preceding onset of MS2,8,10,11 are often used as (circumstantial) evidence for a causal role 
of EBV in MS. Alternatively, this might be an epiphenomena as a result of a dysregulated 
immune system observed in MS patients, leading to an altered handling of the virus. 
Additionally, the virus might be more active in MS patients, although the antibody titers 
against EA-D, a marker for active viral replication, are not increased in MS patients in the 
majority of published studies7 as well as in our study. Lastly, it might be explained that MS 
patients develop infectious mononucleosis at a later age than healthy controls, especially 
because EBV infection at later age is more likely to cause infectious mononucleosis.16 The 
enhanced EBNA-1 IgG titers in MS might at least partially be explained by both HLA and 
non-HLA MS-associated risk genes.13,14 Recently, a study with 1367 Mexican Americans 
assessed association between genome wide over 900.000 SNP and EBNA-1 seropositivity, 
irrespective of antibody titers. They found that only HLA-DRB1 and HLA-DQB1 were 
associated with EBNA-1 positivity. This is slightly in contrast with the current study, 
which might be explained by the fact that we took the EBNA-1 IgG titers into account 
in our models. Additionally, their study might have suffered from a power problem with 
multiple testing issues, whereas we only assessed MS-associated SNP. Lastly, differences 
in population (patients with cardiovascular disease and diabetes mellitus) might explain 
the different results.13
  MS-associated risk SNP are shown to affect the Th- and B-cell transcriptome.17,18 
This may on the one hand, influence humoral immune responses against EBV and on the 
other, influence regulation of EBV latency in B-cells. To assess whether MS risk genes are 
associated with EBNA-1 IgG, we stratified quantitative EBNA-1, EA-D, and VZV IgG titers as 
above the 75th percentile to MS associated SNP in healthy EBV carriers and EBV positive MS 
patients and determined the OR of these polymorphisms.
  In this study, we observed a similar trend between EBNA-1 IgG and of HLA-DRB1*1501 
in line with previously reported associations.12 Moreover, here HLA-DRB1*1501 was 
also associated with EA-D IgG levels, but not VZV IgG. The HLA-DRB1*1501 influences 
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the repertoire of T-cells recognizing peptide antigens.19 It can therefore be suggested 
that this HLA-DRB1*1501 association with EBNA-1 and EA-D IgG levels reflects Th-/B-
cell interactions, having an effect on the EBV-specific humoral immune response of MS 
patients.
  In contrast, we found that the HLA-independent MS-risk SNPs in VCAM-1 and 
PRDX5 inversely correlated with EBNA-1 IgG levels. Interestingly, in a multivariate logistic 
regression model, interactions between VCAM1-PRDX5 and SOX8-MYB-CARD11-CLEC16A 
were associated with EBNA-1 IgG levels in a contrasting manner. Strikingly, the HLA-
DRB1*1501 effect on EBNA-1 IgG titer is overshadowed by these two genetic interactions 
associated with altered EBNA-1 humoral responses. The increased EBNA-1 IgG observed 
in MS patients is partially explained by these genetic interactions.
  A similar genetic association was found in healthy controls previously exposed to 
EBV, although not statistically significant presumably due to lack of statistical power. The in 
part common genetic background of healthy controls and MS patients (e.g. the quite high 
proportion of healthy controls carrying MS risk SNP) might explain the common effects 
observed in the immune response against EBV observed in this study. The identified MS 
risk genes associated with EBNA-1 IgG are likely candidates to be functionally involved in 
the enhanced humoral immune response, as discussed here below.
  EBNA-1 is expressed in all phases of the EBV lifecycle except latency 0, where only 
non-coding EBV transcripts are expressed.20 EA-D, an EBV polymerase processivity protein 
encoded by BamHI fragment M rightward open reading frame 1 (BMRF1), is restricted to 
lytic phase EBV.20 The observed association with EBNA-1 IgG levels therefore suggests that 
the genes associated with MS risk SNP found in this study interact with latency associated 
transcripts of EBV in infected B-cells. Strikingly, the majority of genes associated with the 
SNP that correlate with EBNA-1 IgG levels identified in this study have been shown to 
interact with EBV associated proteins and transcripts.
  VCAM1 is expressed by cytokine-activated blood-brain barrier endothelial cells in 
MS lesions.21 Memory B-cells constitutionally express the ligand of VCAM1, integrin α4β1 
(Very Late Antigen-4; VLA-4).17 EBV infection considerably increases VLA-4 expression 
in B-cell,22 suggesting increased migration of EBV B-cells to the central nervous system 
(Figure 4A). 
  PRDX5 is a member of the peroxiredoxin family of antioxidant enzymes. PRDX5 
expression prevents reactive oxygen species (ROS) mediated damage in mitochondria, 
thereby inhibiting caspase induced apoptosis. The EBV latent membrane protein 2A 
(LMP2A) induces PRDX5 expression in B-cells.23 Alternatively, the PRDX5 associated SNP, 
rs694739 is related to B-cell CLL/lymphoma 2-associated antagonist of cell death (BAD) 
in a type I diabetes study.24 Expression of BAD is induced during caspase-mediated 
apoptosis. The constitutionally EBV expressed miR-BART20-5p targets the 3’-UTR of BAD 
resulting in decreased BAD levels and reducing apoptosis in infected B-cells.25 EBV inhibits 
caspase mediated apoptosis via PRDX5 and BAD during latent and lytic phase infection 
(Figure 4B) resulting in reduced immune exposure of EBNA-1, which may partly explain 
the PRDX5 association with lowered EBNA-1 IgG levels in MS patients (Figure 4B). 
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  The rs11154801 SNP is linked to Abelson helper integration site 1(AHI1) or MYB.26 
MYB is a transcription factor required for B-cell development and expression is reduced 
during the process. Aberrant expression of MYB leads to lymphoproliferative disorders 
by inducing NF-κB and miR-155 expression.27 Direct interaction of EBV transcripts 
or proteins with MYB are not shown. However, LMP1 induces miR-155 and LMP2A/B 
potently induces NF-κB expression during latency I and II, preventing apoptosis and 
promoting proliferation.27–29 CARD11 is a scaffolding protein required for NF-κB activation. 
Interestingly, gain of function mutations in CARD11 lead to B-cell malignancies and 
anergic T-cells by continuous NF-κB activation, which is severely exacerbated by EBV 
infection (Figure 4C).30 
  The rs7200786 SNP is in close proximity of CLEC16A, DEXI and CIITA and alters 
expression of DEXI.31 CIITA and CLEC16A are involved in the regulation of HLA class II 
via the endosomal system.32 In addition, CLEC16A knock-out in mice leads to reduced 
numbers of B-cells and an altered immunoglobulin spectrum.33 The immediate early 
lytic cycle associated EBV transcription factor BZLF1 downregulates MHC class II antigen 
presentation through inhibition of CIITA during EBV reactivation (Figure 4D,E). 
  rs2744148 is located 36.6kb downstream of the nearest gene SOX8, sex determining 
region Y-box 8. To date, no interactions of rs2744148 with SOX8 or EBV transcripts are 
known. 
  As we here followed a candidate gene approach by using a set of predefined recently 
discovered MS risk genes, we did not correct for multiple testing. This can be seen as a 
limitation of this study, with a risk of being underpowered. To attenuate this issue we used 
a first and second cohort to validate the findings. Moreover, higher numbers obtained 
by pooled analysis of patients and controls gave results in the same direction with lower 
p-values. The results are plausible as the SNP associated with elevated EBNA-1 IgG are all, 
except SOX8, highly expressed in B-lymphocytes (data not shown, based on www.biogps.
org) and already shown to be involved in EBV latency machinery. In the current study, we 
were able to assess seventy-eight of the one hundred MS risk SNP currently published, 
thereby possibly missing some genetic associations with EBNA-1 IgG. It is unlikely that 
this has affected the underlying results. It might be an underestimation of the real genetic 
contribution to EBNA-1 IgG levels in MS, as there are even more MS risk genes to be 
identified. Lastly, although we assessed whether or not our results are secondary to MS 
disease itself, and we found that correcting for MS in our regression models did not alter 
the results, we can not fully rule out that MS disease itself is at least partially associated 
with increased EBNA-1 IgG. To fully assess this, we would need a larger cohort of healthy 
controls to draw reliable conclusions for this association. 
  Taken together, the genes associated with the identified genomic MS-risk SNP have 
previously been shown to be involved in migration (VCAM1), anti-apoptosis (PRDX5/BAD, 
MYB/NHI1, CARD11) and MHC class II antigen presentation (HLA-DRB1*1501, CLEC16A/
CIITA) in latently EBV infected B-cells presumably resulting in altered EBNA-1 IgG levels. 
Functional differences in these pathways may lead to distinct viral inhibition and appear 
at the same time in MS related autoimmunity. This deserves to be further explored at a 
functional level.
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Supplementary Table 1. Genes associated with the MS-SNP included in this study
rs11154801 rs11581062 rs12368653 rs228614 rs2293370 rs2303759 
MYB/NHI1 VCAM1 CYP27B1 NF- B1 TMEM39A DKKL1
rs2744148 rs4648356 rs630923 rs1800693 rs2243123 
SOX8 MMEL1 CXCR5 TNFRSF1A IL12A
rs9282641 rs9891119 rs2300603 rs1870071 rs1335532 rs1323292 
CD86 STAT3 BATF EVI5 CD58 RGS1
rs7522462 rs12466022 rs7595037 rs17174870 rs11129295 rs669607
C1ORF106 no gene PLEK MERTK EOMES no gene 
rs2028597 rs6897932 rs4613763 rs2546890 rs12212193 rs13192841
CBLB IL7R PTGER4 IL12B BACH2 no gene
rs1738074 rs354033 rs1520333 rs4410871 rs2019960 rs3118470 
TAGAP ZNF746 IL7 MYC PVT1 IL2RA
rs1250550 rs7923837 rs650258 rs10466829 rs949143 rs4902647 
ZMIZ1 HHEX CD6 CLECL1 ARL6IP4 ZFP36L1
rs2119704 rs13333054 rs180515 rs7238078 rs1077667 rs8112449 
GALC IRF8 RPS6KB1 MALT1 TNFSF14 TYK2
rs874628 rs2425752 rs6062314 rs2283792 rs140522
MPV17L2 CD40 TNFRF6B MAPK1 SCO2
HLA related SNP
rs6457110 rs3135388
HLA-A2 HLA-DRB1*15:01
rs1843938 rs2050568 rs2288904 rs694739 rs12148050 rs3007421 
CARD11 FCLR1 SLC44A2 PRDX5/BAD TRAF3 PLEKHG5
rs11587876 rs666930 rs842639 rs9828629 rs756699 rs941816
DDAH1 PHGDH FLJ16341 FOXP1 TCF7 PXT1
rs2456449 rs793108 rs2688608 rs7120737 rs4772201 rs8042861 
no gene no gene C10ORF55 AGBL2 MIR548AN IQGAP1
rs7204270 rs11865086 rs1886700 rs7196953 rs1870071
MAPK3 MAPK3 CDH3 MAF EPS15L1
SNP from International Multiple Sclerosis Genetics Consortium (IMSGC) et al, Nat Genet. 2013 Nov;45(11):1353-60. 
SNP from: International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium et al, 
rs7200786 
CLEC16A/CIITA
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Abstract
Background: The association between Epstein-Barr virus (EBV) and multiple sclerosis (MS) 
may involve intrathecal EBV-specific T-cell responses targeting the virus or indirectly, 
autoantigens.
Objective: Compare the prevalence and fine-specificity of EBV-specific T-cells in the 
cerebrospinal fluid (CSF) of patients with MS (n=12), clinically isolated syndrome (CIS) 
(n=17) and other neurological diseases (OND) (n=13).
Methods: Intrathecal EBV-specific T-cell reactivity was assayed using CSF-derived T-cell 
lines (CSF-TCL) and autologous EBV-transformed B-cells (autoBLCL) as antigen-presenting 
cells (APC). EBV proteins recognized by autoBLCL-specific CD8+ T-cells were identified 
using human leukocyte antigen class I (HLA-I)-negative monkey cells as artificial APC, 
co-transfected with 59 different EBV genes and the corresponding patient’s HLA-I alleles 
that were involved in autoBLCL T-cell reactivity. Reactivity towards the MS-associated 
autoantigen αB-crystallin (CRYAB) was determined analogously.
Results: CSF-TCL from CIS and MS patients had significantly higher frequencies of 
autoBLCL-reactive CD4+ T-cells, compared to the OND patients. CIS patients also had 
significantly higher autoBLCL-reactive CD8+ T-cells, which correlated with reactive CD4+ 
T-cell frequencies. AutoBLCL-specific CD8+ T-cell responses of four CSF-TCL analyzed in 
detail were oligoclonal and directed to lytic EBV proteins, but not CRYAB endogenously 
expressed by autoBLCL.
Conclusions: Enhanced intrathecal autoBLCL-specific T-cell reactivity, selectively directed 
towards lytic EBV proteins in two CSF-TCL, suggested a localized T-cell response to EBV in 
patients with MS. Our data warrant further characterization of the magnitude and breadth 
of intrathecal EBV-specific T-cell responses in larger patient cohorts.
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Introduction
Multiple sclerosis (MS) is characterized by the development of foci of demyelinating and 
axon-damaging inflammation that spreads throughout the central nervous system (CNS). 
Clinically-isolated syndrome (CIS) may precede definitive MS. The clinical course of MS may 
follow a variable pattern over time and MS is classified into three categories: relapsing–
remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS 
(PPMS).1 Although the clinical course of MS is highly variable, most patients eventually 
develop severe neurological disability.
  The cause and pathogenic mechanisms of MS remain enigmatic. MS is considered 
the result of a local inflammatory response, involving both resident cells (e.g. microglia) 
and infiltrating T-cells in the CNS, in genetically susceptible individuals; initiated by 
environmental factors, most likely viruses.1,2 Recent studies advocate the role of Epstein-
Barr virus (EBV) during the initiation and potentially the perpetuation of MS pathogenesis.2 
Indicative of this are i) both higher EBV seroprevalence and systemic virus-specific 
B- and T-cell responses in MS patients, compared to controls,3–5 ii) the epidemiological 
relationship between infectious mononucleosis and MS6, iii) the presence of EBV-infected 
B-cells in MS lesions and viral deoxyribonucleic acid (DNA) in cerebrospinal fluid (CSF).7–9 
However, evidence for the presence of EBV in the lesions and CSF of MS patients remain 
controversial.10–12
  EBV is a human B-cell tropic γ-herpesvirus that is endemic worldwide.13 The virus’ 
hallmark is to establish a lifelong latent infection in B-cells. The T-cells are pivotal in 
controlling viral latency.13,14 EBV may evoke T-cell-mediated MS pathology in different 
ways. Virus-specific T-cells may recognize EBV-infected cells in the brain,7,15 cross-react 
with myelin antigens,16,17 or recognize autoantigens (e.g. αB-crystallin (CRYAB)) induced 
in B-cells upon EBV infection.18 Given the limited access to brain tissue, studies on local 
antigen-specific T-cell responses in MS patients are restricted to CSF samples. CD4+ 
and CD8+ T-cells that are reactive to autologous EBV-transformed B-cell lines (BLCL), 
in part directed to EBV nuclear antigen 1 (EBNA-1), can be cultured from CSF from MS 
patients.17,19,20 Recently, two analogous studies on larger patient cohorts, including MS 
patients and disease controls, compared EBV- and cytomegalovirus (CMV)-specific T-cell 
responses in paired blood and CSF.21,22 Whereas both groups describe a selective increase of 
intrathecal EBV-specific, but not CMV-specific T-cells, the EBV T-cell responses were either 
restricted to CD8+ T-cells mainly in patients with early MS21 or limited to CD4+ T-cells in 
RRMS patients.22 Furthermore, deep sequencing of T-cell receptor β (TCRBV) gene usage 
in paired blood and CSF samples confirm intrathecal enrichment of EBV-specific CD8+ 
T-cells in MS.23 However, the latter studies did not completely determine the viral proteins 
recognized or were limited to an analysis of a selected set of known immunodominant 
EBV CD8+ T-cell epitopes.19–22
  The aim of the current study was to determine the prevalence and fine specificity 
of EBV-specific T-cells cultured from the CSF of CIS and MS cases, and patients with other 
neurological disease (OND). A schematic overview of the subsequent experimental 
procedures performed to address these important issues in MS pathology is presented in 
Figure 1.
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Materials and methods
Patients and clinical specimens
Between December 2008 and June 2012, paired blood and CSF samples from CIS (n=17), 
MS (n=12) and OND patients (n=5) were obtained as part of a diagnostic workup at the 
Erasmus Medical Center (Rotterdam, the Netherlands). Informed consent was obtained 
from each patient. The study was approved by the local ethical committee and performed 
according to the tenets of the Helsinki declaration. The MS patient cohort consisted of 
RRMS (n=10) and PPMS (n=2) and CIS (n=17) patients, according to the 2010 Revised 
McDonald Criteria. The OND cohort consisted mainly of paraneoplastic neurological 
syndrome patients (n=9) with high serum Human neuroantigen D (HuD)-specific antibody 
titers; and OND patients (n=4), whom suffered from a variety of clinical symptoms, 
including headache and subarachnoid hemorrhage, all sampled between February 2005 
and September 2007.24 Patients received neither corticosteroids, nor immunomodulatory 
therapy at the time of their lumbar puncture, which was always performed >1 month 
after the clinical symptoms began. We typed the HLA Class I (HLA-I) genotype of specific 
patients, using standard diagnostic polymerase chain reaction (PCR) at a 4-digit resolution 
level.
EBV serology and real-time PCR
The total IgG levels, and the IgG levels directed to EBV virus capsid antigen (VCA) and 
EBNA-1, were determined from the serum, using chemoluminescent assays on a Liaison 
XL analyzer (Diasorin, Torino, Italy), as per the manufacturer’s instructions. The EBV-specific 
intrathecal IgG production was determined for EBNA-1 by calculating the Golmann-
Witmer coefficient (GWC), as described previously.25 A GWC >3 was considered indicative 
for intrathecal EBV-specific IgG production. We determined the presence of EBV DNA in 
the CSF, and human CRYAB and β-actin transcript levels in BLCL, by real-time PCR (qPCR) 
and reverse-transcribed qPCR on an ABI Prism 7700 with Taqman Universal Master Mix 
and the custom-made (EBV gene BNRF1)26 or commercial intron-spanning primer/probe-
pairs specific for human CRYAB and β-actin (Applied Biosystems, Foster City, CA, USA), as 
per the manufacturer’s instructions, respectively. We determined the relative transcript 
levels by the formula: 10,000 × 2-(Ct CRYAB - Ct β−actin)
Generation of BLCL and CSF-TCL
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation 
of heparinized peripheral blood and the B-cells were infected with EBV strain B95.8 to 
generate BLCL, as described previously.27 The CSF-derived T-cell lines (CSF-TCL) were 
obtained by nonspecific stimulation of cells from CSF with 1 µg/ml phytohemagglutinin-L 
(PHA-L) (Roche, Branford, CT, USA) in the presence of γ-irradiated allogeneic PBMC (3000 
rad; 105/well) in RPMI-1640 medium supplemented with antibiotics, 10% heat-inactivated 
pooled human serum (Sanquin, Amsterdam, the Netherlands) and 50 IU/ml recombinant 
interleukin-2 (IL-2) (Miltenyi, Bergisch Gladbach, Germany); and then cultured for 
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about 2 weeks at 37°C.24,27 The CSF-TCL with insufficient cell numbers (i.e. < 5x106) were 
restimulated with an anti-CD3, from clone OKT3 (Janssen-Cilag, Tilburg, the Netherlands).28 
At the time of inclusion, the co-authors who generated the CSF-TCL and autologous BLCL 
(autoBLCL) were unaware of the patients’ clinical diagnosis. Identical protocols were 
used previously, to generate paired CSF-TCL and autoBLCL from HuD-PNS patients at the 
same lab (Department of Viroscience, Erasmus Medical Center, the Netherlands), under 
supervision of the senior author.27 For the latter patient group, the researchers were aware 
of their clinical diagnosis beforehand. Notably, of the 47 paired peripheral blood and 
surplus CSF samples obtained between December 2008 and June 2012, the generation 
of BLCL and CSF-TCL with sufficiently high T-cell numbers was unsuccessful for five and 13 
patients, respectively. We obtained successful CSF-TCL to high numbers from all the MS 
patients, but only in 17 of 28 (61%) CIS, and 3 of 5 (60%) of the OND patients. Overall, the 
paired BLCL and CSF-TCL of 29 MS patients and 13 OND patients were available to study 
intrathecal EBV-specific B- and T-cell reactivity (Table 1).
T-cell reactivity to autologous BLCL
EBV reactivity of CSF-TCL was determined by intracellular staining (ICS) for interferon γ 
(IFNγ) using autologous BLCL (autoBLCL) as antigen presenting cells (APC).28 As a positive 
control for T-cell activation, CSF-TCL were stimulated for 6 hours with a combination 
referred to as P/I, of phorbolmyristate-acetate (PMA) at 50 ng/ml and ionomycin at 500 ng/
ml (Sigma, St Louis, MO, USA).27,28 T-cells were phenotyped with fluorochrome-conjugated 
monoclonal antibody (mAb) directed to human CD3 (clone SP34-2; BD Pharmingen, San 
Diego, CA, USA), CD4 (clone SK3; BD Biosciences, San Jose, CA, USA), CD8α (clone RPA-T8; 
eBiosciences, San Diego, CA, USA) and IFNγ (clone B27, BD Pharmingen, San Diego, CA, 
USA) and stained for viability (violet live/dead stain; Invitrogen); and then analyzed using 
a FACSCanto flow cytometer and CellQuest Pro software (BD Biosciences), as described.27,28
  Experiments were performed at least two times and as negative controls, the 
appropriate isotype- and fluorochrome-matched unrelated mAbs were included. 
Except for the HuD-PNS patient cohort, the team was blinded for the patients’ clinical 
diagnosis during autoBLCL T-cell reactivity analyses. All subsequent in-depth T-cell 
analyses were performed on CSF-TCL of selected high autoBLCL responding CIS and MS 
patients. Enumeration of activated T-cells, based on their intracellular IFNγ expression, 
was defined by gating on the viable cells that expressed surface CD3, CD4 or CD8. For 
all assays, at least 5x103 gated viable CD4+ and CD8+ T-cells were obtained; and the 
threshold gate for autoBLCL-reactive T-cells was set at 0.1% IFNγ+ CD4+ and CD8+ T-cells, 
based on unstimulated CSF-TCL for each donor. All T-cell assays were performed and the 
data interpreted by the team, according to longstanding in-house standard operating 
procedures (SOPs) in the Department of Viroscience (Erasmus MC).
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Identification of the HLA-I allele involved in CD8+ T-cell reactivity to BLCL
Identification of the patient’s HLA-I allele involved in autoBLCL CD8+ T-cell reactivity was 
determined using partially HLA-I matched allogenic BLCL as the APC. Furthermore, CSF-TCL 
clonality was determined using a multiparametric analysis tool (IOTest Beta Mark mAb Kit; 
Beckman Coulter, Marseille, France), which contains multiple fluorochrome-conjugated 
mAbs directed to approximately 70% of all known TCRBV.29 Combined extracellular TCRBV 
and intracellular IFNγ staining facilitated the differentiation between BLCL and allo-HLA 
reactivity of the corresponding CSF-TCL by flow cytometry. Experiments were performed 
at least two times.
T-cell reactivity to the EBV proteome and human αB-crystallin
The generation and validation of individual expression vectors (cloned in the pCMV-EHis 
vector) containing the EBV proteome, covering a total of 59 of 85 (69%) of all known EBV 
proteins that were used as target antigens for CSF-TCL, have been detailed elsewhere.30 
Human CRYAB cDNA (Darmacon, Lafayette, CO, USA) was cloned in the custom-made 
eukaryotic pNS.CD8α vector.31
  We determined the EBV proteome and CRYAB T-cell reactivity on artificial APC, 
consisting of Cos-7 monkey fibroblasts (American Type Culture Collection, Manassas, 
VA, USA) that were co-transfected with the patient-matched HLA-I allele-specific cDNA 
(cloned in vector pcDNA3) and expression vectors encoding 59 individual EBV protein-
encoding genes or human CRYAB, as described.28 All co-transfections were performed in 
duplicate; and the appropriate negative (untransfected Cos-7 cells) and positive controls 
(autologous BLCL and P/I) were included. CSF-TCL were added to co-transfected Cos-
7 cells; and then after 24 hrs, the culture supernatants were collected for IFNγ ELISA.28 
Expression of specific EBV proteins (i.e. EBNA-1 [clone OT1x], LMP1 [clone OT21c], BZLF1 
[clone BZ1], BALF2 [clone OT9-2] and BMRF1 [clone OT14e-2]) by BLCL, and expression of 
human CRYAB (clone 2E8) (AbD Serotec, Oxford, UK) by co-transfected Cos-7 cells, was 
confirmed by conventional immunocytology on fixed cells, using fluorescein-conjugated 
goat-anti-mouse IgG (BD Biosciences). Experiments were performed at least two times.
Statistical analyses
Statistical differences were determined by the Mann-Whitney U test, or in the case of 
paired specimens, by Spearman’s rank correlation test using Prism (GraphPad 5.0 Software, 
La Jolla, CA, USA).
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Figure 1. Schematic overview of experimental procedure to identify intrathecal EBV-response. We generated 
paired EBV-transformed BLCL and CSF-TCL. Co-culture of CSF-TCL with the autologous BLCL as APC; followed by 
CD3, CD4, CD8, ICS IFNγ and flow cytometry allowed simultaneous analysis of CD4 and CD8 T-cell reactivity. 
Subsequently, the clonality and HLA-I restriction of BLCL-specific CD8+ T-cells was assayed by co-culture of CSF-
TCL with partially HLA-I-matched allogeneic BLCL, followed by combined IFNγ ICS and T-cell receptor Vβ analysis. 
Next, EBV targets of BLCL-reactive CD8+ T-cells were identified. Therefore, an EBV ORF library encoding 59 of the 
86 EBV proteins and EBV-induced CRYAB was cloned in expression vectors. HLA-I-deficient Cos-7 cells were co-
transfected with expression vectors encoding the EBV ORFeome or CRYAB and the previously-identified patients’ 
HLA-I and used as the artificial APC in a co-culture with CSF-TCL. The conditioned culture supernatants were 
screened for secreted IFNγ using ELISA, for a qualitative identification of the CD8+ T-cell targets. APC: antigen-
presenting cells; BLCL: blood-derived EBV-transformed B-cell lines; CRYAB: alpha-B-crystallin; CSF-TCL: CSF- 
derived T-cell lines; EBV: Epstein-Barr virus; ELISA: enzyme-linked immunosorbent assay; ICS: intracellular 
staining; IFN: interferon; HLA-I: human leukocyte antigen Class I; ORF: open reading frame.
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Results
Intrathecal T-cell reactivity to autologous BLCL increased in CIS and MS patients
To study the role of EBV infection in MS, we analyzed virus-specific B- and T-cell responses 
in surplus CSF from CIS (n=17), MS (n=12) and OND patients (n=13) (Table 1). Laboratory 
diagnostics on paired serum and CSF of the CIS and MS cases showed that all patients were 
EBNA-1 seropositive, except one CIS patient, whom was EBNA-1 seronegative but VCA IgG 
seropositive. Local antibody response to EBNA-1 and EBV DNA were undetectable in the 
CSF of all CIS and MS patients (data not shown). Paired surplus CSF and serum of OND 
patients were not available for retrospective EBV diagnostics.
  To compare intrathecal EBV-specific T-cell responses between patient cohorts, we 
expanded the CSF T-cells non-specifically, with PHA-L and subsequent anti-CD3, to obtain 
high T-cell numbers (Figure 1). In contrast to CD4+ T-cells, CD8+ T-cell frequencies were 
significantly higher in the CSF-TCL of CIS patients (mean ± standard error=31±4; p=0.009), 
compared to the MS (28±6) and OND patients (16±4). AutoBLCL were generated by EBV 
infection of blood-derived B-cells. Concordant with earlier studies, the majority of BLCL 
cells expressed the viral proteins EBNA-1 and LMP1, which represent latently-infected 
B-cells.13 Notably, about 2–5% of the BLCL cells had entered the lytic cycle, and most likely 
expressed the whole EBV proteome (Supplementary Figure 1). Accordingly, BLCL were 
considered appropriate APC to analyze intrathecal EBV-specific T-cell reactivity.14,30
  To determine if our protocol to generate CSF-TCL from different patient cohorts, and 
in particular long-term storage of HuD-PNS cell lines in liquid nitrogen, influenced the 
functionality of CSF-derived T-cells, all CSF-TCL were assayed for IFNγ expression upon P/I 
stimulation. The average frequency of IFNγ+ CD4+ and CD8+ T-cells in P/I-stimulated CSF-
TCL was >80% in all patient groups, indicating that the methodology used and long-term 
storage of CSF-TCL did not negatively affect T-cell immune competence of CSF-derived 
T-cells (Supplementary Figure 2). Subsequently, the CSF-TCL were assayed for autoBLCL 
reactivity.
  Frequencies of autoBLCL-reactive CD4+ T-cells were significantly higher in CSF-TCL 
of CIS (mean ± SE: 1.5±0.3; p=0.003) and MS patients (2.0±0.5; p=0.001), compared to 
disease controls (0.3±0.1), as seen in Figure 2A. For CD8+ T-cells, CIS patients (5.4±1.6; 
p=0.02), but not MS patients (3.5±1.2; p=0.05) had significantly higher autoBLCL-reactive 
Table 1. General characteristics of the study population 
 
Neurological disease entity 
 
Number  
Gender 
male: female 
Median age 
(years and IQR)a  
Median disease duration 
(months and IQR)a 
Multiple sclerosis patients 29 10 : 19 38 (34-41)   7 (2-22) 
Relapsing remitting 10 2 : 8 37 (33-39) 16 (3-69) 
Primary progressive   2 1 : 1 51 & 55b 10 & 54b 
Clinically isolated syndrome 17   7 : 10 38 (34-41)      4 (1.5-10) 
     
Disease controlsc 13 7 : 6 66 (54-70) 3 (2-8) 
HuD-PNS   9 3 : 6 66 (54-70) 3 (3-8) 
miscellaneous   4 4 : 0 64 (57-72) 1 (0.08-8) 
aAll values are medians (interquartile ranges; IQR).  
bThe age and disease duration of 2 patients with primary progressive MS are presented. 
cHuD-PNS: paraneoplastic neurological syndrome patients with high serum HuD-specific antibody titers; 
miscellaneous: patients with variety of clinical symptoms including headache and subarachnoid hemorrhage. 
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T-cell frequencies, compared to disease controls (1.2±0.6). No significant differences were 
detected between MS and CIS patients (Figure 2A). Overall, frequencies of autoBLCL-
reactive CD8+ T-cells (3.7±0.8) were significantly higher than in CD4+ T-cells (1.2±0.2; 
p=0.01). Notably, intra-patient frequencies of CD4+ and CD8+ autoBLCL-reactive T-cells 
correlated significantly; which upon analysis of the three patient groups separately, was 
only significant for the CIS patients (Figure 2B).
Intrathecal CD8+ T-cell reactivity to autologous BLCL is directed to lytic EBV proteins
Recent data argue for the potential role of CD8+ T-cells in MS pathology.1,2 Increased 
frequency of autoBLCL-reactive CD8+ T-cells, predominantly in CIS patients (Figure 2A), 
prompted us to determine if these CSF-derived CD8+ T-cells recognized EBV proteins 
(Figure 1). EBV protein specificity was determined using a recently-developed viral 
proteome approach, using artificial APC, consisting of Cos-7 cells co-transfected with 
59 individual EBV protein-encoding genes and the patient HLA-I alleles identified as 
the restriction element of the autoBLCL-specific CD8+ T-cell response.28 Because both 
high numbers of T-cells and relatively high frequencies of reactive CD8+ T-cells (>4%) 
are mandatory for definitive viral proteome screening hits, the EBV proteome approach 
was only possible for CSF-TCL of three CIS patients (LP33, LP52 and LP54) and one RRMS 
patient (LP51).28
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Figure 2. Increased intrathecal 
CD4+ and CD8+ T-cell reactivity 
to autologous BLCL, in CIS and MS 
patients. (A) T-cell lines generated 
from CSF of MS and CIS patients, and 
as a control, patients with OND; were 
incubated with autologous EBV-
transformed B-cell lines. Phenotype 
and frequency of the reactive T-cells 
was determined by flow cytometry, 
using specific monoclonal antibodies 
directed to CD3, CD4, CD8 and 
intracellular IFNγ. (B) The correlation 
of autoBLCL-reactive CD4+ and CD8+ 
T-cell frequencies of individual CSF-
TCL of all three patient groups (left 
panel) or solely CIS patients: Dots 
represent data of individual CSF-
TCL, presented as the percentage of 
IFNγ+ cells of all CD4+ or CD8+ T-cells 
in the corresponding CSF-TCL, and 
the bars show the average values of 
each patient group. The statistical 
analyses used were the Mann-
Whitney U test (A) and the Spearman’s 
rank correlation test (B). autoBLCL: 
autologous EBV-transformed B-cell 
lines; CSF: cerebrospinal fluid; CSF-
TCL: T-cell lines generated from CSF; 
IFN: interferon; OND: other neurologic 
diseases
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Figure 3. Identification of the patient’s HLA-I allele involved in intrathecal CD8+ T-cell reactivity to 
autologous BLCL. TCL generated from CSF (CSF-TCL) of three CIS patients (numbers LP33, LP52 and LP54) and 
one RRMS patient (LP51) were incubated with autoBLCL and various partially-matched HLA-I allogeneic BLCL. The 
TCRBV gene usage of BLCL-reactive CD8+ T-cells was determined by flow cytometry, using specific mAbs directed 
to different TCRBV (covering about 70% of all known TCRBV), CD8 and intracellular IFNγ. The left panel shows the 
HLA-A, HLA-B and HLA-C alleles, expressed by the allogeneic BLCL, that match the patients’ HLA-I genotype and the 
corresponding frequency of BLCL-reactive CD8+ T-cells, presented as the percentage of IFNγ+ cells of all the CD8+ 
T-cells in the corresponding CSF-TCL (last column). The right panel shows the TCRBV gene usage of all CD8+ T-cells 
in the CSF-TCL (upper row) and the autoBLCL-reactive CD8+ T-cells (subsequent rows). For the latter analysis, the 
percentage of autoBLCL-reactive CD8+ T-cells was set to 100%, to facilitate inter-BLCL comparison of the TCRBV gene 
usage of the BLCL-specific CD8+ T-cells. aHerein, undefined indicates that the corresponding TCRBV could not be 
determined with the TCRBV-specific mAbs used. autoBLCL: autologous EBV-transformed B-cell lines; BLCL: blood-
derived EBV-transformed B-cell lines; CIS: clinically-isolated syndrome; CSF: cerebrospinal fluid; EBV: Epstein-Barr 
virus; HLA-I: human leukocyte antigen Class One; mAbs: monoclonal antibodies; MS: multiple sclerosis; RRMS: 
relapsing–remitting MS; TCL: T-cell lines; TCRBV: T-cell receptor V beta
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  First, we determined the patients’ HLA-I alleles involved in the autoBLCL CD8+ T-cell 
responses, by using a combined flow cytometry assay with partially HLA-I-matched BLCL 
as APC and TCRBV phenotyping, to differentiate between BLCL and allo-HLA-reactive 
T-cells (Figure 1 and 3). Whereas all four CSF-TCL contained a polyclonal CD8+ T-cell 
population, selective IFNγ expression combined with restricted TCRBV usage indicated 
that CD8+ T-cell reactivity was restricted by one (LP52: HLA-B*0702 and LP54: HLA-A*0201), 
two (LP33: HLA-B*0702 and HLA-B*0801) and four (LP51: HLA-A*0201, HLA-A*2902, 
HLA-B*4001 and HLA-C*0304) HLA-I alleles. Our data implicate that the autoBLCL-reactive 
CD8+ T-cell repertoire in all four CSF-TCL is oligoclonal (Figure 3). Finally, the CSF-TCL were 
subjected to the EBV proteome assay, using the identified HLA-I alleles (Figure 1). The EBV 
proteome collection contained 59 of 85 (69%) of all known EBV genes and covered viral 
proteins that are selectively expressed during latency and those co-expressed during lytic 
EBV infection; including immediate early, early and late viral proteins.13,30 In total, four out 
of eight (50%) autoBLCL/HLA-I allele combinations tested revealed reproducible specific 
CD8+ T-cell EBV protein hits (Figure 4).
CD8+ T-cell recognition of autologous BLCL is not directed to αB-crystallin
The inability to identify the cognate EBV protein of the remaining four out of eight 
autoBLCL/HLA-I allele combinations may be because the EBV proteome collection was not 
complete: 26 of the 85 (31%) known EBV proteins are not included.30 Alternatively, CD8+ 
T-cells are directed to host cell antigens expressed by BLCL. The heat shock protein CRYAB 
is a potential candidate host protein, as this protein is identified as a T-cell autoantigen 
in MS patients, and EBV infection of B-cells induces CRYAB expression.1,18 Indeed, readily-
detectable levels of CRYAB transcript were detected in the BLCL of representative patients 
(Figure 5A). Next, we cloned and expressed human CRYAB in Cos-7 cells, along with 
the respective HLA-I alleles identified as the restriction element of the autoBLCL CD8+ 
T-cell response (Figure 3). The CRYAB protein expression was detectable in transfected 
Cos-7 cells (Figure 5B). However, no CSF-TCL recognized Cos-7 cells transfected with the 
respective CRYAB/HLA-I combinations, indicating that the intrathecal autoBLCL CD8+ 
T-cell response was not directed to CRYAB (Figure 5C).
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◄Figure 4. Intrathecal 
autoBLCL-reactive CD8+ 
T-cells recognize lytic EBV 
proteins. T-cell lines generated 
from CSF, of three CIS patients 
(numbers LP33, LP52 and 
LP54) and one RRMS patient 
(LP51) were incubated, in 
duplicate, with Cos-7 cells that 
co-expressed the respective 
donor-specific HLA-I allele 
and individual EBV proteins 
(n=59); and T-cell reactivity 
was measured by quantifying 
IFNγ secretion in the cultures’ 
supernatants. The EBV proteins 
are arrayed on their kinetic class 
level in a nominal genomic 
order on the x-axis and the IFNγ 
secretion levels (mean ± SD) of 
2–3 independent experiments 
are shown. The names of EBV 
proteins that are specifically 
recognized are indicated by 
an arrow. The results of the 
EBV proteome analyses on the 
CSF-TCL for individual HLA-I 
alleles of patients LP33 (n=2) 
and LP51 (n=4) are shown in 
black and grey values. The 
negative and positive controls 
were CSF-TCL incubated with 
untransfected Cos-7 cells or 
CSF-TCL stimulated with PMA 
and ionomycin, respectively.
autoBLCL: autologous EBV-
transformed B-cell lines; CIS: 
clinically-isolated syndrome; 
CSF: cerebrospinal fluid; 
EBV: Epstein-Barr virus; IFN: 
interferon; MS: multiple 
sclerosis; P/I: PMA and 
ionomycin; PMA: phorbol-
myristate acetate; RRMS: 
relapsing–remitting MS; TCL: 
T-cell lines.
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▲Figure 5. CD8+ T-cell recognition of autologous BLCL is not directed 
to αB-crystallin. (A) Relative CRYAB transcript levels were determined by 
reverse transcriptase human CRYAB-specific real-time PCR on RNA isolated 
from BLCL from the indicated patients. Relative transcript levels were 
determined by the formula 10,000 x 2(-delCt), where delCt equals Ct ((CRYAB) - 
Ct (β-actin)). (B) The Cos-7 cells transfected with human CRYAB were assayed 
for CRYAB protein expression by immunocytology, using a specific mAb, 
and subsequently visualized using a fluorescein-conjugated secondary 
antibody (arrowheads). The nuclei were stained with DAPI (asterisks). 
Original magnification was 400x. (C), T-cell lines generated from CSF of 
three CIS patients (patients LP33, LP52 and LP54) and one RRMS patient 
(LP51) were incubated, in duplicate, with Cos-7 cells that co-expressed the 
respective donor-specific HLA-I allele and human CRYAB. T-cell reactivity 
was measured by quantifying IFNγ secretion in conditioned medium, 
presented as (mean ± SD) of 2–3 independent experiments. The results of 
the CRYAB analyses on the CSF-TCL for individual HLA-I alleles, of patients 
LP33 (n=2) and LP51 (n=4), are shown in multiple colors. The negative and 
positive controls were CSF- TCL incubated with Cos-7 cells, transfected 
with a control vector (vector) or untransfected Cos-7 cells (TCL), and the 
CSF-TCL were stimulated with P/I.
BLCL: EBV-transformed B-cell lines; CRYAB: alpha B crystalline; DAPI: 4’, 
6-diaminidino-2- phenylindole; EBV: Epstein-Barr virus; mAb: monoclonal 
antibody; P/I: PMA and ionomycin; TCL: T-cell lines.
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Discussion
Despite strong epidemiological evidence, the potential pathological mechanisms 
initiated by EBV in MS remain unclear.1,2,11 If EBV is involved then the virus’ signature, 
either directly as viral remnants (e.g DNA) or indirectly as target of a local host immune 
response, should be selectively detectable or increased in brain tissue or alternatively CSF 
of MS patients. Most likely at early onset of disease.1,2 Data presented here supported the 
involvement of intrathecal EBV-specific T-cell responses in MS, particularly in CIS patients. 
We detected significantly higher frequencies of autoBLCL-reactive CD4+ T-cells in the CSF-
TCL from both CIS and MS patients, compared to OND patients (Figure 2A). Moreover, CIS 
patients also had significantly higher autoBLCL CD8+ T-cell reactivity, which only in this 
patient group was correlated with paired reactive CD4+ T-cell frequencies. This suggested 
a coordinated intrathecal CD4+ and CD8+ T-cell response directed toward either EBV or 
host antigens, expressed by autoBLCL (Figure 2B).
  Data are consistent with earlier reports on T-cell reactivity to autoBLCL in the CSF of 
MS patients.17,19,20 In contrast, neither EBV DNA nor intrathecal virus-specific IgG production 
was detectable in the CSF of the CIS and MS patients (data not shown). Whereas the 
latter data concur with reports that refute the role of EBV in MS,10–12,25 other groups did 
find EBV remnants and increased virus-specific IgG in the CSF of MS patients.7–9,32,33 The 
relatively long time interval at which the CSF samples of our patient cohort were obtained 
(>1 month after onset of disease) may have impeded detection of EBV DNA, but most 
likely not intrathecal EBV-specific IgG production.12,14 This B-cell/T-cell discrepancy may 
be methodological.2,3 Whereas intrathecal T-cell reactivity was performed on BLCL that 
in part expressed the whole EBV proteome, local antibody production was assayed 
only on one EBV protein (EBNA-1). Alternatively, the autoBLCL T-cell reactivity was not 
directed to EBV proteins, but to host proteins like the MS-associated autoantigen CRYAB, 
endogenously expressed by BLCL.2,18 Previous studies had not completely deciphered this 
autoBLCL phenomenon.17,19,20 They were either restricted to the analysis of a selective set 
of known immunodominant EBV peptides or used autologous dendritic cells pulsed with 
EBV or BLCL protein lysates as APC.19–22 Besides the limited number of peptides tested, 
which discounts issues like inter-HLA allele peptide affinity and post-translational peptide 
modifications, the caveat of the latter strategy is restriction to structural viral proteins 
and potential contamination of host proteins in case of EBV and BLCL protein lysates, 
respectively.13,14,30
  The artificial APC system applied here overcomes these potential drawbacks, by 
assaying CD8+ T-cell reactivity on cells that both endogenously express individual EBV 
proteins or human CRYAB, along with the HLA-I alleles that are involved in autoBLCL 
CD8+ T-cell recognition.28 Concurrent with a previous report no autoBLCL reactive T-cell 
recognized CRYAB.18 Although BLCL predominantly contained B-cells expressing latent 
viral proteins (Supplementary Figure 1), the intrathecal CD8+ T-cell targets were restricted 
to the lytic EBV proteins, classified as immediate early (BRLF1), early (BaRF1 and BXLF1), 
and late (BCRF1 and BBRF3) proteins (Figure 3).
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  The antigen diversity and kinetic class of the EBV CD8+ T-cell targets identified do 
not support CD8+ T-cell cross-reactivity between EBV and neuroantigens, but agreed 
with the current concept that early lytic EBV proteins are prominent CD8+ T-cell targets, 
respectively.13,14 Herein, we provide the first evidence for CD8+ T-cell recognition of the 
lytic EBV proteins BXLF1, BCRF1 and BBRF3. However, we did not confirm specific EBV 
proteins, especially EBNA-1 and DNA polymerase (BALF5), as targets of the intrathecal 
EBV-specific T-cells in MS patients.17,20,23 This discrepancy, likewise increased intrathecal 
EBV CD4+ T-cell reactivity though indifferent between MS and OND patients as reported 
by two independent groups19,22 is puzzling that needs follow-up. Despite differences on 
patient cohorts and experimental set-up, including autoBLCL versus peptides/lysates as 
antigens in functional assays on T-cells ex vivo versus CSF-TCL, the current data support 
the involvement of EBV-specific T-cells in the intrathecal inflammatory response in 
MS patients in the absence of a detectable intrathecal EBV infection.17,19–23 Additional 
support for this notion is provided by recent studies on the experimental autoimmune 
encephalomyelitis (EAE) model in common marmosets, suggesting the pivotal role of 
CD20 B-cells, infected with the EBV-like simian γ-herpesvirus CalHV3, as the APC for the 
pathogenic T-cell response.34
  Potential limitations of our study are i) a relatively large part of CSF-TCL from OND 
patients were generated several years ago, from a HuD-PNS study group (9/13 OND 
patients), ii) the potential bias in data interpretation due to prior knowledge of the 
patients’ diagnosis.27 First, all CSF-TCL were generated and subsequently analyzed in 
functional T-cell assays in the same lab (Department of Viroscience, Erasmus Medical 
Center) according to the same in-house SOPs. Moreover, we showed that even long-
term storage of CSF-TCL, particularly those generated from HuD-PNS patients, does 
not impair the immunocompetence of T-cells upon stimulation with P/I (Supplemental 
Figure 2). Second, the co-authors involved in generating and assaying the CSF-TCL for 
autoBLCL reactivity were blinded from the patients’ diagnosis, except for the HuD-PNS 
patient cohort. Subsequent in-depth analyses (i.e. TCRBV, EBV target antigen and CRYAB 
T-cell analyses) of selected high autoBLCL responders were performed on CSF-TCL of 
unmasked CIS and MS patients. In our opinion, the use and interpretation of T-cell assays 
performed according to in-house SOPs by the same operators, using appropriate controls 
and settings, have contained this potential drawback of our study.
  In conclusion, the current study provided novel insights into the association 
between EBV and MS. First, intrathecal T-cell reactivity towards autoBLCL was significantly 
increased in both CIS and MS patients, compared to other diseased controls. Second, in-
depth analysis of four high autoBLCL T-cell responders demonstrated that the intrathecal 
autoBLCL-specific CD8+ T-cell responses were oligoclonal and in two CSF-TCL directed 
toward the lytic EBV proteins, but not to CRYAB that was endogenously expressed 
by BLCL. The data suggested a local T-cell response to EBV in MS. This warrants further 
characterization of the magnitude and breadth of intrathecal EBV-specific T-cell responses 
using the whole EBV proteome in larger cohorts of patients and disease controls.
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Supporting information
Supplementary Figure 1. Human Epstein-Barr virus transformed B-cell lines express latent and lytic cycle 
viral proteins. Immunocytology of a representative Epstein-Barr virus (EBV) transformed B-cell line that shows 
widespread expression of latent (EBNA-1 and LMP1) and lower frequency expression of lytic cycle EBV proteins 
(BZLF1, BALF1 and BMRF1, indicated with white arrowheads). Cells were spotted on glass slides and stained 
with monoclonal antibodies directed to indicated EBV proteins and subsequently incubated with a fluorescein-
conjugated secondary antibody (white color). Nuclei were stained with DAPI (grey color). Bars indicate 100 µM 
and original magnification was 100-times.
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Supplementary Figure 2. T-cells in cerebral spinal fluid-derived T-cell lines are immunologically 
competent. Cerebrospinal fluid-derived T-cell lines (CSF-TCL) obtained from patients with other neurological 
disease (OND), clinically isolated syndrome (CIS) and multiple sclerosis (MS) were stimulated with a combination 
of phorbolmyristate-acetate (PMA; 50 ng/ml) and ionomycin (500 ng/ml) to determine the immunecompetence 
of CD4+ and CD8+ T-cells. Stimulated cells were stained for viability, surface CD3, CD4 and CD8, and intracellular 
interferon-γ and subsequently analyzed using flow cytometry. Dots represent data of individual CSF-TCL, 
presented as percentage IFNγ+ cells of all CD4+ or CD8+ T-cells in the corresponding CSF-TCL, and bars and 
whiskers indicate the mean and standard deviation.
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Abstract
T-cells are considered pivotal in the pathology of multiple sclerosis (MS), but their function 
and antigen-specificity are unknown. To unravel the role of T-cells in MS pathology, we 
performed a comprehensive analysis on T-cells recovered from paired blood, cerebrospinal 
fluid (CSF), normal-appearing white matter (NAWM) and white matter lesions (WML) 
from 27 MS patients with advanced disease shortly after death. The differentiation 
status of T-cells in these compartments was determined by ex vivo flow cytometry and 
immunohistochemistry. T-cell reactivity in short-term T-cell lines (TCL), generated by non-
specific stimulation of T-cells recovered from the same compartments, was determined 
by intra-cellular cytokine flow cytometry. Central memory T-cells predominated in CSF 
and effector memory T-cells were enriched in NAWM and WML. WML-derived CD8+ T-cells 
represent chronically activated T-cells expressing a cytotoxic effector phenotype (CD95L 
and granzyme B) indicative for local antigenic stimulation (CD137). The same lesions 
also contained higher CD8+ T-cell frequencies expressing co-inhibitory (TIM3 and PD1) 
and co-stimulatory (ICOS) T-cell receptors, yet no evidence for T-cell senescence (CD57) 
was observed. The oligoclonal T-cell receptor (TCR) repertoire, particularly among CD8+ 
T-cells, correlated between TCL generated from anatomically separated WML of the same 
MS patient, but not between paired NAWM and WML. Whereas no substantial T-cell 
reactivity was detected towards seven candidate human MS-associated autoantigens 
(cMSAg), brisk CD8+ T-cell reactivity was detected in multiple WML-derived TCL towards 
autologous Epstein-Barr virus (EBV) infected B-cells (autoBLCL). In one MS patient, the T-cell 
response towards autoBLCL in paired intra-lesional TCL was dominated by TCRVβ2+CD8+ 
T-cells, which were localized in the parenchyma of the respective tissues expressing 
a polarized TCR and CD8 expression suggesting immunological synapse formation in 
situ. Collectively, the data suggest the involvement of effector memory cytotoxic T-cells 
recognizing antigens expressed by autoBLCL, but not the assayed human cMSAg, in WML 
of MS patients.
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Introduction
Multiple sclerosis (MS) is a chronic debilitating disease characterized by inflammation of 
the central nervous system (CNS), leading to demyelination and axon damage. The cause 
and pathogenic pathways involved remain enigmatic. MS is considered the result of a local 
inflammatory response in genetically susceptible individuals initiated by environmental 
factors.1,2
  MS immunopathology has been widely studied in experimental autoimmune 
encephalomyelitis (EAE) animal models. EAE is induced by immunization with candidate 
MS-associated CNS autoantigens (cMSAg) in adjuvant and by adoptive transfer of cMSAg-
specific CD4+ T-cells. These studies reinforced the idea that MS is an autoimmune disease 
mediated by cMSAg-specific CD4+ Th1/Th17-cells.3 Indeed, CD4+ T-cell responses to 
the majority of EAE-inducing cMSAg have been identified in peripheral blood (PB) and 
occasionally CSF of MS patients.2–4 However, their frequency in PB of MS patients was 
indifferent compared to controls, questioning their pathogenic potential.2,5 The additional 
role of CD8+ T-cells in MS and EAE immunopathology has only recently emerged.3,5 In 
MS patients, CD8+ T-cells outnumber CD4+ T-cells in active lesions and closely interact 
with oligodendrocytes and demyelinating axons.1,5,6 CD8+ T-cells infiltrates in active 
white matter lesions (WML) are oligoclonal and persist in CSF and peripheral blood.7–9 
Human cMSAg-specific CD8+ T-cells lyse human leukocyte antigen (HLA) class I-matched 
oligodendrocytes in vitro.10–12 The cytotoxic effector mechanisms involve both the Fas/
FasL and perforin/granzyme B (grB) pathways.12–15
  Current data advocate Epstein-Barr virus (EBV) infection as risk factor in MS.16,17 
The epidemiological similarity of MS and EBV-induced infectious mononucleosis (IM), 
enhanced systemic B- and T-cell responses to EBV in MS patients compared to (disease) 
controls, and the putative presence of EBV-infected B-cells in MS lesions are indicative.18–20 
Even though evidence for the presence of EBV in MS lesions remains incredulous,21 EBV 
may evoke T-cell-mediated MS immunopathology in different ways.22,23 Virus-specific 
T-cells may recognize EBV-infected cells in the brain or alternatively cross-react with 
cMSAg.24 Alternatively, IM-associated systemic immune activation may result in a cytokine 
environment that activates pathogenic T-cells, including cMSAg-specific T-cells, in an 
antigen independent manner.16,17
  The aims of this study were to characterize the differentiation status and antigen-
specificity of T-cells recovered from paired white matter tissues containing WML, normal-
appearing white matter (NAWM), CSF and PB from 27 patients with advanced MS.
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Materials and methods
Clinical specimens
Heparinized PB (3-6 ml; n=19), CSF (8-20 ml; n=17), and macroscopically-defined NAWM 
(n=23) and WML (n=29), were obtained from 27 MS patients (median age 59 yr, range 35-95 
yr) at autopsy with a median post-mortem interval of 9.6 hr (range 4.8-14 hr) (Supplementary 
Table 1). All patients had advanced disease (median disease duration 25 yr, range 10-54 yr), 
expanded disability status scale >6 and the majority had primary or secondary progressive 
MS (22 of 25, 88%). Leading cause of death was legally granted euthanasia for 11 of 27 
(44%) patients. Additionally, 12 formalin-fixed and paraffin-embedded (FFPE) tissues of 
10 diseased MS patients were collected (Supplementary Table 2). Clinical specimens of 
deceased MS patients were collected by the Netherlands Brain Bank (NBB; Amsterdam, The 
Netherlands) and genital skin biopsies of six patients with herpes simplex virus type 2 (HSV-
2) genital herpes (GH) were obtained by the department of Dermatology and Venereology 
(Erasmus MC, Rotterdam, The Netherlands). Written informed consent for brain autopsy 
and genital skin biopsies, use of clinical specimens and clinical information for research 
purposes have been obtained in advance from all study participants. Study procedures 
were performed in compliance with Dutch legislation and institutional guidelines, approved 
by the respective local ethical committees for use of MS patient material (project number 
2009/148; VU University Medical Center, Amsterdam) and skin biopsies of GH patients 
(project number MEC 167.153/1998/15; Erasmus MC) performed in accordance with the 
ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments 
or comparable ethical standards. During autopsy, WML was distinguished macroscopically 
from NAWM based on grey appearance and by being firm to touch. PB was used to generate 
EBV-transformed B-cell lines (BLCL) and for 2-digit HLA typing as described.25 Part of white 
matter tissues (1-4 gr) were snap-frozen and stored at -80°C for subsequent in situ analysis. 
Remaining tissue was dispersed to single cell suspensions as described.25 About one-tenth 
of the single cell suspension was snap-frozen for subsequent EBV-specific EBER1 transcript 
expression analysis and remaining cells were used for ex vivo flow cytometric analysis and to 
generate short-term T-cell lines (TCL) as described.25 In brief, CSF and lymphocyte-enriched 
brain tissue cell suspensions were stimulated with phytohemaglutinin-L (1 µg/ml; Roche, 
Branford, CT) for 10-14 days and subsequently with an anti-CD3 monoclonal antibody (mAb) 
(clone OKT-3; Janssen-Cilag, Tilburg, the Netherlands) for 10-14 days in the presence of 
g-irradiated (3,000 rad) allogeneic PBMC and recombinant human interleukin 2 (rIL-2 IU/ml) 
and rIL-15 (25 ng/ml; both Miltenyi biotec, Bergisch Gladbach, Germany).20 
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In situ analyses of brain tissues
To classify the WM tissues of MS patients, brain tissues were characterized by 
immunohistochemistry (IHC) as NAWM, diffuse white matter abnormalities (DWMA), active 
lesions (AL), mixed active/inactive lesions (mAIL) and inactive lesions (IL) as described in 
the recently updated classification system for MS brain lesions26 (representative stainings of 
defined WM tissues of MS patients are shown in Supplementary Figure 1).  In brief, consecutive 
7-9 µm cryostat brain sections were air-dried, fixed with acetone and subsequently assayed 
for: i) (de-) myelination by anti-myelin oligodendrocyte protein (MOG) (clone Z12; kindly 
provided by prof. Sandra Amor, VU medical center, Amsterdam), ii) immune activation using 
anti-HLA-DP/DQ/DR mAb (CR3/43; Dako, Glostrup, Denmark), iii) presence of macrophages 
and microglia using anti-CD68 (clone EMB11; Dako). Granzyme B expressing T-cells were 
detected in consecutive 6 µm sections of FFPE mAIL tissue of four representative MS patients 
stained for CD3 (clone F7.2.38), CD8 (C8/144B), grB (GrB-7, all Dako). Stainings were visualized 
by 3-amino-9-ethylcarbazole as described.25 Intracellular localization of grB and cytotoxic 
potential of CD8+ T-cells was assessed in 8 µm FFPE sections by triple immunofluorescent 
stainings using mAb directed to CD8 (clone YTC182.20, AbD Serotec), grB and cleaved 
caspase 3 (cCASP3; clone G7481, Promega, Madison, USA). The presence of tissue-resident 
T-cells (T
RM
) was assessed analogously by detecting CD8, CD69 (FN50, Biolegend) and CD103 
(2G5.1, Thermo Fisher) expression in WML of MS patients and as control skin biopsies of 
GH patients. CD8+ T-cells expressing grB in the parenchyma and perivascular space of mAIL 
sections were counted in multiple z-stack scans acquired at 400x magnification. To determine 
the CNS cell types encountered by intra-lesional CD8+ T-cells, double immunofluorescence 
stainings were performed on 8 μm FFPE sections of WML biopsies. CNS cell types were 
visualized using mAbs directed to neuron-specific neurofilament heavy chain (NF-H, clone 
SMI-31, Biolegend), microglia-specific ionized calcium-binding adapter molecule 1 (Iba1; 
clone 019-19741, Wako, Osaka, Japan), oligodendrocyte-specific proteolipid protein (PLP; 
clone plpc1, AbD serotec) and astrocyte-specific glial fibrillary acidic protein (GFAP; clone 
Z0334, Dako) combined with an anti-CD8 mAb (C8/144B). Antibody binding was visualized 
by AF488-conjugated Rat IgG (A-11006), AF568- conjugated IgG1 (A-21124), AF488- or 
AF647-conjugated IgG2a (A-21131 or A-21241) or AF647- conjugated rabbit IgG-specific (A-
21246, all Invitrogen) antibodies. To detect T-cell receptor beta chain 2 (TCRVβ2) expressing 
T-cells in situ, 8 µm cryostat brain sections were stained with APC-conjugated CD8 (RPA-T8, 
BD), FITC-conjugated TCRVβ2 (MPB2D5; Beckman Coulter) and laminin (L9393; Sigma) mAb 
combined with AF594-conjugated anti-rabbit IgG (R37119; Invitrogen). TCRVβ2 staining was 
amplified using the FASER kit (Miltenyi biotec). For all fluorescent stainings, nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI) to visualize nuclei and sections scanned 
using LSM700 confocal microscope and Zen 2010 software (Zeiss; Oberkochen, Germany). 
Appropriate (fluorochrome-) matched Ig isotype antibodies were used as negative controls 
for all stainings and stainings scored by two independent observers.
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Ex vivo T-cell phenotyping
Paired PB-, CSF-, NAWM- and WML-derived cells were incubated with combinations of 
fluorochrome-conjugated mAb directed to following markers: CD3 (clone UCHT1), CD4 
(SK3 or RPA-T4), CD8 (SK1 or RPA-T8), CD27 (M-T271), CD45 (TU116), CD56 (B159), CD137 
(4-1BB; all Becton Dickinson (BD), Franklin Lakes, NJ), CD57 (HCD57), CD95L (NOK-1), ICOS 
(C398.4A), PD1 (EH12.2H7), TIM3 (F38-2E2; all Biolegends, San Diego, CA) and CD45RA 
(HI100; Pharmingen, San Diego, CA). Cells were measured on a Canto II flow cytometer (BD). 
Negative controls consisted of stainings with appropriate Ig isotype control antibodies. If 
a parent-population contained <100 events, the gated cell population was omitted from 
further analysis.
Quantitative EBV transcript expression analysis
Snap-frozen brain tissue-derived single cell pellets were used for RNA isolation and 
cDNA synthesis as described.25 EBV EBER1 transcript expression was quantified by real-
time quantitative PCR (qPCR) using forward primer 5’-TCATAGGGAGGAGACGTGTGT-3’, 
reverse primer 5’-TGACCGAAGACGGCAGAAAG-3’ and probe 5’FAM-
AGACAACCACAGACACCGTGGTGACCA-3’MGB (all Eurogentec; Liege, Belgium). RNA 
isolated from water and BLCL served as negative and positive controls in each run, 
respectively. For each sample β-actin transcripts (Hs01060665_g1, Applied Biosystems) 
were used as positive control for RNA isolation and cDNA synthesis. Sensitivity of the 
EBER1-specific qPCR was determined as 1-10 BLCL per 106 PBMC (data not shown). An ABI 
prism 7500 and Taqman Universal Master Mix (both Applied Biosystems; Nieuwerkerk, the 
Netherlands) were used for all qPCR reactions as described.25
Functional T-cell assays
T-cell reactivity towards EBV-infected B-cells in CSF-, NAWM- and WML-TCL was determined 
by incubation with autologous EBV-transformed B-cell lines (autoBLCL) as antigen presenting 
cell (APC) as described previously.20 The frequency of B-cells in BLCL lines (n=5) undergoing 
spontaneous lytic cycle infection was determined by flow cytometric analysis of EBV 
glycoprotein 350 expression (clone OT.1C-2, kindly provided by Prof.dr. J.M. Middeldorp, VU 
medical Centre, Amsterdam, the Netherlands). An allogeneic BLCL (BLCL-GR; HLA-A*01;03, 
HLA-B*07;27, HLA-C*02;07, HLA-DRB1*13;15, HLA-DQB1*06;06), carrying the major MS-
associated HLA class I and II risk alleles (HLA-A*03, HLA-DRB1*15 and HLA-DRB1*13),27 was 
transduced to express the 7 following human cMSAg constitutively: i) oligodendrocyte-specific 
proteins [myelin-associated glycoprotein (MAG), myelin basic protein isoform 1 (MBP1) 
and myelin oligodendrocyte glycoprotein (MOG)], ii) neuron-specific proteins [contactin-2 
(CNTN2) and 155kD isoform of neurofascin (NFASC)] and iii) glia-specific proteins [inwards 
rectifying potassium channel (KIR4.1) and S100 calcium binding protein B (S100B)].28 Stable 
cMSAg-expressing BLCL-GR lines, validated by flow cytometry using cMSAg-specific mAb, 
were used as allogeneic APC to detect cMSAg-specific CD4+ and CD8+ T-cells simultaneously 
in TCL of HLA-matched MS patients (Supplementary Table 1).28 To validate this BLCL platform, 
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we also transduced BLCL-GR to express measles virus fusion protein (MVF) and assayed 
their APC function by incubation with MVF-specific CD4+ (4-F99) and CD8+ (2-F40) T-cell 
clones (TCC) as described previously.28 Stimulated T-cells were stained with fluorochrome-
conjugated mAb to human CD3 (SP34-2), CD4 (SK3), CD8α (RPA-T8) and for viability (violet 
live/dead stain; Invitrogen). Subsequently, cells were fixed, permeabilized and stained 
for intracellular IFNγ (B27) and CD137 (4-1BB, all BD) and finally measured on a Canto II 
flow cytometer. Combined intracellular IFNγ and CD137, two independent T-cell activation 
markers induced upon antigenic stimulation, was set as criterion to identify antigen-specific 
T-cells.20,29 TCL stimulated with phorbolmyristate-acetate (PMA; 50 ng/ml) and ionomycin 
(Iono; 500 ng/ml; both Sigma), or mock-stimulated TCL, were used as positive and negative 
control, respectively. Netto reactivity of CD4+ and CD8+ T-cells towards cMSAg-transduced 
BLCL-GR was calculated by subtracting T-cell reactivity to cMSAg-transduced BLCL-GR with 
mock-transduced BLCL-GR. Threshold for positive cMSAg T-cell reactivity was calculated as 
previously reported.28 Experiments were performed in at least two independent occasions.
T-cell receptor repertoire analysis
The clonality of NAWM- and WML-derived TCL was determined using a set of fluorochrome-
conjugated mAb to 24 different human TCRVβ chains covering approximately 70% of the 
known human TCRVβ repertoire (IOTest Beta Mark mAb kit; Beckman Coulter, Marseille, 
France) combined with mAb to CD3, CD4 and CD8. TCRVβ usage of autoBLCL-specific T-cells 
in WML-TCL was identified by CD3, CD4, CD8 and TCRVβ combined with intracellular IFNγ 
staining and flow cytometry. T-cell clonality was also determined by the TCR gamma (TCRγ) 
gene rearrangement Assay 2.0 (Invivoscribe, San Diega, CA) performed in duplo on DNA 
isolated from FACSsorted viable CD8+ T-cells of paired brain tissue-derived TCL of 8 MS 
patients, and as control PBMC and two monoclonal human T-cell leukemic cell lines (MOL3 
and KL 1985-001), according to manufacturers’ instructions (Invivoscribe).
Data analysis and statistics
Flow cytometry data was analyzed with FlowJo (Tree Star Inc.; Ashland, OR) software. 
Paired data was assessed using Wilcoxon-signed rank test. Significance of variation in 
cMSAg- and autoBLCL-specific T-cell reactivity was determined by ANOVA for CD4+ and 
CD8+ T-cells separately. Unpaired t-test was used to determine significance of autoBLCL 
T-cell reactivity. All statistical analyses were performed using Graphpad Prism 5 software 
(Graph Pad Inc.; La Jolla, CA).
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Results
Macroscopically-defined NAWM of MS patients 
with advanced disease contain diffuse white matter 
abnormalities
To characterize the role of T-cells in MS, we collected 
paired PB, CSF, NAWM and WML specimens from 27 
deceased patients with advanced MS (Supplementary 
Table 1). The presence and classification of the 
WM tissues sampled was determined by IHC on 
representative snap-frozen sections of surplus NAWM 
and WML sections (Supplementary Figure 1);26 
provided adequate size of brain tissues was available. 
All macroscopically-defined lesions were confirmed as 
WML and all contained demyelinated areas classified as 
AL, mAIL or IL.26 Notably, 9 of 20 (45%) macroscopically-
defined NAWM tissues presented as DWMA consisting 
of increased numbers of macrophage/microglia and 
high HLA class II expression (Supplementary Table 
1). These DWMA represent periplaque abnormalities, 
Wallerian degeneration or pre-lesional changes.26 The 
spatial distribution of T-cells was determined on paired 
NAWM and WML tissues from 5 MS patients. In both 
NAWM and active WML, T-cells were mainly detected 
in the Virchow-Robin space (Figure 1A). However, 
parenchyma-infiltrating T-cells were selectively 
observed in WML suggesting that these T-cells are not 
part of immune surveillance, but rather involved in the 
local inflammatory response.6,30
Effector memory CD8+ T-cells are the main T-cell 
subset in NAWM and WML of MS patients
To determine the phenotype and differentiation status 
of T-cells in MS patients ex vivo, paired PB, CSF, and 
lymphocyte-enriched NAWM- and WML-derived single 
cell suspensions of 17 MS patients were subjected to 
multiplex flow cytometric analysis. T-cells were selected 
by lymphocyte, CD45high and CD3 gating, and finally 
sub-classified as CD3+CD4high and CD3+CD8high T-cells 
based on PB-derived T-cells. In contrast to PB and CSF, 
brain tissue derived CD3+ cells frequently expressed 
low levels of CD4 or CD8, and on occasion were devoid 
◄ Figure 1. CD8+ T-cells in normal-
appearing and diseased white 
matter tissues of MS patients 
preferentially express an effector 
memory phenotype. (A and B) 
Parenchymal T-cells are selectively 
detected in active MS lesions. 10-µm 
cryostat sections of paired (A) normal-
appearing white matter (NAWM) 
and (B) white matter lesion (WML) of 
two representative patients of five 
MS patients analyzed. CD3 express- 
ing cells (T-cells) were stained with 
3-amino-9-ethylcarbazole (red color) 
and counterstained with hematoxylin 
(blue color). Whereas perivascular 
T-cells were detected in both NAWM 
and WML, parenchymal T-cells were 
exclusively detected in active WML of 
MS patients. (C) Percentages of CD4+ 
and CD8+ T-cells, and CD4+/CD8+ 
T-cell ratio, are shown for paired PB 
(open circles), CSF (closed cir- cles) and 
histologically defined as NAWM (open 
squares) and WML (filled squares). 
Lymphocytes were isolated from paired 
peripheral blood (PB), cerebrospinal 
fluid (CSF), NAWM and WML (lesion) 
from patients with advanced MS 
(n=17) and subjected to multi- plex 
flow cytometry. Gating procedure 
of CD4+ and CD8+ T-cells is shown 
in Online Resource 3. (D) CD8+ 
T-cells were subdivided in naïve 
(CD27+CD45RA+), central memory 
(CM; CD27+CD45RA−), effector 
memory (EM; CD27−CD45RA−) and 
terminally differenti- ated effector 
memory (EMRA; CD27−CD45RA+) 
T-cells. Gating procedure is shown 
for representative paired PB and 
WML-derived CD8+ T-cells. (E) The 
frequency of naïve, CM, EM and EMRA 
CD8+ T-cells is shown for paired PB, 
CSF and white matter brain tissues 
that were immunohistologically 
classified as NAWM, diffuse white 
matter abnormalities (DWMA), 
active lesions (AL), mixed active/
inactive lesions (mIAL), inactive 
lesion (IL) or unconfirmed white 
matter tissues (UWM) (see Online 
Resource 3 for criteria applied for 
MS WM classification). Horizontal 
lines represent the mean frequen- 
cies. Wilcoxon matched pairs test 
was used to calculate significance 
Sensitivity
Thesis final.indd   127 05-12-17   09:35
Phenotype and function of intralesional T-cells of MS patients7
Ch
ap
te
r 7
128
of CD4 and CD8 expression (Supplementary Figure 2). As 
these different T-cell subtypes are difficult to differentiate 
by flow cytometry and no consensus exists in literature on 
their origin, we omitted them from further analysis and only 
focused on T-cells expressing high levels of CD4 or CD8. 
The latter uniform gating strategy was chosen to compare 
the activation and differentiation status of the same CD4+ 
and CD8+ T-cells between multiple anatomic locations of 
the same individual. In both NAWM and WML, CD8+ T-cells 
dominated as shown by the significantly lower CD4+/CD8+ 
T-cell ratio in NAWM and WML compared to PB and CSF 
(Figure 1C).
  Next, the differentiation status of T-cells was compared 
between compartments based on differential surface 
expression of CD45RA and CD27 (Figure 1C).29 Naive (TNA; 
CD27+CD45RA+) CD8+ T-cells were readily identified in PB, 
less frequently in CSF and rarely in NAWM and WML (Figure 
1D). Central memory (TCM; CD27+CD45RA-) CD8+ T-cells 
were the dominant phenotype in CSF. Effector memory 
(TEM; CD27-CD45RA-) CD8+ T-cells predominated in both 
NAWM and WML, with frequencies 2-fold higher compared 
to PB and CSF. Finally, terminally differentiated memory 
(TEMRA; CD27-CD45RA+) T-cell frequencies were equivalent 
in PB, NAWM and WML, but lower in CSF. No significant 
differences in CD4+/CD8+ T-cell ratio and CD8+ T-cell 
differentiation status were observed between different 
WM types. Low numbers of CD4+ T-cells in most WML and 
NAWM specimens precluded conclusive definition of their 
differentiation status (data not shown). In conclusion, CD8+ 
TEM cells are enriched in both NAWM and WML of the MS 
patients analyzed.
  The expression of CD69 and CD103, two proteins described to enhance long-term 
retention of T-cells within peripheral tissues also referred as TRM cells,
31 was determined on 
CD8+ T-cells in WML cryosections of 6 MS patients by triple immunofluorescence staining. 
We first validated our staining protocol by analyzing skin biopsies of 6 HSV-2 GH patients. 
In agreement with a previous study, the majority of human genital skin CD8+ TRM expressed 
CD69 and about 20% of these cells co-expressed CD103 (Figure 2A).31,32 In contrast, both 
perivascular and parenchymal CD8+ T-cells in WML of MS patients exclusively expressed 
the CD8+CD69+CD103- phenotype (Figure 2B). These data contrast previous studies 
on mouse CNS- and human glioma-derived CD8+ T-cells showing that about half of 
CD8+CD69+ TRM cells in CNS tissue co-express CD103.
33 Because CD69 is also expressed 
by T-cells early after TCR and cytokine activation,29 and since CD103 is debated as reliable 
TRM marker,
34 the CD8+CD69+CD103- T-cells detected in WML of the MS patients analyzed 
may denote genuine CD8+ TRM cells, represent activated T-cells or a mixture thereof.
29,31,33,34
►Figure 2. CD8+ T-cells in white 
matter lesions of MS patients 
preferentially express CD69, 
but not CD103. Representative 
triple immunofluorescent 
stainings on 8 μm cryosections 
of (A) skin biopsies from six 
genital herpes patients and 
(B) immunohistochemically 
classified white matter lesions 
(WML) of six MS patients. 
Tissues were stained for CD8 
(green color), CD69 (white 
color) and CD103 (red color) 
using specific monoclonal 
antibodies (mAbs) and isotype 
specific fluochrome-conjugated 
secondary antibodies. Sections 
were counterstained with 
4’,6-diamidino-2-phenylindole 
(DAPI; blue color) and analyzed 
using a Zeiss LSM-700 confocal 
laser microscopy and ZEN 
software. Skin biopsies of genital 
herpes patients were stained 
as positive control to validate 
staining strategy by confirming 
localization tissue-resident CD8+ 
T-cells based on differential 
CD69 and CD103 staining: 
CD8+CD69+CD103- (A; inset 1) 
and CD8+CD69+CD103+ T-cells 
(A inset 2). In WML of MS patients 
(B), perivascular (top panels) 
and parenchymal CD8+ T-cells 
(bottom panels) were incidentally 
CD69-CD103- T-cells (B; insets 
3 and 5) and predominantly 
CD69+CD103- T-cells (B; inset 4 
and 6). Size bar is indicated in top 
right image.
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Figure 3. CD8+ T-cells in white matter lesions of MS patients are chronically activated T-cells expressing a 
cytotoxic effector T-cell phenotype. Flow cytometric analysis of cytotoxic molecule CD95L and co-stimulatory 
receptor CD137 (A and B), co-inhibitory receptors TIM3 and PD1 (C and D) and co-stimulatory molecule ICOS 
and senescence marker CD57 (E and F) expression on CD8+ T-cells in paired peripheral blood (PB, open circles), 
cerebrospinal fluid (CSF, closed circles) and brain tissues histologically defined as normal-appearing white 
matter (NAWM, open squares) and white matter lesions (WML, filled squares) classified as diffuse white matter 
abnormalities (DWMA), active lesions (AL), mixed active/inactive lesions (mIAL) and inactive lesions (IL) of 17 
MS patients (see Supplementary Figure 1for criteria applied for MS WM classification). Lymphocyte gating was 
performed as described in the legend of Supplementary Figure 2. Gating strategies and percentages of marker 
positive CD8+ T-cells in paired anatomic compartments are shown. If a parent population contained <100 
events, daughter populations were omitted in further analysis. Horizontal lines indicate the mean. Wilcoxon 
matched pairs test was used to calculate significance.
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Phenotype of CD8+ T-cells in white matter lesions of MS patients implicate a local 
antigen-specific cytotoxic T-cell function
To determine the effector function and activation status of CD8+ T-cells ex vivo between 
different compartments of MS patients, expression of the death signal and co-stimulatory 
receptor FasL (CD95L) and the early activation marker CD137 were determined by 
multiplex flow cytometry on CD8+ T-cells (Figure 3A). Expression of both CD95L and 
CD137 is induced on antigen stimulated CD8+ T-cells and interaction of FasL with its 
receptor Fas may lead to target cell lysis.29 Compared to PB, significantly more CD8+ T-cells 
in WML were positive for CD95L and CD137, which was predominantly observed in DWMA 
(Figure 3B).
  In addition to the Fas/FasL-pathway, T-cell cytotoxicity involves exocytosis of 
granules containing perforin and granzymes.35 Previous studies showed lowered30 or 
absent36 intrathecal expression of perforin and grB by CD8+ T-cells in non-inflammatory 
CNS conditions, suggesting a functionally repressed phenotype of CNS surveilling T-cells. 
Contrastingly, grB+CD8+ TEM cells appeared enriched in CSF of MS patients.
37 To address 
this issue, consecutive sections of mAIL WML from four MS patients were stained for 
CD3, CD8 and grB (Figure 4A). Whereas the majority of CD8+ T-cells showed abundant 
whilst punctated grB expression, a fraction of CD8+ T-cells showed a more polarized 
grB expression pattern in both perivascular and parenchymal CD8+ T-cells (Figure 4A). 
GrB distribution and cytotoxic potential of CD8+ T-cells was confirmed using Z-stack 
confocal laser microscopy on 12 WML biopsies of 10 additional MS patients assayed by 
triple immunefluorescence staining for CD8, grB and the early apoptotic marker “cleaved 
caspase 3” (cCASP3). Occasionally adjacent cells expressed cCASP3 suggesting CD8+ T-cell 
mediated cytotoxity in situ (Figure 4B). Parenchymal CD8+ T-cells were most frequently 
identified in mAIL (data not shown). The frequency of grB-expressing CD8+ T-cells in 
the parenchyma tended to be higher compared to the paired perivascular regions in 
mAIL (Figure 4C). Collectively, the data indicate that CD8+ T-cells in WML of MS patients 
analyzed express a cytotoxic phenotype indicative for T-cells recognizing their cognate 
antigen in situ.35
CD8+ T-cells in white matter lesions of MS patients are chronically activated T-cells 
expressing a cytotoxic effector T-cell phenotype
The repertoire of co-stimulatory and co-§inhibitory receptors determines the fate of 
T-cells after antigenic challenge.29,38 Chronic antigenic stimulation leads to upregulation 
of co-inhibitory receptors that negatively affect their proliferative potential, effector 
function and survival.29 In CNS, co-signaling via transmembrane immunoglobulin mucin 
3 (TIM3) and programmed cell death type 1 (PD1) are important immunoregulatory 
mechanisms.39 Hence, the frequency of CD8+ T-cells expressing TIM3 and PD1 ex vivo was 
compared between different compartments by multiplex flow cytometry (Figure 3C and 
3D). Compared to PB, significantly more CD8+ T-cells in both CSF and MS lesions expressed 
TIM3 and PD1. In WML, this was largely attributed to CD8+ T-cells in DWMA. Chronic T-cell 
Thesis final.indd   131 05-12-17   09:35
Phenotype and function of intralesional T-cells of MS patients7
Ch
ap
te
r 7
132
stimulation may ultimately result in an apoptosis-
resistant and senescent phenotype, characterized by 
human natural killer-1 receptor expression (CD57). 
This phenotype is potentially reverted by specific 
cytokines (e.g., IL-2 and IL-15) resulting in upregulated 
expression of the inducible co-stimulator (ICOS) 
molecule on T-cells.38 No significant difference was 
observed in ex vivo CD57 expression by CD8+ T-cells 
between different compartments, arguing against 
senescent CD8+ T-cells in MS (Figure 3E and 3F). 
Frequencies of ICOS+CD8+ T-cells were significantly 
elevated in WML compared to PB and CSF, but were 
similar between NAWM and the different types of 
WML. Collectively, the data demonstrate that CD8+ 
T-cells in WML of MS patients exhibit characteristics of 
chronically activated T-cells.
  To identify the brain cell types that interact with 
CD8+ T-cells, double immunofluorescence stainings 
on WML tissue sections of 12 FFPE tissues of 10 MS 
patients were performed (Supplementary Table 2). 
Hereto, anti-CD8 mAb was combined with antibodies 
directed to specific proteins expressed by human 
astrocytes (GFAP), microglia (Iba1), oligodendrocytes 
(PLP) and neurons (NF-H) (Figure 5). Perivascular 
CD8+ T-cells interacted preferentially with astrocytes 
and microglia. Parenchymal CD8+ T-cells interacted 
with astrocytes, microglia, oligodendrocytes in 
fully myelinated and partially demyelinated areas. 
Moreover, they interacted with neurons in areas 
with and without prominent axonal swelling, 
indicative of neuronal stress or axonal damage due to 
demyelination.40 Hence, CD8+ T-cells in WML of the MS 
patients analyzed showed no preferential interaction 
with a specific brain cell type (Figure 5).
►Figure 4. CD8+ T-cells in white 
matter lesions of MS patients express 
granzyme B. (A) Representative 
stainings on 6 µm sections of a formalin-
fixed and paraffin-embedded (FFPE) 
mixed active/inactive white matter 
lesion (mAIL) of 1 of 4 MS patients 
analyzed. CD3 (top panel), CD8 (middle 
panel) and granzyme B (grB) expressing 
cells (bottom panel) were stained with 
3-amino-9-ethylcarbazole (red color) and 
counterstained with hematoxylin (blue 
color). Abundant punctate expression of 
grB was detected in perivascular (insets 
I, III and V) and parenchymal (insets 
II, IV and VI) CD8+ T-cells. Granzyme 
B polarization was observed in both 
perivascular and parenchymal CD8+ 
T-cells (insets V and VI). (A) Representative 
maximum intensity projections of 
z-stack laser confocal microscopy 
images of immunofluorescent triple 
stainings for grB (green color), CD8 
(red color) and the early apoptotic cell 
marker “cleaved caspase-3” (cCASP3; 
white color). Stained sections were 
counterstained with DAPI (blue color). 
Representative stainings of three mAIL 
are shown of 12 immunohistochemically 
classified WML tissues of 10 MS patients 
analyzed. Punctated (inset 1) and 
polarized grB expression by CD8+ T-cells 
(insets 3 and 5), as well as grB-negative 
CD8+ T-cells are shown (insets 2, 4 and 
6). Co-localization of grB and cCASP3 is 
observed in a cell adjacent to a CD8+ 
T-cell with polarized grB suggesting grB-
mediated killing of the respective target 
cell (inset 5). Dotted line represents the 
glia limitans separating the perivascular 
space and parenchyma. (C) The grB-
expressing CD8+ T-cells were counted in 
the perivascular space and parenchyma 
of mAIL of four MS patients analyzed. 
Wilcoxon matched pairs test was used to 
calculate significance.
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Correlation of TCR repertoire between TCL generated 
from distinct lesions of the same MS patient
The markers expressed by CD8+ T-cells in WML suggest 
antigen-driven activation and potentially retention of 
specific TCC in affected tissue of MS patients (Figure 
3 and 4). Given the low T-cell numbers in the clinical 
specimens obtained, T-cell clonality was assayed on 
short-term TCL generated by non-specific stimulation 
of T-cells recovered from paired CSF, NAWM and WML 
specimens. TCRVβ chain usage of CD4+ and CD8+ 
T-cells was determined by flow cytometry on paired 
NAWM- and WML-TCL (n=4 patients) and paired WML-
TCL (n=6 patients) (Supplementary Figure 3). Most TCL 
showed oligoclonal TCRVβ repertoires, but no specific 
TCRVβ predominated among patients. Whereas the 
TCRVβ repertoire of paired NAWM- and WML-TCL did 
not match, a significant correlation was observed for 
CD4+ and particularly CD8+ T-cells in paired WML-TCL 
of 2/6 and 4/6 MS patients, respectively (Supplementary 
Figure 3). The shared TCRVβ chain usage implicates 
enrichment of specific TCC in distinct WML of the same 
MS patient. To address this issue in more detail, we 
assayed the composition of the TCR repertoire of CD8+ 
T-cells in paired NAWM/WML- (n=3) and WML/WML-TCL 
(n=5) by performing TCRγ-rearrangement spectratyping 
on sorted CD8+ T-cells (Supplementary Figure 4).41 The 
TCRG locus is rearranged early during T-cell development 
in both TCR-αβ and -γδ lineage precursors and is 
considered the prototypic TCR locus for the detection of 
T-cell clonality in clinical specimens.41 Typical polyclonal 
Gaussian curves signifying polyclonality, or one or two 
peaks illustrative for the rearrangement of the TCRG locus on one or both chromosomes, 
were detected when human PBMC or monoclonal T-cell leukemic cell lines (MOLT3 and KL 
1985-001) were assayed, respectively (Supplementary Figure 4).41 TCRG GeneScan analyses 
demonstrated a reproducible, markedly restricted pattern of TCRG rearrangements by 
CD8+ T-cells in the brain-derived TCL analyzed. These data confirm that the oligoclonal 
CD8+ T-cell populations in TCL generated from paired NAWM and WML of the same MS 
patient were clonally distinct (patients #2, #4 and #8; Supplementary Figure 4), whereas 
CD8+ T-cells in paired WML-TCL of multiple MS patients showed a strong clonal overlap 
(patients #5, #6, #7 and #9; Supplementary Figure 4). These data suggest that the paired 
WML sampled contained identical CD8+ TCC potentially involved in the disease process.
◄ Figure 5. CD8+ T-cells interact 
with all major brain-resident cell 
types in white matter lesions of 
MS patients. Representative double 
immunofluorescence stainings 
on 8 μm sections of 12 formalin-
fixed paraffin-embedded white 
matter lesion (WML) tissues from 
10 MS patients are shown for (A) 
glial fibrillary acidic protein (GFAP: 
marker for astrocytes), (B) ionized 
calcium-binding adapter molecule 
1 (Iba1: marker for microglia), (C) 
proteolipid protein (PLP: marker 
for oligodendrocytes) and (D); 
neurofilament heavy chain (NF-H: 
marker for neurons; all green color) 
combined with CD8 (red color), 
counterstained with 4’,6-diamidino-
2-phenylindole (DAPI; blue color) 
and finally  analyzed using a Zeiss 
LSM-700 confocal laser microscopy 
and ZEN software. Perivascular CD8+ 
T-cells interact with astrocytes (A; left 
and middle panel) and microglia (B; 
left and middle panel). Parenchymal 
CD8+ T-cells also interact with 
astrocytes (A; right panel), microglia 
(A; right panel) and oligodendrocytes 
(C) in fully myelinated (left panel) and 
partially demyelinated areas (middle 
and right panels). Parenchymal CD8+ 
T-cells also interact with neurons (D) 
in areas without (left panel), with 
moderate (middle panel) and with 
prominent axonal swelling (right 
panel). The latter is indicative of 
axonal damage. Insets show specific 
interactions between CD8+ T-cells 
and the major brain-resident cells 
analyzed for. Scale bar is indicated (A, 
top left panel).
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No substantial T-cell responses towards 
human candidate MS-associated 
autoantigens in T-cell lines generated from 
cerebrospinal fluid and white matter of MS 
patients 
Previous studies, both on EAE and MS 
patients, support a key role of pathogenic 
T-cells directed to various cMSAg including 
glia- (KIR4.1, S100B), oligodendrocyte- 
(MAG, MBP, MOG) and neuron-specific 
proteins (CNTN2 and NFASC).2,4,5 However, 
autoreactive T-cells are also a physiological 
component of the healthy immune 
system making disease association 
difficult.2,4,5 Among the various genetic 
predictors of MS development, 3 specific 
HLA-I and -II alleles have been identified: 
HLA-A*0301, -DRB1*1501 and -DRB*1301.27 
Their association with MS may involve 
presentation of specific cMSAg-derived 
peptides that trigger pathogenic T-cell 
responses.42
  To test this hypothesis, CD4+ and CD8+ 
T-cell reactivity towards these 7 human 
cMSAg was determined for TCL of MS patients 
(n=14) carrying the three MS-associated HLA 
risk alleles (Supplementary Table 1). Hereto, 
an allogeneic BLCL (BLCL-GR), matched for 
these three HLA alleles, was transduced and 
selected in vitro to express the individual 
cMSAg, and measles virus fusion protein as 
control T-cell antigen, constitutively at high 
level (data not shown).28 Because no human 
cMSAg-specific T-cell clone or lines were 
available, we used MVF-transduced BLCL-
GR as APC to validate the applicability of our 
expression system to process and present 
endogenously expressed antigens by both 
HLA-I and II. As shown previously, both the 
MVF-specific CD4+ (4-F99) and CD8+ TCC (2-
F40) recognized MVF-transduced GR-BLCL 
efficiently (data not shown).28 Next, human 
►Figure 6. T-cell lines generated from paired 
cerebrospinal fluid and white matter brain 
tissue of MS patients show no substantial 
T-cell reactivity towards candidate human MS-
associated autoantigens. Short-term T-cell lines 
(TCL) were generated by non-specific stimulation 
of T-cells recovered from paired cerebrospinal fluid 
(CSF) and white matter brain tissues from 14 MS 
patients, which were immunohistologically classified 
as normal-appearing white matter (NAWM), diffuse 
white matter abnormalities (DWMA), active lesions 
(AL), mixed active/inactive lesions (mAIL), inactive 
lesions (IL) or undefined white matter tissue (UWM) 
(see Supplementary Figure 1 for criteria applied for 
MS WM classification). An HLA-matched Epstein-Barr 
virus transformed B-cell line (i.e., BLCL-GR) was used 
to assay T-cell reactivity towards candidate human 
MS-associated autoantigens (cMSAg). (A) Antigen-
specific T-cells were enumerated by determining co-
expression of intracellular interferon gamma (IFNγ) 
and CD137 using multiplex flow cytometry. Gated 
CD8+ T-cells from mAIL-derived TCL of MS patient 
#27 (see Supplementary Table 1) is representatively 
shown. CD8+ T-cells alone (top panel), stimulated 
with un-transduced BLCL-GR (middle panel) or with 
phorbolmyristate-acetate (PMA) and ionomycin 
(Iono) are shown. (B) The frequency of IFNγ and 
CD137 co-expressing CD4+ (left panel) and CD8+ 
T-cells (right panels) that were cultured alone (top 
panels) or co-cultured with untransduced BLCL-GR 
(middle panels) are shown. The bottom panel shows 
the frequency of IFNγ-expressing CD4+ (left panel) 
and CD8+ T-cells (right panel) after stimulation with 
a cocktail of T-cell mitogens (i.e., PMA and Iono). (c) 
BLCL-GR were nucleofected with human candidate MS 
autoantigens (cMSAg) expression vectors encoding 
human contactin-2 (CNTN2), inwards rectifying 
potassium channel (KIR4.1), myelin associated 
glycoprotein (MAG), myelin basic protein isoform 1 
(MBP1), myelin oligodendrocyte glycoprotein (MOG), 
neurofascin (NFASC) or S100 calcium binding protein 
B (S100B). TCL were co-cultured with the respective 
cMSAg-expressing BLCL-GR and the phenotype and 
frequency of cMSAg-specific T-cells determined 
by flow cytometry. The netto frequency of cMSAg-
specific T-cells, corrected for reactivity towards un-
transduced BLCL-GR, is shown as the percentage 
IFNγ+CD137+ CD4+ (left panel) and CD8+ T-cells 
(right panel). Symbols represent the individual MS 
patients analyzed (n=14; specified at the bottom of 
the figure). The majority of TCL were assayed at least 
2-times, of which vertical lines represent the mean 
and standard deviation. Horizontal dashed lines 
depict the cut-off for positive calls for CD4+ and CD8+ 
T-cells, allowing a 0.1% false discovery. Significance 
of variation in cMSAg-specifc T-cell reactivity was 
determined by ANOVA for CD4+ and CD8+ T-cells 
separately.
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cMSAg-specific T-cell reactivity was determined 
by multiplex flow cytometry on CSF-, NAWM- 
and WML-TCL of HLA-matched MS patients 
using the cMSAg-transduced BLCL-GR as 
antigen presenting cells (Figure 6). Whereas TCL 
only and TCL co-cultured with untransduced 
BLCL-GR showed limited T-cell responses, TCL 
stimulated with a cocktail of the T-cell mitogens 
PMA and Iono showed a uniformly high 
expression of the T-cell activation marker IFNγ 
demonstrating that the T-cells in the TCL were 
immunecompetent and not exhausted (Figure 
6A and B).
  The BLCL-GR reactive CD4+ (mean ± 
SD: 2.1% ± 2.4) and CD8+ (1.3% ± 2.0) T-cell 
responses of the CSF- and brain tissue-derived 
TCL were low and the inter-assay variation was 
1.69% for CD4+ T-cells and 1.44% for CD8+ 
T-cells in independent replicate experiments. 
Consequently, the threshold for positive 
calls was 5.6% for CD4+ T-cells and 4.4% for 
CD8+ T-cells allowing a one-tailed 0.1% false 
discovery rate.28 Marginal cMSAg-specific T-cell 
responses were detected in only 4 of 207 (1.9%) 
cMSAg/TCL-combinations, including two CSF-
TCL (Figure 6C). Overall, the limited cMSAg-
specific T-cell reactivity in paired CSF-, NAWM- 
and WML-TCL argues against their involvement 
in the perpetuation of disease in the 14 MS 
patients analyzed.
T-cells recovered from white matter lesions 
of MS patients recognize autologous 
Epstein-Bar virus infected B-cells
Epstein-Bar virus infection is a major 
environmental risk factor to develop MS in 
genetically predisposed individuals.16,27 Recent 
data argue for a role of EBV-specific T-cells in 
MS pathology,20,43,44 but proof of their presence 
in brain tissues of MS patients is lacking. This 
prompted us to investigate T-cell responses 
towards autoBLCL in paired CSF-, NAWM- and 
►Figure 7. White matter lesion-derived 
CD8+ T-cells recognize autologous Epstein-
Barr virus transformed B-cells and localize in 
the parenchyma to form immune synapses.
(A) short-term T-cell lines (TCL) were generated 
by non-specific stimulation of T-cell recovered 
from paired cerebrospinal fluid (CSF) and white 
matter brain tissues from 9 MS patients, which 
were immunohistologically classified defined as 
normal-appearing white matter (NAWM), diffuse 
white matter abnormalities (DWMA), active lesions 
(AL), mixed active/inactive lesions (mAIL) and 
inactive lesions (IL)  (see Supplementary Figure 1 
for criteria applied for MS WM classification). The 
TCL were incubated with autologous Epstein-
Barr virus transformed B-cell lines (autoBLCL). 
Next, the phenotype and frequency of autoBLCL-
specific T-cells was determined by co-expression 
of intracellular interferon gamma (IFNγ) and 
CD137 using multiplex flow cytometry. The 
frequency of autoBLCL reactive T-cells is shown 
as the percentage of IFNγ+CD137+ CD4+ (left 
panel) and CD8+ T-cells (right panel). Symbols 
represent individual donors (n=9; specified in the 
legend) and vertical lines represent the mean and 
standard deviation of at least two independent 
experiments per TCL. Significance of variation 
in autoBLCL T-cell reactivity was determined by 
ANOVA for CD4+ and CD8+ T-cells separately. (B) 
TCL generated from two anatomically distinct 
mAIL of MS patient #6 (see Supplementary Table 
1) were cultured with autoBLCL to assay the T-cell 
receptor variable β chain (TCRVβ) usage of the 
reactive T-cells, determined by intracellular IFNγ 
expression, using multiplex flow cytometry. The 
frequency of CD4+ (left x-axis) and CD8+ T-cells 
(right x-axis) of specific TCRVβ families (y-axis) are 
depicted (gray bars = lesion #1, black bars = lesion 
#2). The frequency of autoBLCL reactive CD4+ 
T-cells and CD8+ T-cells of each TCRVβ family is 
shown (stacked green bars = IFNγ+ T-cells). Results 
shown are representative for two independent 
experiments. “Und.” refers to T-cells expressing 
a TCRVβ chain not covered by the TCRVβ-family 
specific monoclonal antibody panel used. (C) Triple 
immunofluorescence staining for TCRVβ2 (green 
color), laminin (orange color) and CD8 (red color) 
in surplus WML tissue sections (8 µm) containing 
WML #1 and #2, from which the corresponding 
TCLs shown in panel “A” were generated. Nuclei 
were stained with DAPI (blue color). TCRVβ2+ 
CD8+ T-cells reside in the perivascular cuff 
(open arrowhead) and the parenchyma (closed 
arrowhead) of both distinct WML of the same 
patient. The majority of parenchymal T-cells show 
polarization of both CD8 and TCRVβ2 (encircled 
cells in top-right insets). Images of representative 
stainings are shown.
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WML-TCL. Concordant with earlier studies, about 5% of autoBLCL cells expressed the late 
lytic viral antigen glycoprotein 350, demonstrating that these cells have spontaneously 
entered the lytic cycle and most likely expressed the whole EBV proteome (Supplementary 
Figure 5). Accordingly, autoBLCL were considered appropriate APC to analyze EBV-specific 
T-cell reactivity.20,45 Due to limited cell numbers and viability, autoBLCL could only be 
generated for 9 MS patients. In contrast to NAWM- and DWMA-TCL, substantial T-cell 
responses towards autoBLCL, predominantly CD8+ T-cells, were detected in multiple 
mAIL- and the sole AL-TCL analyzed. This response was most pronounced among mAIL-
TCL: 5 of 7 mAIL-TCL assayed had brisk T-cell responses towards autoBLCL-specific 
(Figure 7A). Notably, these strong CD8+ T-cell responses correlated between paired TCL 
generated from distinct mAIL of the same patient: MS patients #6 and #9 (Figure 7A). 
The data implicate enrichment of autoBLCL reactive CD8+ T-cells in AL and mAIL of MS 
patients that are potentially involved in the disease process.12
  These autoBLCL reactive T-cells are potentially enriched in brain tissue due to local 
stimulation by EBV proteins.18 Hence, we determined the presence of the EBV transcript 
EBER1, which is highly expressed during both latent and lytic EBV infection,46 in surplus 
brain tissue from which the respective NAWM- and WML-TCL were generated. No EBER1 
RNA was detected implicating that productive EBV infection or the presence of latently 
EBV-infected B-cells in the brain tissues sampled is highly unlikely (data not shown). 
Clonally expanded autologous BLCL reactive CD8+ T-cells are located in brain 
parenchyma and form immune synapses
The combined data on congruent TCR clonality, selective TCRVβ expression by CD8+ 
T-cell showing reactivity towards autoBLCL in paired intra-lesional TCL suggest local 
enrichment of the same CD8+ TCC. Among the high autoBLCL T-cell responders, sufficient 
T-cell quantities were only available for the mAIL-TCLs of MS patient #6 for follow-up 
studies. TCRVβ analysis revealed that TCRVβ2+ T-cells dominated the oligoclonal CD8+ 
T-cell response towards autoBLCL in the paired intra-lesional TCL of MS patient #6: mAIL-
TCL#1 (32%) and #2 (89%) (Figure 7B). Furthermore, the autoBLCL reactive CD4+ T-cell 
response in mAIL-TCL#2 was restricted to TCRVβ22 (99%) expressing T-cells. Next, we 
localized TCRVβ2+CD8+ T-cells, as proxy for the dominant autoBLCL reactive CD8+ TCC, 
by IHC in the respective WML tissues. The TCRVβ2+CD8+ T-cells were detected in the 
Virchow-Robin space and parenchyma in both mAIL of patient #6 (Figure 7C). Notably, 
the majority of parenchymal TCRVβ2+CD8+ T-cells showed polarization of both TCR and 
CD8, indicative for immune synapse formation and confirmed by Z-stack analysis (Data 
not shown). Collectively, the data suggest the involvement of CD8+ T-cells recognizing 
antigens expressed by autoBLCL, and potentially the same TCC, in the inflammatory 
process in two distinct mAIL of the same MS patient.
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Discussion
The current study provides novel insights into the phenotypic and functional 
characteristics of the T-cell response in CSF and (non-)affected brain tissue of MS patients. 
Three main findings are reported. First, T-cells in MS lesions are predominantly CD8+ TEM 
cells expressing a cytotoxic effector phenotype indicative for local antigenic stimulation. 
Second, T-cells cultured from WML in 4 of 9 MS patients recognize autoBLCL. This reactivity 
was profound in TCL generated from AL and mAIL. Third, no substantial T-cell reactivity 
was observed towards 7 human cMSAg in CSF- and brain tissue-derived TCL of MS patients 
expressing the major MS-associated HLA risk alleles HLA-A*03, -DRB1*15 and -DRB1*13.
  During the past decade, the focus on the role of CD4+ T-cells in MS pathology has 
shifted towards CD8+ T-cells; the most abundant T-cell subset identified in active WML 
of MS patients.1,5 The antigen-specificity (e.g., autoantigens and/or EBV proteins) and the 
potential role of intralesional CD8+ T-cells (cytotoxic or regulatory) in MS pathology is 
still a matter of debate.6,37,47,48 The infrastructure of the Netherlands Brain Bank and the 
commitment of MS patients to donate their tissues after death for research purposes, 
offered us the unique opportunity to compare the phenotype, function and reactivity of 
T-cells between paired PB, CSF, NAWM and WML of 27 MS patients. Notably, the study 
design enabled comparison of T-cells between compartments intra-individually, hereby 
limiting influence of inter-patient immune differences that are potentially unrelated to MS. 
A limitation of our study was, however, that all MS patients included had a long progressive 
disease course. Nevertheless, in situ characterization of the macroscopically-defined 
NAWM and WML tissues obtained clearly demonstrated the presence of lesions covering 
the complete spectrum of MS disease activity ranging from DWMA to IL.26 Markedly, about 
half of the macroscopically defined NAWM contained DWMA that represent periplaque 
abnormalities, Wallerian degeneration or pre-lesional abnormalities.26 The relative high 
frequency of these type of diffuse abnormalities outside of focal MS lesions in end-stage 
MS patients raises doubt if all DWMA will progress to active lesions, which necessitates 
identification of specific markers that identifies the origin and fate of DWMA in time.
  Concordant with previous studies, T-cells were located in perivascular spaces of both 
NAWM and WML, whereas parenchymal T-cells were restricted to WML of MS patients.6,49 
The ex vivo distribution of CD8+ TNA, TCM, TEM and TEMRA cells in NAWM, WML and CSF of 
MS patients resembled data on WM and CSF under normal CNS conditions.30,50 However, 
compared to paired PB, CD8+ T-cells in WML of the MS patients analyzed showed 
significantly increased expression of markers indicative for antigen-induced cytotoxicity 
(CD59L and grB) and activation (CD69, grB and CD137). The increased expression of the 
co-inhibitory (TIM3 and PD1) and co-stimulatory receptors (ICOS), whilst not accompanied 
with increased CD57 expression, suggests that the CD8+ T-cell underwent chronic 
activation in situ while retaining their proliferative potential. In comparison, CSF-derived 
CD8+ T-cells had increased expression of both co-inhibitory markers, which refutes active 
involvement in CNS pathology.49 Contrary to normal CNS conditions,30 CD8+ T-cells 
in MS lesions expressed grB, suggesting that they encountered their cognate antigen 
locally and are potentially cytotoxic T-cells.35,36 Indeed, occasionally CD8+ T-cells with 
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polarized grB expression were localized adjacent to cells showing signs of early apoptosis. 
However, detailed in situ analysis could not demonstrate a specific brain-resident cell type 
preferentially targeted by CD8+ T-cells in the WML analyzed. Furthermore, the majority of 
WML-derived CD8+ T-cells expressed CD69, which in the absence of CD103 co-expression 
may reflect their activated state or indicate a specific subset of TRM cells.
29,33 Overall, the 
activated and cytotoxic effector memory phenotype of CD8+ T-cells in WML, along with 
overlapping TCRVβ repertoires between paired WML-TCL of the same patient, implicate 
clonally expanded T-cells recognizing their cognate antigen locally. These CD8+ T-cells 
are potentially involvement in the deleterious CNS inflammation that contributes to MS 
pathogenesis.35 
  To decipher the cognate antigen driving T-cell activation in MS lesions, we analyzed 
T-cell reactivity in short-term TCL generated from different compartments of the same 
patient using autologous or alternatively an allogeneic HLA-matched BLCL stably 
transduced with 7 human cMSAg (i.e., CNTN2, KIR4.1, MAG, MBP1, MOG, NFASC and 
S100B).20,28 The expression of 3 well-described MS-associated HLA-I and -II risk alleles 
(i.e., HLA-A*0301, -DRB1*1501 and -DRB*1301)27 by the allogeneic BLCL-GR facilitated 
simultaneous detection of CD4+ and CD8+ T-cell responses in TCL of HLA-matched MS 
patients towards endogenously synthesized and processed human cMSAg.28 Notably, 
no substantial cMSAg-specific T-cell reactivity was detected in TCL generated from CSF, 
NAWM and WML of 14 MS patients. The data concur with recent studies on CSF-TCL of 
patients with early MS describing negligible intrathecal cMSAg-specific T-cell reactivity,28,51 
but are in contrast to other studies showing brisk systemic and occasional local T-cell 
reactivity towards distinct cMSAg-specific synthetic peptides in MS patients.2,4,52–54 
These discrepancies may be methodological or related to the timing of tissue sampled 
during the course of disease. Most studies assayed cMSAg-specific T-cell reactivity using 
autologous PBMC as APC pulsed with high concentrations synthetic peptides (10-250 µM) 
or recombinant (animal) cMSAg. However, disease-irrelevant T-cells expressing low-avidity 
TCR are potentially activated by these super-physiological peptide concentrations.55 Also, 
due to species differences, amino acid composition and conformation of the synthetic 
peptides used may differ from natural T-cell epitopes.56 The BLCL/cMSAg platform used in 
this study offered a more physiological approach to detect cMSAg-specific CD4+ and CD8+ 
T-cell responses as compared to more conventional APC platforms used previously.28 Our 
inability to detect cMSAg-specific T-cell reactivity may be due to the inclusion of specimens 
from patients with advanced MS disease in which the disease-initiating cMSAg-specific 
T-cell response that potentially sparked of disease is not actively involved in perpetuating 
MS pathology. Alternatively, cMSAg-derived peptides were presented by other HLA alleles 
not shared with the allogenic BLCL-GR. Nevertheless, the inability to detect intra-lesional 
cMSAg-specific T-cell responses in end-stage MS patients, as well as in CSF of patients with 
clinical isolated syndrome and early MS,28 does not support the long-held hypothesis that 
the cMSAg assayed here are prominent targets of local pathogenic T-cell responses in MS 
patients.
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  Contrastingly, brisk T-cell reactivity (mainly CD8+ T-cells) was detected towards 
autoBLCL, preferentially among TCL generated from AL and mAIL, but not DWMA and 
IL, suggesting their involvement in lesion activity. On occasion, these strong CD8+ T-cell 
responses were identified in TCL generated from anatomically separated WML of the 
same MS patient, suggesting involvement of the same TCC in both lesions. Indeed, even 
though observed in a single MS patient and not confirmed at the TCR level, the autoBLCL 
reactive CD8+ T-cell response in the paired mAIL-TCL of this particular MS patient was 
dominated by TCRVβ2+ CD8+ T-cells. These T-cells were detected in the parenchyma of 
the respective WML tissues of the same patient with polarized TCR and CD8 expression 
suggesting immunological synapse formation in situ. Recently, we and others have shown 
intrathecal CD8+ T-cell reactivity to EBV antigens in patients with early MS.20,57,58 Because 
no EBV transcripts could be detected in the corresponding WML assayed here, the 
autoBLCL-specific CD8+ T-cell responses identified are most likely not involved to combat 
intracerebral EBV infection as suggested by others.18,44 The cognate antigen could be an 
EBV protein, an autoantigen induced or selectively processed in EBV-infected B-cells or 
an EBV/cMSAg-cross-reactive autoantigen.24,43,59–62 A limitation of our APC platform, using 
BLCL as APC, is that it withholds clear distinction between these options. Unfortunately, 
autologous activated B-cells were not available to determine if the T-cell reactivity 
towards autoBLCL truly targeted EBV antigens. Furthermore, due to limited numbers of 
T-cells available from the autoBLCL reactive TCL, in-depth cognate EBV antigen discovery 
as described previously was also not possible.20
  In conclusion, the data presented suggest that cytotoxic CD8+ TEM cells directed to 
autoBLCL, but not to the seven human cMSAg assayed in combination with three major 
MS-associated HLA risk alleles, are potentially involved in the immunopathology of white 
matter lesions of the MS patients analyzed. Follow-up studies on WML-derived T-cells are 
warranted to identify the cognate virus and/or host antigen recognized by this potential 
deleterious autoBLCL reactive T-cell response in MS patients.
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Supporting information
►Supplementary Figure 1. Examples of distinct white matter phenotypes of MS patients. Representative 
examples of MS white matter stainings according to Kuhlmann et al., Acta Neuropathol (2017).26 We used myelin 
oligodendrocyte glycoprotein (MOG), HLA class II (HLA-II) and CD68, expressed by macrophages and microglia, 
as markers to discriminate normal appearing white matter (NAWM: HLA-II+/−Myelin+CD68+/-), diffuse white 
matter abnormalities (DWMA: HLA-II++Myelin+CD68+), active lesions (AL: HLA-II++Myelin+/−CD68+), mixed 
active/inactive lesions (mAIL; hypercellular rim: HLA-II++Myelin+/−CD68++ and hypocellular center: HLA-
II+/−Myelin−CD68+/−) and inactive lesions (IL: hypocellular: HLA-II+/− Myelin−CD68+/-) in consecutive 8 μm 
sections of snap-frozen MS brain tissues. Scale bar is indicated in top left image.
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Supplementry Figure 2. Gating procedure of paired PB- and white matter lesion-derived lymphocytes 
from MS patients.  Lymphocytes were isolated from paired peripheral blood (PB), cerebrospinal fluid (CSF), 
normal-appearing white matter (NAWM) and white matter lesions (lesion) from patients with advanced MS 
(n=17) and subjected to multiplex flow cytometry. Pseudocolored density plots of paired PB (top panels) and 
white matter lesion (bottom panels) samples from one representative MS patient are shown. Lymphocytes 
were identified based on low forward, intermediate sideward scatter (FSC and SSC, respectively) and high CD45 
expression, which was followed by subgating for CD3 and either high CD4 or high CD8 expression.
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TCRVß20 0.1 4.9 0.3 0.1 1.7 54.6 30.3 0.0 2.7 10.4 9.5 0.0 0.2 1.4 7.7 19.0 1.9 11.6 82.9 0.4
TCRVß21.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.7 0.4 0.1 0.8 4.7 2.3 0.7 1.3 2.3 5.8 0.0 0.0
TCRVß22 0.0 0.0 0.1 0.1 0.0 0.7 0.0 3.0 1.0 1.9 0.6 62.2 1.6 5.1 1.8 3.7 0.3 1.6 0.0 8.1
TCRVß23 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0
undetermined 11.0 8.9 22.9 73.0 4.8 10.1 30.2 35.9 41.4 41.5 57.0 27.6 52.8 48.2 37.8 24.4 53.4 48.0 7.3 54.3
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TCRVß1 0.0 0.1 3.6 0.1 36.3 0.1 0.0 0.1 14.9 1.0 0.0 0.0 1.7 0.3 2.2 1.4 28.2 0.2 0.0 4.3
TCRVß2 8.1 1.9 2.2 0.4 23.3 3.8 0.0 0.0 5.2 0.6 23.1 58.0 7.3 16.8 5.0 5.7 7.4 0.1 0.1 1.4
TCRVß3 0.1 3.7 0.0 4.2 0.0 0.0 0.1 0.1 0.0 0.0 9.7 0.2 19.6 3.1 8.0 2.3 0.2 4.5 0.0 0.0
TCRVß4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
TCRVß5.1 0.0 0.0 0.4 11.2 1.4 0.0 0.0 0.0 1.8 0.5 0.0 0.0 1.2 3.7 0.2 0.0 0.2 0.1 0.0 4.4
TCRVß5.2 0.2 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.0 0.0 0.2
TCRVß5.3 0.1 0.7 0.7 0.2 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 2.0 0.0 3.5 0.0 0.7
TCRVß7.1 1.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.2 16.5 0.3 0.7 0.1 0.1 0.0 0.0
TCRVß7.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.4 0.2 0.0 0.0 0.1 0.2 0.2 0.0 0.0 0.5 0.0 0.0
TCRVß8 0.0 0.0 3.2 0.0 1.3 30.4 0.0 0.1 0.2 0.0 23.2 10.0 7.6 1.2 6.8 5.7 1.1 0.1 0.0 0.0
TCRVß9 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 1.6 0.0 2.9 0.1 3.8 0.0 0.4 0.9 0.1 0.0 0.0 6.5
TCRVß11 0.2 0.0 0.2 0.0 0.0 14.8 0.2 0.1 0.2 0.0 0.4 0.3 0.8 0.1 0.3 0.0 0.2 0.5 0.2 0.0
TCRVß12 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.6 0.0 0.0 0.0 3.4 0.6 2.9 2.9 0.0 0.0 0.0 0.0
TCRVß13.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.9 7.2 4.9 0.0 4.3 1.3 1.4 2.3 0.1 0.5 40.4 1.0
TCRVß13.2 0.0 0.1 0.0 0.1 0.0 4.4 0.4 0.2 0.2 0.0 0.0 0.1 0.1 0.3 1.0 0.7 0.0 16.1 0.0 2.2
TCRVß13.6 0.3 16.9 0.3 11.8 0.4 0.1 0.0 0.0 2.2 0.1 0.2 0.0 6.4 0.2 0.0 0.2 1.1 0.4 0.0 1.8
TCRVß14 25.1 65.6 2.3 0.5 27.4 0.0 46.7 1.0 9.0 45.1 1.8 0.1 0.5 15.9 1.5 11.6 23.1 0.4 27.8 7.5
TCRVß16 0.0 0.1 0.0 0.4 1.7 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.5 4.1 0.1 0.6 14.4 0.3 13.3 0.0
TCRVß17 0.2 0.0 0.4 0.1 0.0 3.5 0.0 0.0 7.1 0.3 0.1 0.0 1.4 2.3 5.6 0.1 0.3 29.0 0.0 47.9
TCRVß18 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0
TCRVß20 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.5 0.3 0.0 0.0 0.0 3.1 3.3 0.0 0.0 0.0 0.4
TCRVß21.3 0.0 0.0 1.5 0.2 0.5 3.0 0.0 0.1 1.9 0.0 1.4 0.7 1.0 0.4 1.4 0.7 18.0 2.8 0.0 0.3
TCRVß22 0.3 0.2 0.0 72.7 0.0 4.1 0.1 0.1 7.7 0.3 0.0 0.0 0.3 1.9 0.7 1.3 0.5 0.0 0.1 0.0
TCRVß23 0.0 3.0 0.3 0.8 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.6 0.2 2.8 2.2 0.0 0.0 0.0 0.0
undetermined 63.8 7.6 84.3 0.0 3.8 35.6 52.3 97.4 43.2 44.0 31.5 30.2 35.1 30.8 55.7 55.1 4.9 40.6 17.8 21.4
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Supplementary Figure 3. Correlation in T-cell receptor variable beta chain protein expression of CD4+ 
and CD8+ T-cells expanded from anatomically distinct white matter lesions of the same MS patient. Short-
term T-cell lines (TCL) were generated by non-specific stimulation of T-cells recovered from paired white matter 
brain tissues that were histologically classified as normal-appearing white matter (NAWM) and white matter 
lesios (WML) classes; diffuse white matter abnormalities (DWMA), active lesions (AL), mixed active/inactive 
lesions (mAIL) and inactive lesions (IL) (see Online Resource 2 for criteria applied for MS WM classification). The 
T-cell receptor variable beta chain (TCRVβ) protein expression profile was determined for 10 MS patients by flow 
cytometry using monoclonal antibodies (mAb) directed to 24 distinct human TCRVβ chains for CD4+ (upper 
rows) and CD8+ T-cells (lower rows) of the indicated TCL for each MS patient (column pairs). Light to dark color 
grading indicate the lowest to highest frequencies of specific TCRVβ expressed by CD4+ and CD8+ T-cells in 
each TCL. The mean TCRVβ chain expression of PB-derived CD4+ and CD8+ T-cells from 85 unrelated healthy 
individuals are provided as reference (data provided by Beckman Coulter). “Undetermined” refers to T-cells 
expressing a TCRVβ chain not covered by the TCRVβ-specific monoclonal antibody panel used. Spearman’s rank 
correlation test were used for statistical analysis.
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Supplementary Figure 4. Increased clonal overlap in paired white matter lesions compaired to normal 
appearing white matter derived CD8+ T-cells in MS patients. The T-cell receptor gamma chain (TCRγ) 
rearrangement spectra was determined by multiplex PCR and fragment length analysis on  DNA isolated from (A) 
peripheral blood mononuclear cells (PBMC, top panel) and two T-cell clones (bottom panel) with one (blue bars; 
KL1985-001) or two rearranged alleles (red bars; MOLT-3). Both TCC display additional +1 base pair (bp) peaks 
due to the addition of a 3’-adenosine residue by the non-proof reading polymerase used. TCRγ rearrangement 
spectra of DNA isolated from 10.000-200.000 sorted viable CD8+ T-cells of short-term T-cell lines generated 
from (B) histologically classified paired normal appearing white matter (NAWM; red bars), diffuse white matter 
abnormalities (DWMA), active lesions (AL), mixed active/inactive lesions (mAIL) and inactive lesions (IL) (blue 
bars) of 3 MS patients and (C) paired white matter lesions (blue and red bars) of 5 MS patients are shown. The 
avarage size and peak height (bars) and peak height range (vertical line) of two independent PCRs are shown. 
Overlapping fragments are indicated by black (0-0.25 bp length difference) and white arrow heads (0.25-0.5 bp 
length difference).
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Supplementary Figure 5. Low frequency of cultured latently Epstein-Barr virus infected human B-cell 
lines express the viral glycoprotein 350. Long-term cultured EBV-infected B-cell lines (BLCL) were stained 
using fluorescent viability marker and a monoclonal antibody (moAb) specific for EBV glycoprotein 350 (gp350), 
or as control an IgG1 isotype moAb, and staining visualized using a FITC-conjugated rabbit-anti- mouse IgG 
secondary antibody. EBV-specific glycoprotein 350 is expressed on the cell surface of EBV-infected B-cells 
undergoing productive virus infection, but not on latently EBV-infected B-cells. Single viable B-cells were gated 
based on sideward scatter (SSC-A) and forward scatter area (FSC-A) and height (FSC-H), intermediate liveDEAD 
staining. Gating of donor #8 is shown  representative for 6 donors analysed.
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Summary
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
leading to motoric, cognitive, sensory deficits and fatigue. The etiology of MS is unknown. 
Both a genetic predisposition and infection with the herpesvirus family member Epstein-
Barr virus (EBV) are risk factors for the development of MS.
  Innate and adaptive immune cells, mainly T-cells, are involved in the inflammatory 
process in white matter lesions (WML) of MS patients yet the phenotype and function are 
poorly defined.  In Chapter 7 we determined the phenotype and function of T-cells in WML, 
normal appearing white matter (NAWM), cerebrospinal fluid (CSF) and blood of deceased 
end-stage MS patients. In NAWM and WML T-cells were located in the perivascular space. 
However, additional T-cells in the brain parenchyma were selectively detected in WML, 
suggesting these are involved in lesion development. NAWM- and WML-derived T-cells 
were mainly effector memory CD8+ T-cells. T-cells in WML expressed markers of chronic 
antigenic stimulation and cytotoxicity. Furthermore, CD8+ T-cells cultured from WML and 
NAMW by mitogenic stimulation were clonally enriched. The repertoire of CD8+ T-cells 
corresponded between anatomically distinct WML of the same patient but not between 
paired NAWM and WML. This suggests T-cells from distinct WML recognize a shared 
antigen, and are likely enriched due to antigen-specific activation and proliferation. These 
results indicate an important role of CD8+ T-cells in WML of MS patients.
  The cognate Ag driving activation and proliferation of T-cells in WML is unknown. 
Several oligodendrocyte-, glia- and neuron-specific antigens are suggested to drive 
WML T-cells. In Chapter 2 we developed and validated a T-cell/antigen presenting cell 
(APC) platform to readout T-cell reactivity towards a panel of endogenously expressed 
candidate MS-associated autoantigens (cMSAg). In Chapter 2 we used this platform to 
readout cMSAg-reactivity of T-cells cultured from CSF of early MS patients and in Chapter 
7 of T-cells cultured from CSF, NAWM and WML of deceased end-stage MS patients. No 
substantial reactivity towards cMSAg was detected in MS patients. These data do not 
support the role of T-cells specific for these cMSAg in MS pathogenesis.
  MS is thought to result from intrathecal virus infection with a yet unidentified causal 
infectious agent. Human herpes viruses (HHV), are likely candidates to cause refractory 
disease episodes or induce chronic intrathecal inflammation in MS patients because 
of their endemic nature, their ability to establish lifelong latency with intermittent 
reactivation and their ability to modulate immune responses. Because HHV are highly 
cell-associated, we determined the prevalence of all known HHV in CSF-derived cells of 
early MS patients and controls with other neurological diseases (OND) in Chapter 3. No 
HHV DNA was detected in CSF-derived cells of MS patients. These data do not support 
intrathecal HHV infection early in disease development.
  The presence of intrathecal antibodies may indicate local infection in absence of 
detectable viral DNA. In Chapter 4 we determined if the intrathecal EBV-specific humoral 
response in MS patients is indicative of local infection. The repertoire of CSF-derived EBV-
specific IgG targets was comparable between MS patients and controls. EBV IgG responses 
were strongest towards the latency-associated Epstein-Barr nuclear antigen 1 (EBNA-1). 
Amino acids 394 to 451 of EBNA-1 (EBNA-1394-451) contained the immunodominant 
EBNA-1-specific epitopes. EBNA-1394-451 IgG levels were increased in CSF of MS patients 
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compared to controls. However, correcting EBNA-1394-451 IgG for total CSF IgG or 
albumin levels abolished this difference. These data indicate increased EBNA-1394-451 
levels in MS patients are not the result of intrathecal synthesis, but rather of leakage from 
serum due to blood-brain barrier dysfunction.
  The risk of developing MS is partly genetic. Currently 230 different, mostly immune 
related single nucleotide polymorphisms are associated with MS risk (MS-SNP). Potentially, 
MS-SNP are associated with EBV-specific humoral immune responses. In Chapter 5 we 
determined the association of 78 MS-SNP with the EBV-specific latency-associated EBNA-
1 IgG and the lytic cycle-associated EA-D IgG levels. Additionally, VZV IgG levels were 
determined as a non-MS-associated highly prevalent control herpesvirus. The dominant 
MS-associated genetic risk factor HLA-DRB1*1501 associated with EBNA-1 and EA-D 
IgG levels, but not VZV IgG levels. Furthermore, MS-SNP and combinations of MS-SNP 
associated with B-cell migration (VCAM-1), inhibition of apoptosis (PRDX5/BAD, MYB/NHI1 
and CARD11) and HLA class II antigen presentation (CLEC16A and CIITA) correlated with 
EBNA-1 IgG levels. Notably, regulation of these genes or their ligands is highly affected 
by EBV infection, which strengthens these associations. These data indicate the genetic 
background for MS in part determines EBV-specific humoral responses.
  In absence of detectable EBV DNA and intrathecal EBV-specific IgG synthesis, 
intrathecal EBV-specific T-cells may indicate local EBV infection. Alternatively, T-cells specific 
for EBV-infected B-cells (BLCL) may be involved in MS pathogenesis. BLCL-specific T-cells 
may recognize EBV antigens, EBV-/host-cross-reactive antigens or autoantigens that are 
expressed by EBV-infected B-cells (BLCL) like αB-crystallin. In Chapter 6 we determined 
the frequency of T-cells specific for BLCL and their fine-specificity in short-term T-cell lines 
(TCL) cultured from the CSF of early MS patients and OND. The frequency of BLCL-specific 
T-cells, especially CD8+ T-cells, was increased in MS patients. Furthermore, the frequencies 
of BLCL-specific CD4+ and CD8+ T-cells correlated, suggesting a coordinated response. 
CD8+ T-cells in CSF of MS patients selectively recognized lytic EBV antigens but not latent 
EBV antigens or αB-crystallin.
  To determine if BLCL-specific T-cells are involved in MS pathogenesis, we determined 
their frequency in TCL cultured from post mortem collected paired CSF, NAWM and 
WML of end-stage MS patients in Chapter 7. Contrary to NAWM and inactive WML, TCL 
from active and mixed active/inactive WML showed brisk CD8+ T-cell reactivity towards 
autologous BLCL. In two anatomically separated mixed active/inactive WML of one MS 
patient the BLCL-specific CD8+ T-cell response was oligoclonal. In both lesions, T-cell 
receptor variable β-chain 2 (TCRVβ2) expressing CD8+ T-cells dominated the response. 
TCRV2+CD8+ T-cells were localized in the perivascular space and brain parenchyma of both 
WML. Furthermore, these TCRVβ2+CD8+ T-cells showed polarized expression of the T-cell 
receptor and CD8α co-receptor indicating the formation of an immunological synapse. 
However, no EBV transcripts were detected in the corresponding tissues. Although not 
confirmed at the clonal level, these results indicate BLCL-specific CD8+ T-cells recognize 
an autoantigen in WML. This may be an autoantigen induced by EBV in BLCL, an EBV/self 
cross-reactive antigen due to molecular mimicry or an autoantigen that is targeted due to 
epitope spreading. Together, these results show a prominent role for chronically activated 
BLCL-specific memory CD8+ T-cells in active WML of MS patients.
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General discussion
Multiple sclerosis (MS) is widely classified as an autoimmune disease, but there is 
currently no conclusive evidence for this.1 A unifying cognate autoantigen that causes 
immunopathology is unknown and therefore neither the original,2 nor the revised 
Witebsky’s criteria to classify MS as an autoimmune disease are met.3 Moreover, it 
is currently unknown if MS is a neurodegenerative disease with a secondary (auto-) 
immune effect or and (auto-) immune disease with secondary neurodegeneration.1,4 
Defining whether MS has an autoimmune component and dissecting the temporal 
relation between immunopathology and neurodegeneration is key to our understanding 
of MS. This would ultimately pave the way for improved and more specific therapeutic 
intervention, like immune tolerization. Potentially, MS is the result of a spectrum of 
different (autoimmune) diseases, where different neurological deficits or immune targets 
drive clinically distinct disease forms. The large variation in the clinical presentation and 
disease progression between different patients,1 as well as in the pathological features of 
MS lesions5,6 supports this view.
  Currently the only known common feature of MS patients is infection with Epstein-
Barr virus (EBV), which is considered a prerequisite for developing MS.7 All MS patients 
are latently EBV-infected and virus-specific immune responses are altered in MS patients 
compared to healthy EBV carriers, in advance of clinical disease.8,9 Potentially, EBV drives 
immunopathogenesis in MS by activating autoreactive or EBV/autoantigen cross-reactive 
lymphocytes. Depending on the mechanism, therapies that enhance EBV immune 
responses might therefore be beneficial or detrimental for MS patients.
  In this thesis, we aimed to clarify the putative role of T-cells in MS pathogenesis by 
analyzing their phenotype and function in cerebrospinal fluid (CSF) of early MS patients 
and in white matter lesions (WML) of end-stage MS patients and controls. We further set 
out to clarify the putative role of EBV in MS pathogenesis by analyzing the breadth and 
magnitude of humoral and cellular EBV-specific immune responses in MS patients and 
(disease) controls.
Phenotype and function of T-cells in white matter lesions of MS patients
Based on genetic associations, histopathology and the efficacy of current treatments 
targeting specific lymphocyte subsets a key role of B- and T-cells in the immunopathology 
of MS is anticipated.6,10–13 Infiltrating lymphocytes in white matter lesions (WML) are mostly 
T-cells, with lower frequencies of B-cells.13,14 Supported by early pathology studies of MS 
lesions15  and experimental autoimmune encephalomyelitis (EAE) animal models for MS, 
specific CD4+ T-helper subsets are considered key regulators of CNS inflammation.16 In EAE, 
activation of Th17 and Th17.1 subsets in the central nervous system results in expression 
of interferon gamma (IFNγ), interleukin 17 (IL-17), IL-22 and granulocyte monocyte colony 
stimulating factor (GM-CSF). This leads to activation of endothelial cells of the vessel 
wall, increased permeability of the blood-brain barrier (BBB) and bystander activation 
of astrocytes. Subsequently, activated astrocytes express CCL2 and CXCL12 whereby 
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additional lymphocytes are recruited.17,18 However, contrary to earlier reports on MS15 and 
EAE,19 the frequency of CD4+ T-cells in human WML is low and CD8+ T-cells predominate.20 
Clonal expansion of T-cells in WML is most prominent among CD8+ T-cells,21–23 which 
hints at antigen-specific proliferation of CD8+ T-cells in WML of MS patients. However, the 
phenotype and functions of these intralesional CD8+ T-cells are poorly defined.
  In Chapter 7 we analyzed the spatial orientation and phenotype of T-cells in post 
mortem collected paired normal appearing white matter (NAWM) and WML biopsies 
and compared these T-cells to peripheral blood (PB), cerebral spinal fluid (CSF) T-cells 
of the same patient.24 A limitation of this study was that all included patients had a 
long progressive disease course, hereafter classified as end-stage MS. Nevertheless, 
by characterizing the NAWM and WML tissues by immunohistochemistry (IHC), we 
demonstrated WML covered the complete spectrum of MS disease activity, including 
diffuse white matter abnormalities in absence of demyelination (DWMA), active lesions 
(AL), mixed active/inactive lesions (mAIL) and inactive lesions (IL).6 By IHC we showed that 
T-cells in NAWM are located in the perivascular Virchow-Robin space, confined by the glia 
limitans. Notably, WML contain parenchymal T-cells suggesting these T-cells are not part 
of surveilling lymphocytes, but are rather involved in the local inflammatory process.25,26
  Brain tissues were dispersed to single cell suspensions and T-cells were phenotypically 
characterized by ex vivo flow cytometry. We confirmed the predominance of CD8+ T-cells 
in NAWM and WML. The proportion of CD27+CD45RA+ naïve (TNA), CD27+CD45RA- central 
memory (TCM), CD27-CD45RA- effector memory (TEM) and CD27-CD45RA+ terminally 
differentiated (TEMRA) CD8+ T-cells was approximately evenly distributed in PB of end-
stage MS patients. In all CNS samples, however, negligible frequencies of CD8+ TNA cells 
were detected. While CSF-derived CD8+ T-cells were mostly TCM, NAWM- and WML-derived 
CD8+ T-cells preferentially expressed a TEM or TEMRA phenotype.
26,27 To determine if these 
differentiated intralesional CD8+ T-cells are long-lived tissue-resident memory T-cells (TRM), 
we performed IHC on WML tissues of MS patients to assay expression of the TRM-associated 
cell surface markers CD69 and CD103 on CD8+ T-cells.28 Perivascular and parenchymal 
CD8 T-cells were mostly CD69+CD103- T-cells. Because CD69 is also expressed within a 
few hours upon T-cell receptor (TCR) mediated stimulation, or cytokine and chemokine 
activation27, and CD103 is debated as TRM-specific marker,
29 these CD69+CD103-CD8+ 
T-cells may be denote genuine TRM, activated T-cells or a mixture thereof.
27–30
  Compared to PB, increased frequencies of CD8+ T-cells in MS lesions expressed the 
co-stimulatory molecules ICOS, CD137 and CD95L, indicative of co-stimulation, Ag-specific 
stimulation and cytotoxic effector function respectively.27 Also the frequency of the co-
inhibitory molecules TIM3 and PD1 was increased on CD8+ T-cells in WML compared to 
PB, suggesting both functional inhibition and chronic stimulation.27,31 Expression of co-
stimulatory and –inhibitory molecules on CD8+ T-cells was most prominent in DWMA 
tissues, which may represent periplaque abnormalities, Wallerian degeneration or pre-
lesional changes.6 Contrastingly, CD57 expression was not increased arguing against 
senescence of intralesional CD8+ T-cells.31 The majority of CD8+ T-cells in WML expressed 
the cytolytic molecule granzyme B (grB).32 The frequency of grB-expressing cells tended to 
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be higher among parenchymal compared to perivascular CD8+ T-cells. While the majority 
of these T-cells showed a punctated and distributed expression of grB, a minority showed 
polarized grB expression. Occasionally the adjacent cells expressed the early apoptotic 
marker cleaved caspase-3, suggesting active CD8+ T-cell mediated cytolysis.32
  To define the brain cell type targeted by CNS-infiltrating CD8+ T-cells in MS patients, 
we performed double-IHC stains using monoclonal antibodies (mAbs) directed to CD8 
and the neuron-specific neurofilament heavy chain (NF-H), microglia-specific ionized 
calcium-binding adaptor molecule (Iba1), oligodendrocyte-specific proteolipid protein 
(PLP) and astrocyte-specific glial fibrillary acidic protein (GFAP). Close interactions of 
perivascular CD8+ T-cells with astrocytes and microglia were observed. Parenchymal 
CD8+ T-cells interacted with astrocytes and oligodendrocytes in fully myelinated and 
partially demyelinated areas and with neurons in areas with and without prominent 
axonal swelling, which indicates neuronal stress or damage.4 However, no preferential 
interaction between CD8+ T-cells and a specific brain cell type was observed. 
  Using a panel of T-cell receptor variable ß-chain (TCRVß)-specific mAbs, combined 
with multiplex PCR-based TCR gamma-chain spectratyping, we confirmed that brain-
derived T-cells are clonally enriched and showed there is increased sharing of TCRVß usage 
in paired WML compared to NAWM, especially among CD8+ T-cells. This supports the model 
that T-cells specific for an antigen that is shared between different lesions contribute to 
immune pathology.21–23 Collectively these data demonstrate that CD8+ T-cells in WML of 
end-stage MS patients are activated memory cytotoxic T-cells that recognize their target 
antigen locally and are potentially actively involved in MS pathogenesis.
Putative targets of auto-reactive T-cells in MS patients
The notion that lesion-infiltrating pathogenic T-cells are autoreactive is mainly based on 
the striking similarity in pathology between MS and the various EAE mouse, rat and monkey 
models.19,33–35 EAE is induced using various CNS-specific proteins or peptides and results in 
an encephalogenic T-cell response that induces brain and spinal cord inflammation and 
demyelination. Moreover, adoptive transfer of autoreactive T-cells is sufficient to induce 
MS-like disease in naïve animals.19,36 Depending on the antigen used to immunize animals, 
distinct forms of neuropathology can be induced with variable clinical effect. The different 
forms of clinical disease and variation in disease progression suggest that intra-cerebral 
immune responses to various antigens may cause different MS entities.37–41
  Studies on EAE models have provided novel insight into intra-cerebral inflammatory 
processes, lymphocyte migration and testing of potential therapeutic agents, best 
exemplified by the therapeutically highly efficacious VLA-4 mAb.12,42,43 However, despite 
the pathological similarity between EAE and MS, care should be taken in extrapolating 
findings to human disease. Especially, in relation to MS-associated etiological factors 
because i) the non-physiological nature of inducing autoimmune responses with peptides 
in adjuvant, ii) interspecies immune differences, iii) the mostly monophasic disease in 
mouse and rat EAE compared to the often relapsing remitting nature of human disease 
and iv) interspecies differences in the virome and microbiome.
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  EAE-inducing autoantigens are nevertheless considered candidate MS-associated 
antigens (cMSAg). These cMSAg are mostly oligodendrocyte myelin proteins including 
myelin-associated glycoprotein (MAG), myelin basic protein isoform 1 (MBP1), myelin 
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP).33–35,44 Also various glia-
specific proteins, including inwards rectifying potassium channel 4.1 (KIR4.1) and S100 
calcium binding protein B (S100B) and neuron-specific proteins including contactin-2 
(CNTN2) and the 155kDa isoform of neurofascin (NFASC) are considered cMSAg.33–35,44 
Many studies have focused on analyzing T-cell responses against these targets in MS 
patients and controls, but with conflicting outcome.33–35 Some observed increased 
frequencies of peripheral cMSAg-specific T-cells, but others described similar frequencies 
in HLA-matched controls, questioning their relevance.44,45 As the HLA haplotype endows 
dominant MS-associated risk, and even protective alleles,10,46 a strict HLA-matching of 
patients and controls is mandatory when assaying autoreactive T-cells. 
  T-cells specific for cMSAg are mostly analyzed using synthetic peptides or recombinant 
(animal) cMSAg using autologous peripheral blood mononuclear cells (PBMC) as antigen 
presenting cells (APC).33,45 This type of study design poses several limitations. The poor 
correlation in T-cell phenotype between blood and CSF refutes extrapolation of systemic 
T-cell data to the CNS.47 These recombinant, synthetic or even xenotypic antigens may 
have different amino acid compositions, post-translational modifications and structural 
conformations compared to naturally expressed human antigens. For instance, the 
immunogenicity of MBP largely depends on its citrullination profile, which may not be 
physiological.48–51 These differences may affect the antigen processing and presentation 
of cMSAg-derived peptides.52 Also, CD8+ T-cells preferentially recognize intra-cellular 
synthesized and processed antigens or alternatively exogenous antigens cross-presented 
by professional APC like dendritic cells (DC). This is only partially overcome by using 
protein-spanning synthetic peptides, as the derived epitopes may not be presented in 
similar form when endogenously expressed.52 Furthermore, typically super-physiological 
peptide or protein concentrations (10-250 µM) are used to pulse APC. This may lead to 
activation of disease-irrelevant T-cells expressing low-avidity T-cell receptors.53
  In Chapter 2, we developed a novel in vitro APC/T-cell platform to simultaneously 
assay antigen-specific CD4+ and CD8+ T-cell responses against intracellular synthesized 
human antigens.54 This platform enables stable expression of individual antigens in EBV-
transformed B-cells (BLCL) to be used as APC in functional T-cell assays. A limitation of this 
APC/T-cell platform is that the background EBV-specific T-cell response hampers detection 
of low frequency T-cell responses. However, the magnitude of specific T-cell responses 
usually exceeds these frequencies in compartmentalized autoimmune diseases like 
chronic Chagas’ cardiomyopathy55 and auto immune thyroiditis.56,57 Another limitation is 
that the use of BLCL refutes analysis of potential EBV/cMSAg-cross-reactive peptides. Even 
though antigen processing and presentation of antigens may differ between BLCL and 
the yet unidentified local APC in MS lesions, we consider this a reasonable compromise to 
detect cMSAg-specific T-cells.
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  In Chapter 2 and 7 we used the APC/T-cell platform to determine the frequency of 
T-cells specific for a panel of cMSAg in (1) CSF from patients with clinical isolated syndrome 
(CIS) and early MS, and (2) paired CSF, NAWM and WML of end-stage MS patients.24,54 The 
cMSAg analyzed were: oligodendrocyte-specific antigens (MAG, MBP isoform 1 (MBP1), 
MOG and PLP), glia-specific proteins (KIR4.1 and S100B), and neuron-specific proteins 
(CNTN2 and NFASC). Ideally, the specificity of T-cells is determined ex vivo. However, 
limited T-cell numbers in CSF samples and white matter tissues precluded direct analysis 
of isolated T-cells. Therefore, short-term T-cell lines (TCL) were generated by a single 
round of non-specific stimulation of CSF-derived cells of CIS and early MS patients, and 
two rounds of non-specific stimulation for paired CSF-, NAWM- and WML-derived cells 
of end-stage MS patients. No substantial T-cell reactivity was detected against any of the 
assayed cMSAg in CSF-TCL of early MS patients and in paired CSF-, NAMW- and WML-TCL 
of end-stage MS patients. Few studies have quantified cMSAg-specific T-cell responses in 
CSF or brain tissues using endogenously processed antigens.44,45,58 In line with our study, 
Wuest and colleagues also did not observe significant reactivity of CSF-derived T-cells 
towards cMSAg using human cell-, myelin and brain-derived lysates and autologous DCs 
as APC.58 However, these data are in contrast to the only other study that determined 
cMSAg-specific T-cell reactivity in human WML.59 Here, post-mortem tissue samples were 
collected from 16-year-old female with aggressive RRMS. Contrary to our study cohort, 
CD4+ T-cells were predominant in 2 of 3 WML assayed, but not the paired NAWM tissue. 
T-cell reactivity in the WML- and NAWM-TCLs was determined using HLA class II matched 
allogeneic PBMC pulsed with synthetic peptides spanning parts of the proteins cyclic 
nucleotide phosphodiesterase, myelin-associated oligodendrocyte basic protein, MOG, 
MBP and PLP.59 CD4+ T-cells from WML showed reactivity towards MOG aa11-30 (MOG11-
30), MOG21-40, PLP190-209 and MBP13-32. Notably, T-cell reactivity towards the same peptides 
and additionally towards PLP89-106 was observed in the paired NAWM-TCL, indicating that 
this T-cell reactivity is not specific for WML. These discrepancies may be methodological or 
related to the timing of tissue sampling during the disease course. In conclusion, our data 
do not support that T-cells specific for the assayed cMSAg are involved in MS pathology, 
and refute these cMSAg as prominent target antigen in both early and end-stage MS 
patients.
Prevalence of intrathecal human herpesviruses in MS patients
Besides a genetic predisposition, the exposure to environmental factors comprises 
crucial risk factors for the development of MS. The CNS inflammation in absence of 
detectable microbes (bacteria, fungi, protozoans, etcetera) in MS hints at an initiating 
role of virusses.60–62 Bearing in mind the endemic nature of human herpes viruses (HHVs), 
their ability to establish lifelong latency, intermittent reactivation of latent virus and their 
ability to modulate immune responses, these viruses are considered likely candidates 
to cause refractory disease episodes or induce chronic intrathecal inflammation in MS 
patients. The role of the prime MS-associated HHV, EBV (HHV4), is widely debated.63–66 
Ideally, the presence of HHV is assayed at the site of disease, during onset of inflammation, 
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early in disease development. As the access to brain tissue is very limited early in 
disease development, studies on the prevalence of HHV in MS patient are restricted to 
CSF samples collected early in disease or brain biopsies collected post-mortem after 
prolonged disease. In Chapter 3 we report on a comprehensive study of the prevalence 
of all eight known HHVs in CSF of CIS patients,1,67 and patients with relapsing remitting 
(RR-) and primary progressive (PP-)MS and non-inflammatory neurological disease (NIND) 
patients as disease controls.68
  HHV are typically highly cell-associated and may be misdiagnosed in cell-poor CSF 
samples.69,70 Also the interval between disease onset or disease exacerbation and time of 
sampling may affect HHV detection.69 In our study, we focused on cell-rich CSF samples 
that were collected within 2 weeks after onset of clinical symptoms. No genomic DNA 
of HHV1-8 was detected; implicating that intrathecal HHV infection is not involved in 
the early phase of MS disease. However, considerable discrepancies on the prevalence 
of intrathecal HHV in MS patients are reported. While disease association with VZV,71–73 
EBV,72,74–79 and HHV6 were reported,73,75,80–86 others could not verify these findings,61,72,80,83,87–90 
including our group (Chapters 3, 6 and 7)24,68,91 and collaborators.92 These discordances 
may relate to: i) the types of clinical specimen analyzed. HHV prevalence in CSF was 
either analyzed in unfractioned CSF samples,75,80,82,84 or CSF samples that were split into 
cell-free supernatant71–73,83,85,86,89–91 and cell pellets.83,85,87,88,93 Presence of EBV-specific 
nucleic acids and protein were analyzed on either preselected WML tissues, which 
included the juxtaposition meninges that contained abundant B-cell infiltrates,74,76,79 or 
extensive collections of randomly selected WML tissue specimens that partly included 
the associated inflamed meninges.24,92,94 ii) the clinical characteristics of the included MS 
patients. Most studies included patients with various MS entities, some studies focused 
on CIS81,82,85, while others selectively included RRMS patients.71,88–90,93 For studies on CSF, 
the mean disease duration varied greatly between studies (between 0 and 128 months, 
where specified), as did the timeframe between disease onset or exacerbation and 
sampling (within 72 hours to 14 days, if specified at all). The presence of EBV in MS brain 
tissues was selectively analyzed on post mortem tissues from MS patients with end-stage 
disease. iii) the sensitivity and specificity of the applied methods. While most studies 
aimed to detect HHV genomic DNA by conventional PCR,93 quantitative PCR71,72,81,83,84,87,88 
or nested PCR73,75,80,82,85,86,89,90, others selectively screened for EBV transcripts by reversed-
transcriptase PCR (RT-PCR)24,79, in situ RNA hybridization (ISH)76,77,92,94,95, or EBV protein-
specific IHC.76,77,79,92,94,95 
  Despite detailed assessment of all aforementioned variations in clinical specimens, 
patient characteristics and detection methods, no consensus was obtained that explains 
these discrepancies in CSF and brain tissue samples.68 To discuss the discordancy on EBV 
prevalence CNS tissue of MS patients, two focused expert meetings were organized: 
March 2010 (at the VUMC; Amsterdam, the Netherlands) and second one in June 2010 
(at the center for brain research; medical university of Vienna, Austria).63 Reagents, 
techniques and clinical specimens were exchanged between participating groups to 
identify potential technical caveats. Consecutive sections of suspect EBV-positive brain 
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tissues were stained by different labs, again with conflicting results.63 These experiments 
excluded that differences in the selected patients, post-mortem autolysis times, fixation 
and handling of tissue blocks were culprit for the conflicting results. Instead the sensitivity 
and specificity of the applied methods to detect EBV RNA and protein are the likely 
cause of the conflicting results.63,95 Using well-validated EBV-specific ISH, RT-PCR and 
quantitative RT-PCR protocols, EBV could be readily detected with high specificity and 
sensitivity in EBV-induced glioma and oral hairy leukoplakia tissues,92 EBV-spiked PBMC24 
and in a CSF cell pellet of an herpes simplex type 2 encephalitis patient68. Thus, our data 
do not support a role of intrathecal and -cerebral HHV infection in patients with early and 
end-stage MS.24,68,91 
Intrathecal EBV-specific humoral responses in MS patients
A hallmark for MS is the presence of intrathecally synthesized oligoclonal IgG bands, which 
correlate with high risk of MS and WML load.1,67,96 These are clonally related to peripheral 
B-cell clones and are generally directed against ubiquitous intracellular autoantigens that 
are not CNS-specific.97,98 Intrathecal IgG in MS patients are therefore considered to be mainly 
produced as a secondary response to chronic CNS inflammation and tissue damage.98 
Nonetheless, fractions of intrathecally produced IgG may be involved in MS pathogenesis. 
The peripheral and intrathecal humoral response against the latency-associated Epstein-
Barr virus nuclear antigen 1 (EBNA-1) is elevated in MS patients compared to healthy EBV 
carriers and correlates with disease prognosis and activity.7,9,65,99–101 Contrastingly, the 
humoral response towards lytic EBV proteins, particularly the viral capsid antigen (VCA), 
is not or only marginally increased in MS patients.7,99 This suggests that increased EBV-
specific humoral responses in MS patients are mainly directed to latent EBV proteins, 
although one may argue that viral proteins that are located in the nucleus of EBV-infected 
cells like EBNA-1 are only accessible to antibodies after cell death. EBNA-1 may therefore 
represent a secondary immune target. The presence of EBV in CSF, perivascular regions and 
meninges of MS patients is unclear.63 Chronic local EBV infection may result in intrathecal 
IgG production specific for viral antigens. Intrathecal EBV-specific IgG production may 
therefore indicate intrathecal EBV infection. Alternatively, if EBNA-1 IgG are involved in 
immune pathogenesis, local synthesis of EBNA-1 IgG is anticipated. Detection of EBNA-
1 IgG cross-reactivity with citrullinated collagen and keratin in rheumatoid arthritis 
patients102 and several nuclear host antigens in systemic lupus erythematosus patients,103 
has fueled this hypothesis. 
  In Chapter 3 we determined the breadth of EBV antigens recognized by intrathecal 
IgG by immunoblot using cell lysates of lytically EBV-infected B-cells.104 A normal diversity 
pattern of IgG reactivity was observed towards proteins that (co-) migrated with the EBV 
proteins EBNA-1 (BKRF1), VCA-p18 (BFRF3), VCA-p40 (BDRF1) and Zebra (BZLF1) and 
several undefined proteins, with immunodominance of EBNA-1 in both MS and NIND 
patients. Subsequently, the EBNA-1 B-cell epitopes were defined in serum of healthy 
EBV carriers using 12-meric synthetic peptides spanning the entire EBNA-1 protein. 
Immunodominant regions in EBNA-1 ranged from amino acid 395 to 451 (EBNA-1395-
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451) and the glycine-alanine repeat EBNA-190-325. However, numerous proteins contain a 
glycine-alanine repeat,105,106 implicating that EBNA-190-325 IgG reactivity may not be EBNA-
1 specific.  Based on the predefined immunoreactive regions in EBNA-1, longer synthetic 
peptides - predicted to have secondary structures - were designed using in silico minimal 
energy calculations. Using these longer peptides, EBNA-1 IgG reactivity was determined 
in paired serum and CSF samples of both MS and NIND patients. Whereas the overall IgG 
reactivity profile was similar in both patient groups, reactivity towards EBNA-1394-420, EBNA-
1424-451 and to a lesser extent EBNA-1436-461 were selectively increased in both serum and CSF 
of MS patients. Based on the 12-mer and longer synthetic peptides we showed that EBNA-
1394-451 contains the immunodominant epitopes of EBNA-1 specific IgG.
  The increased intrathecal EBNA-1394-451 IgG levels in MS patients may have been 
synthesized by local plasma cells or merely reflect leakage of serum IgG into the CSF due to 
BBB dysfunction. Normalization of EBNA-1394-451 IgG for the total IgG levels in the respective 
CSF samples annulled the difference between MS and NIND patients. Furthermore, the 
strong correlations between intrathecal EBNA-1394-451 IgG and total IgG and albumin levels 
in CSF suggests the increased local EBV response is not due to intrathecal synthesis, but 
rather due to blood-brain barrier (BBB) dysfunction. While others detected intrathecally 
synthesized EBV-specific IgG in a subset of MS patients, these antibodies represent low-
affinity IgG. These are likely not involved in MS pathogenesis because affinity maturation 
of disease relevant antibodies expressed by chronically stimulated B-cells would result 
in high-affinity IgG.107 Whether high-affinity EBNA-1 IgG are involved in MS pathogenesis 
remains to be determined. Potentially, the increased intrathecal EBNA-1 IgG levels are 
because they affect BBB integrity directly. Recent insights in fluid dynamics of the CSF that 
include paraventricular flow (glymphatics)108 and drainage to cervical lymph nodes (CNS 
lymphatics)109,110 imply that soluble inflammatory mediators like IgG which are produced 
distant from the brain ventricles, like in WML, cannot be sampled by lumbar puncture.111,112 
This suggests IgG measured in CSF, which is collected via lumbar puncture, mainly reflects 
disease processes near ventricles such as the meninges. The lack of intrathecal EBV-specific 
IgG synthesis therefore negates the role of a widespread intrathecal or meningeal EBV 
infection in MS patients and is congruent with our studies being unable to demonstrate 
EBV nucleic acids in CSF samples of patients with early and end-stage disease.24,68,91,92
Involvement of MS-associated genetic factors in EBV-specific humoral immune 
responses
The risk of developing MS is partially dictated by genetic predisposition.1,113 The majority 
of MS-associated genetic variants are single nucleotide polymorphisms (MS-SNP), which 
are located in enhancer regions of multiple immune related genes.10,11,114,115 There is a 
striking overlap in the open chromatin profile of activated B-cells and MS-SNP, indicating 
their functional relevance in B-cells.116 EBV establishes a latent infection in B-cells, which is 
regulated by host and viral proteins. The latency-associated EBV proteins LMP1 and LMP2A 
chronically activate B-cells. Therefore, the MS-SNP linked genes are potentially functionally 
affected by EBV infection and vice versa. As virtually all MS patients are infected with 
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EBV,7,117 MS-SNP may be functionally involved in the regulation of EBV latency in B-cells 
or in EBV-specific immunity. HLA-DRB1*1501 is the strongest MS-associated genetic 
factor, which also poses increased risk to infectious mononucleosis and MS on an additive 
scale.118,119 Recently, HLA-DRB1*1501 carriership has also been correlated with increased 
EBNA-1 IgG titers in otherwise healthy EBV carriers.120,121 Furthermore, the prevalence of 
MS-SNP was considerably increased in healthy EBV carriers with high EBNA-1 titers, but 
which variants contribute to this association was only partially defined.120
  In Chapter 4 we determined the association of MS-SNP10,114 with the EBV-specific IgG 
responses towards EBNA-1 and the early lytic cycle associated EBV early-antigen-D (EA-D, 
encoded by BMRF1) in MS patients and healthy controls. Total varicella zoster virus (VZV)-
specific IgG were determined as a highly prevalent, non-MS-associated control HHV.87 We 
confirmed the increased serum EBNA-1 IgG responses in MS patients7, associated with 
unchanged serum IgG levels towards the EBV protein EA-D and VZV. Furthermore, we 
confirmed the EBNA-1 IgG association with HLA-DRB1*1501 carriership.120 We observed 
an additional HLA-DRB1*1501 association with EA-D IgG levels, but not VZV IgG. Of the 
78 MS-SNP analyzed, one SNP related to VCAM-1 and one related to PRDX5 and BAD 
(PRDX5/BAD)10,122 were associated with low EBNA-1 IgG levels. In a multivariate analysis, 
interactions between MS-SNP related to VCAM-1 and PRDX5/BAD were associated with 
low EBNA-1 IgG. These associations are counterintuitive given the positive correlations 
between EBNA-1 IgG titers and MS-SNPs with MS risk.8 VCAM-1 is associated with migration 
of B-cells. The increased expression of the ligand for VCAM-1, VLA-4 on B-cells by EBV 
infection123 suggests increased migration to the CNS. PRDX5/BAD are both associated 
with caspase-induced apoptosis. EBV inhibits both genes during latent and lytic infection, 
respectively.124,125 The resulting reduced immune exposure of ENBA-1 may partly explain 
the lowered EBNA-1 IgG levels in MS patients that carry this SNP. Interactions between 
MS-SNP related to SOX8, MYB/NHI1, CARD11 and CLEC16A/CIITA were selectively 
associated with high EBNA-1 IgG levels. The respective MS-SNP host genes are involved 
in lymphocyte migration (VCAM-1),42 anti-apoptosis (PRDX5/BAD, MYB/NHI1 and 
CARD11)124–127 and HLA class II presentation (CLEC16A, CIITA and HLA-DRB1*1501).128,129 
Because not all known MS-SNPs were assessed, our study potentially underestimates 
genetic association with EBNA-1 IgG. The majority of genes that are associated with the 
identified EBNA-1 IgG correlated MS-SNP have been shown to be functionally affected by 
EBV proteins and transcripts.123–127,130,131 Functional differences in the affected pathways 
(migration, apoptosis and HLA class II presentation) may therefore lead to distinct viral 
inhibition by EBNA-1 IgG that are more likely to occur in MS-related autoimmunity. Taken 
together, the aberrant EBV-specific humoral immune responses are partly due to the 
genetic background of MS patients.
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EBV-specific intrathecal T-cell responses in early MS patients
Even in absence of detectable EBV DNA, transcripts and proteins,24,68,91 and intrathecal 
EBV-specific IgG synthesis,104 the virus’ signature may be reflected by the presence of 
intrathecal EBV-specific T-cells in MS patients. Studies on peripheral blood of MS patients 
indicated that EBV-specific T-cell responses are most prominently increased early in disease 
development.132 Apart from indicating a cleared infection,74,76 EBV-specific T-cells may be 
involved in MS pathology by recognizing viral peptides cross-reacting with CNS-specific 
antigens, referred to as molecular mimicry.133–135 Alternatively, autoreactive T-cells are 
activated by B-cells that upon EBV infection express autoantigens, like αB-crystallin.136,137 
EBV-specific CD4+ and CD8+ T-cells have been demonstrated in CSF of MS patients using 
peptide138,139 or autologous EBV transformed B-cells (autoBLCL) stimulation,138 tetramer 
staining using immunodominant EBV epitopes140 and by T-cell receptor sequencing.141 
However, these studies have not, or only partially scrutinized the EBV proteins recognized 
by intrathecal EBV-specific T-cells.
  In chapter 6 we determined the frequency and phenotype of intrathecal EBV-
specific T-cells in patients with CIS and early MS, and as control cohort patients with 
other neurological diseases (OND). Short-term CSF-derived T-cell lines (CSF-TCL) were 
generated by non-specific stimulation and autoBLCL were generated.91 We demonstrated 
that about 1-5% of autoBLCL spontaneously entered the lytic cycle in vitro, representing 
B-cells expressing the whole EBV proteome. Thus, autoBLCL are the ideal autologous 
APC to determine EBV-specific T-cell responses. Intrathecal CD4+ and particularly CD8+ 
T-cell responses towards autoBLCL were increased in early MS patients compared to OND 
patients. Interestingly, autoBLCL-specific CD4+ and CD8+ T-cell responses correlated, 
suggesting a coordinated T-cell response. However, congruent with our previous studies, 
neither EBV DNA68,104 nor intrathecally synthesized EBNA-1 IgG104 was detected in the 
respective CSF samples. The inability to detect EBV DNA and EBNA-1 IgG is potentially due 
to the relatively long interval (> 1 month) between disease onset and collection of the 
respective CSF samples because soluble IgG and cell-free virus particles are continuously 
drained to the cervical lymph nodes and are sensitive to enzymatic degradation compared 
to CSF cells.110,111 
  The EBV antigens recognized by intrathecal autoBLCL-specific T-cells was determined 
using an artificial APC system consisting of non-human primate Cos7 cells expressing 
the majority of the EBV proteome (69% of all annotated EBV proteins) together with the 
responsive HLA-I allele of the MS patient analyzed. Alternatively, T-cells may be directed 
towards host antigens which expression is induced by EBV: e.g. heat shock protein αB-
crystallin136 that is highly upregulated in MS lesions.142 αB-crystallin has been identified 
as a possible T-cell autoantigen in MS patients.136,143 Interestingly, oligoclonal autoBLCL-
specific CD8+ T-cell responses selectively recognized lytic viral antigens of distinct kinetic 
classes, presented on several specific HLA-I alleles. These responses included immediate 
early (BRLF1), early (BaRF1 and BXLF1) and late EBV proteins (BBRF3 and BCRF1). Four out 
of eight identified autoBLCL/HLA-I combinations did not show reactivity to EBV proteins. 
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This may be explained by the incomplete EBV antigen collection (31% EBV proteins were 
not assayed), or by reactivity towards host antigens. It is plausible that the intrathecal 
autoBLCL-specific T-cell response in early MS patients comprises EBV-reactive and 
autoreactive T-cells.
 T hese data concur with previous studies describing T-cell reactivity towards 
structural EBV proteins, particularly the lytic viral proteins,58,140,144,145. However, other 
studies showing selective T-cell reactivity towards the latency-associated antigens 
EBNA-1 and EBNA-3A.133,139,141,145 These differences may relate to T-cell culture conditions 
applied, because some groups used EBV protein-spanning synthetic peptide pools to 
expand Ag-specific CSF-derived T-cells,133,139,145 which may lead to an overrepresentation 
of specific EBV reactive T-cell clones. Furthermore, latency-associated EBV protein reactive 
intrathecal T-cells were detected using PBMC pulsed with synthetic peptides as APC.133,145 
This may result in activation of disease-irrelevant T-cells, as discussed previously.50,52–54 
Nevertheless, the MS patient cohorts studied are too small to draw firm conclusions on 
whether intrathecal EBV-specific T-cells are preferentially directed towards the latent or 
lytic EBV proteins.
  Several lines of evidence support a key role in antigen presentation, co-stimulation 
and cytokine production functions of B-cells.146–149 The coordinated oligoclonal autoBLCL-
specific CD4+ and CD8+ T-cell response in CSF of early MS patients suggest BLCL are the 
culprit APC.150 Potentially, EBV-infected B-cells may erroneously stimulate autoreactive 
T-cells. In support of this hypothesis, B-cells infected with the common marmoset 
lymphocryptovirus (CalHV3), a simian γ-herpesvirus resembling EBV, are considered 
pivotal in the development of MS-like pathology in the marmoset EAE model.151 This non-
human primate EAE model, that closely resembles MS pathology and progressive disease 
progression, is mediated by HLA-E-restricted CD8+ T-cells induced by CalHV3-infected 
B-cells. Due to alterations in the antigen presentation pathways, these CalHV3-infected 
B-cells selectively present erroneous MOG peptides to pathogenic T-cells and induce a 
pathogenic autoreactive T-cell respons.152 
  Our study provides insights in the potential role of EBV in MS pathogenesis. The 
intrathecal T-cell response towards autoBLCL is oligoclonal and is increased in MS patients 
compared to disease controls. AutoBLCL-specific CD8+ T-cells selectively reacted towards 
lytic EBV antigens which supports a role for EBV reactivation in MS. Studies in larger 
cohorts to determine the immunodominant kinetic class of EBV antigens recognized by 
intrathecal T-cells are warranted. 
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Intralesional T-cell responses towards autologous EBV-transformed B-cells
It is not known if the increased autoBLCL-specific CSF-derived T-cells responses observed 
in early MS patients are involved at the site of disease: the MS lesion. This prompted us to 
investigate the frequency of autoBLCL-specific T-cells in paired CSF-, NAWM- and WML-
derived short-term TCL of end-stage MS patients (Chapter 7). In contrast to NAWM- and 
DWMA-TCL, substantial autoBLCL-specific T-cell responses were detected in AL- and mAIL-
TCL. These T-cell responses were most prominent among CD8+ T-cells in mAIL, where 5 
of 7 TCL analyzed from 5 MS patients showed brisk T-cell reactivity towards autoBLCL. 
Anatomically distinct paired WML-derived TCL of two patients showed a strong correlated 
CD8+ T-cell response in both lesions. The presence of autoBLCL-specific CD8+ T-cells in 
WML argues for their role in disease progression. These T-cells are potentially enriched 
due to local stimulation by EBV antigens. Hence, we determined the presence of the 
most abundant EBV transcript (EBER1) in surplus dispersed brain tissue originally used to 
generate the respective TCL. Because no EBER1 RNA was detected lytic EBV infection or 
the presence of latent EBV in the sample CNS tissues are unlikely.
  By TCRVβ analysis combined with functional T-cell analysis, we determined the 
TCRVβ usage of autoBLCL-specific CD8+ T-cells in TCL generated form two distinct mAIL 
of one MS patient. The oligoclonal autoBLCL-specific CD8+ T-cell response in WML of this 
specific MS patient was dominated by TCRVβ2+CD8+ T-cells, which were readily detected 
in both WML by IHC. Notably, these particular CD8+ T-cells were detected in both lesions 
in the Virchow-Robin space and the parenchyma. The majority of the parenchymal 
TCRVβ2+CD8+ T-cells showed strong polarization of both TCR and CD8, indicative of the 
formation of an immunological synapse. Unfortunately, insufficient T-cells were available 
to define if the cognate antigen is EBV or host-specific. Although not confirmed at the 
clonal level, these data suggest that the same CD8+ T-cell clone, specific for an antigen 
expressed by autoBLCL, is involved in the inflammatory process in two distinct mAIL of the 
same MS patient. The autoBLCL-specific CD8+ T-cells in active WML, intriguingly devoid 
of detectable EBV DNA and RNA, suggest that these T-cells are not targeting a local EBV 
infection like suggested by others.74,76,140 The cognate antigen may be an EBV antigen, and 
autoantigen expressed or selectively processed in EBV-infected B-cells or and EBV/cMSAg 
cross-reactive autoantigen.133–136,152,153 These data suggest autoBLCL-specific cytotoxic 
T-cells are involved in MS immunopathology and warrant the follow-up studies to identify 
the cognate antigen of WML T-cells.
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Future perspectives
In Chapter 2 and 7 we reported no substantial T-cell reactivity to a panel of well-known 
cMSAg. In Chapter 7 we showed that part of the WML-derived T-cells are chronically 
stimulated and express markers suggesting their status of exhausted T-cells.27,154 
Potentially, these cells are less responsive when stimulated in vitro and as a consequence 
were underrepresented in our T-cell cultures. Currently, antagonists of these co-inhibitory 
pathways are available including PD-1, TIM3 and LAG-3 blocking mAbs and p38MAPK 
inhibitors.154–156 Improved T-cell culture methods that include these compounds may 
rescue responsiveness and proliferation of these T-cells in vitro.
  Using BLCL as APC for cMSAg, the analysis of potential EBV/cMSAg cross-reactive 
T-cells is hampered because we normalized for reactivity towards BLCL that may 
intrinsically present the cross-reactive epitope. Currently, alternative methods to 
immortalize autologous B-cells independent of EBV are available using expression of Bcl-
6 and Bcl-xL.157 Using these EBV negative B-cell lines as APC for expression individual EBV 
and cMSAg would enable the analysis of potential EBV/cMSAg cross-reactive T-cells.158 
  The prevalence of EBV nucleic acids and protein in CSF and brain tissues of MS 
patients remains a matter of debate. In Chapter 3, 6 and 7 we were unable to detect EBV 
DNA and RNA remnants in CSF samples of early MS patients and WML of end-stage MS 
patients. Together with the absence of intrathecal EBV-specific IgG as shown in Chapter 
4, these findings do not support lytic EBV infection and presence of latently EBV-infected 
B-cells in the CNS of MS patients. Besides the difficulty in collecting relevant clinical 
specimen, the sensitivity and specificity of detection may be culprit to the conflicting 
results.
  Strikingly, all studies aimed to detect EBV by ISH used the same EBER-specific 
probe sequences. Although these probes robustly detect EBV in EBV-related tumors, the 
conflicting reports63,74,76,92,94,95 show the necessity of improved in situ staining methods. 
Current available ISH methodologies facilitate detection of (fragmented) RNA and DNA 
molecules with high specificity and sensitivity. Lead companies in ISH technology, including 
ACD (https://acdbio.com), indicate that their ISH platforms enable detection of only a few 
RNA molecules. To our knowledge, no studies are reported on the presence of EBV in 
WML tissues using these novel ISH platforms. Recent studies on the EBV transcriptome 
revealed several additional transcripts that are abundantly expressed during different 
latency programs of EBV, besides EBER.159–161 Re-designing EBV-specific probes for EBER, 
and several other putatively expressed EBV transcripts like EBNA-1, BHRF1 and the BHRF1 
and BART miRNAs162, in comparison with the classic EBER probe sequences may aid in 
increasing the sensitivity and specificity of detection of EBV transcripts.
  The sensitivity of current qPCR based methods to detection of EBV DNA is limited 
due to the relatively low copy number of EBV genomes compared to EBV transcripts.161 
Analysis using RT-qPCR specific high abundant EBV transcripts may increase the sensitivity 
of detection for EBV compared to qPCR-specific for viral DNA sequences.161 To broaden the 
scope of PCR-based analysis also next-generation sequencing (NGS) may be beneficial 
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to detect EBV transcripts. Despite the recent advances in NGS, only a few studies used 
these methods to analyze CSF or WML of MS patients.163,164 Enrichment of the B-cells 
from WML by ex vivo fluorescent assisted cell sorting (FACS) or laser-capture microscopy, 
combined with advanced ultra-deep NGS methods and enrichment of EBV targets165 may 
considerably increase sensitivity of detection. 
  Intrathecal synthesis of EBV-specific IgG was not observed in Chapter 4. 
Nevertheless, the clonally enhanced repertoire of intrathecal B-cells indicate that antigen-
specific B-cell responses are triggered, particularly in the ectopic germinal centers in the 
leptomeninges of MS patients.13,79,166 Currently, these B-cells are thought to mainly have 
an important role in GM pathology during the progressive phase of MS, possibly as a 
source of autoantibodies.167–171 After EBV infection, naïve B-cells differentiate into memory 
B-cells independent of antigenic stimulation and without negative selection. The EBV-
transformed memory B-cell pool may therefore include autoreactive B-cells. Even though 
the presence of EBV in these cells is debated,63 recent insights implicate EBV infection as a 
potential source of intrathecal autoreactive B-cells.172 Because EBV replication efficiency in 
B-cells is recently shown to be limited, part of infected B-cells may become EBV negative 
after multiple replication cycles.172 Identifying the antigenic targets of these potentially 
autoreactive B-cells may shed light on inflammatory mediators in progressed disease. This 
is of particular interest because the efficacy of current therapies that target the progressive 
phase of MS is limited.1,12 
  In Chapter 5 we showed the increased EBNA-1 IgG response is associated with specific 
MS-associated genetic factors. However, further studies are needed to functionally dissect 
these interactions. Recent advances in CRISP/Cas9-mediated genome editing enables the 
analysis of the functional contribution of individual MS-SNP on the regulation of host 
genes and pathways and the regulation of EBV latency in vitro. Additionally, including MS-
SNP and HLA-I/II genotyping of patients and controls that are analyzed using functional 
T-cell analysis may provide novel insights on the causal pathways involved in the aberrant 
T-cell response towards EBV or cMSAg in MS patients. 
  The increased frequency of BLCL-specific T-cells in CSF of early MS patients in 
Chapter 6 and active WML of end-stage MS patients in Chapter 7 suggests a key role of 
autoBLCL-specific T-cells in MS pathology. Of note, because no other virus than EBV has 
withstood the scrutiny of scientific research, we did not include reactivity towards other 
viruses in our T-cell assays. Potentially, this leads to an excess significance bias due to the 
limited number of parameters. Including chronic and acute control viruses like VZV or 
cytomegalovirus and influenza and measles would strengthen our associations with EBV. 
  The selective reactivity towards lytic viral antigens in the CSF of early MS patients 
is in sharp contrast to healthy EBV carriers, where mostly latent EBV antigens are 
immunodominant CD8+ T-cell targets.173–175 These data suggest that the intrathecal T-cell 
control of latent EBV in MS patients is impaired. Potentially, this leads to more frequent 
or a further progressed EBV reactivation due to a delayed T-cell response in MS patients. 
Contrastingly, the increased humoral response towards EBNA-1, and not EA-D and VCA, 
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suggests the control of latent virus is affected. However, one may argue that nuclear 
antigens are only accessible for IgG after cell death, and therefore EBNA-1 may represent 
a secondary immune target.
  Recently, Pender and colleagues studied the function and frequency of peripheral 
EBV-specific CD8+ T-cells in a large cohort of age, gender and HLA-I matched MS patients 
and healthy EBV carriers.176 They showed the BLCL-specific T-cell function decreases as 
disease progresses. Interestingly, similar compromised EBV-specific T-cell responses 
have been shown in rheumatoid arthritis177,178 and systemic lupus erythematosus which 
strengthens the hypothesis of a shared pathogenic mechanism in these autoimmune 
diseases.179,180 Contrary to our findings, they showed EBV-specific CD8+ T-cells in MS 
patients mainly recognize latent antigens and mainly lytic EBV antigens in healthy EBV 
carriers. However, this was shown with very limited HLA-I-restricted peptide pools, 
including 13 peptides from EBV latent antigens and 5 peptides from EBV lytic antigens, 
which is neither proportional to nor representative for the complete EBV ORFeome. To 
draw firm conclusions on a potential altered immunodominance of EBV antigens, these 
data should be confirmed by screening intrathecal T-cell reactivity towards the entire EBV 
proteome. The high BLCL-reactivity and large number of T-cells needed for EBV ORFeome 
screens as detailed in Chapter 6, hampers the analysis patients with lower frequencies 
of autoBLCL-specific CD8+ T-cells and limits the number of patients that can be included 
in these type of analysis. Alternatively, CRISPR/Cas9-mediated genome editing of EBV 
is used to target latent or lytic cycle EBV in autoBLCL.181 Full EBV knock-out autoBLCL or 
autoBLCL with BZLF1 and BMRF1 knock-out EBV variants can be generated and used as 
APC to determine if latent or lytic viral antigens are immunodominant for intrathecal EBV-
specific T-cells.
  The potential discrepancy in immune dominance of EBV antigens91 and T-cell 
functionality176,182 between MS patients and healthy EBV carriers is of particular interest 
because it would provide a rational for boosting T-cell immunity against specific EBV 
antigens by subunit vaccines or adoptive immunotherapy to restore T-cell control of latent 
EBV in MS patients. The adoptive transfer of in vitro stimulated and expanded autologous 
CD8+ T-cells specific for several immunodominant epitopes of the latent antigens EBNA-1, 
LMP1 and LMP2A was used to treat one patient with severe SPMS.183 This patient showed 
substantial clinical improvement without serious adverse events. Also, intrathecal IgG 
production and disease activity on MRI was decreased.183 This type of therapy is not 
without risk as CNS inflammation may be aggravated due to the potential cross-reactivity 
of the re-infused CD8+ T-cells with autoantigens but may offer a opportunity to treat 
MS.184
  The cognate antigens recognized by WML-derived autoBLCL-specific T-cells in the 
absence of detectable EBV DNA or transcripts are puzzling (Chapter 7). More detailed 
knowledge of what host antigens are induced by EBV in B-cells would be highly interesting 
to identify novel cMSAg for MS T-cells. Host transcriptomics and proteomics of B-cells prior 
and after EBV infection, after establishment of latency and by reactivation of EBV can be 
used to identify cMSAg. Alternatively, characterizing the HLA-associated peptidome using 
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mass spectrometry of BLCL during latency and reactivation may aid to identify disease 
relevant epitopes for MS-relevant T-cells.185 Of the identified cMSAg, surface proteins are 
attractive candidates as primary B-cell targets of lesion- or meninges-derived B-cells of 
MS patients. Genetic programming using Bcl-6 and Bcl-xL may enable the culture of the 
respective B-cells of MS patients and controls. These B-cell lines may be used to generate 
human IgG, which can be used to screen reactivity towards identified cMSAg. Preferentially 
these IgG are screened using cell-based assays that express the relevant conformational 
B-cell epitopes.186,187 
  To study the role of EBV infected B-cells in MS in vivo, the marmoset EAE animal 
model is particularly interesting.188 In this model CalHV infected B-cells are shown to be 
capable of presenting erroneous MOG peptides towards autoreactive CD8+ T-cells in 
vitro.152 Notably, it is unknown if EBV has a similar potential and this deserves follow-up. 
It is not known if CalHV infected B-cells are required to induce EAE as currently no CalHV 
seronegative marmoset are available for comparative analysis. The previously discussed 
CRISPR/Cas9-mediated genome editing may aid in the adoptive transfer of CalHV 
knockout B-cells after B-cell depletion. 
  The T-cell culture methods used in Chapter 2, 6 and 7 are inadequate to obtain 
sufficient T-cell numbers for in-depth characterization of the target antigen repertoire and 
the respective epitopes. The above suggested improved culture methods with the addition 
of antagonists of inhibitory pathways may result in larger T-cell numbers, but the in vitro 
proliferative capacity of T-cells may nevertheless be limited. Furthermore, prolonged 
expansion of TCL may lead to a skewed T-cell repertoire, which impedes the accurate 
quantification of Ag-specific T-cell responses. Alternatively, ex vivo isolated CNS-derived 
CD4+ and CD8+ T-cells are analyzed at the single cell level using fluorescence activated cell 
sorting. Sorted single cells can be used for α- and β-chain TCR sequencing and quantifying 
expression of phenotypic or functional transcripts including co-inhibitor (TIM3, PD-1, CD57 
and CTLA-4) and stimulatory receptors (CD137, FasL, CD107a), cytokines (TNFα, IL-2, IL-17 
and GM-CSF) and effector molecules (granzymes, perforin). Thereby the phenotype and 
function of the dominant T-cell clones can be determined.189,190 Furthermore, by ISH using 
probes complementary to the variable CDR3 region of the TCR, Ag-specific T-cells can be 
localized in surplus tissue and interactions with CNS resident (microglia, oligodendrocytes 
and neurons) or infiltrating cells  (B-cells, T-cells, macrophages) can be determined. The 
TCR cDNA sequence of dominant WML-derived T-cell clones can be cloned and using 
synthetic DNA constructs. These TCR cDNA can be cloned and expressed in recombinant 
T-cell lymphoma reporter cells.191 High-throughput screening of these TCR-recombinant 
reporter cells using peptide libraries or endogenously synthesized proteins of newly 
identified cMSAg can be used to identify the culprit target antigen(s).
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Concluding remarks
Autoreactive T-cells likely contribute to MS immunopathology yet their target antigen 
remains enigmatic. Detailed knowledge of the culprit MS antigen(s) would enable the 
development of new therapies to tolerize MS patients in an autoantigen-specific manner. 
Despite conflicting reports on cMSAg, these therapies are currently being implemented 
in clinical trials for several myelin peptides in MS patients.192,193 Host antigens expressed 
by BLCL may be valuable candidates for this type of immune therapy. On the other side of 
the spectrum, sub-unit vaccines to boost immunity towards particular EBV antigens may 
aid to restore the immune control of EBV in MS patients. Besides the potential benefits for 
MS patients, given the wide arrange of EBV-related diseases and a lack of effective antiviral 
therapies, safe and preferably therapeutic EBV subunit vaccines are called for.183,184,194,195 
However, defining if specific EBV target antigens are involved in MS pathology is imperative 
to assure that EBV vaccine targets do not induce a cross-reactive autoimmune response.
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Multiple sclerose (MS) is een chronische ontstekingsziekte van de hersenen en 
ruggenmerg, oftewel het centraal zenuwstelsel (CZS). Deze ontstekingen leiden tot 
vermoeidheid en problemen met cognitie, bewegen, tast en zien. MS komt bij ongeveer 
1 op de 1000 individuen voor en is daardoor, buiten trauma, de meest voorkomende 
oorzaak van invaliditeit. Genezing van MS is op het moment niet mogelijk maar er zijn 
diverse therapieën die het verloop van de ziekte kunnen vertragen of de plotselinge 
aanvallen verzachten. Helaas hebben de meest effectieve therapieën ook de ernstigste 
bijwerkingen.
  Vroeg in de ontwikkeling van MS bevinden de meeste ontstekingen zich in de 
witte stof van de hersenen en het ruggenmerg en later ook in de grijze stof. In de witte 
stof bevinden zich de uitlopers van zenuwcellen (axonen) die de verschillende delen 
van de hersenen met elkaar verbinden en oligodendrocyten. In de grijze stof bevinden 
zich de zenuwcellichamen. De oligodendrocyten beschermen en voeden de axonen 
door hier een eiwitmantel omheen te vormen (myelineschede). Kenmerkend voor MS is 
dat deze myelineschede beschadigd raakt en verloren gaat (demyelinisatie), waardoor 
zenuwcellen kwetsbaar worden en niet goed meer kunnen functioneren. De aangeboren 
afweercellen in de hersenen (glia) en afkomstig uit bloed (macrofagen) zijn betrokken bij 
het afbreken van myeline. Daarnaast zijn verworven afweercellen (lymfocyten) betrokken 
bij de ontstekingsreactie en de beschadiging van oligodendrocyten. De verworven afweer 
bestaat uit antistof producerende cellen (B-cellen) en celgemedieerde afweer (T-cellen).
  In de witte stof zitten twee unieke barrières rond de bloedvaten die de toegang 
van afweercellen reguleren om mogelijke beschadiging als gevolg van een lokale 
ontstekingsreactie te beperken. Vanuit de bloedbaan zijn dit eerst de bloed-brein-
barrière en als tweede de glia limitans. In de hersenontstekingen in de witte stof van MS 
patiënten (verder laesies genoemd) bevinden zich karakteristieke infiltraten van uit bloed 
afkomstige afweercellen; met name T-cellen, en in mindere mate B-cellen en macrofagen. 
De mate van infiltratie is gerelateerd aan de hoeveelheid schade. Het is echter onbekend 
of deze afweercellen in het hersenweefsel de oorzaak of een gevolg zijn van laesies.
  De oorzaak van MS is nog niet bekend. Wel is aangetoond dat zowel een genetische 
aanleg als blootstelling aan omgevingsfactoren zoals virus infecties, in het bijzonder 
Epstein-Barr virus (EBV), ten grondslag liggen aan het ontwikkelen van MS. EBV is één 
van de acht humane herpesvirussen (HHV). Herpesvirussen komen vaak voor en blijven 
levenslang in een rustende, latente staat aanwezig in de gastheer. Sporadisch reactiveren 
deze virussen waardoor zij herhaaldelijk voor ziekteverschijnselen kunnen zorgen. 
Herpesvirussen zijn in staat de immuniteit van de gastheer sterk te onderdrukken. 
Bekende voorbeelden van herpesvirussen zijn herpes simplex virus (HSV), de oorzaak van 
de koortslip, en varicella zoster virus (VZV), de oorzaak van waterpokken en gordelroos. 
Infectie met EBV op jonge leeftijd is meestal asymptomatisch. Bij infectie op latere leeftijd, 
zoals tijdens de pubertijd leid dit echter vaak tot infectieuze mononucleose, ook bekend 
als de ziekte van Pfeiffer. Personen met een voorgeschiedenis van Pfeiffer hebben een 
verhoogde kans op het ontwikkelen van MS op latere leeftijd.
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Er wordt verondersteld dat met name T-cellen een belangrijke rol spelen in het ontstaan 
en/of voortduren van laesies, maar de eigenschappen van deze cellen zijn onduidelijk. 
In hoofdstuk 7 van dit proefschrift hebben we een vergelijking gemaakt van T-cellen in 
bloed, hersenvocht, laesies en niet-aangedane witte stof ('normal appearing white matter': 
NAWM) van overleden MS patiënten met een relatief lang ziektebeloop van gemiddeld 25 
jaar. In laesies en NAWM vonden we hoofdzakelijk T-cellen rondom bloedvaten tussen de 
bloed-brein-barrière en de glia limitans, ook perivasculaire ruimte genoemd. Uitsluitend 
in laesies vonden we sporadisch T-cellen voorbij de glia limitans in het zogenoemde 
parenchym van het hersenweefsel. Deze T-cellen zijn hoogstwaarschijnlijk direct 
betrokken bij de ontstekingsreactie en het voortduren van laesies.
  In zowel laesies als NAWM vonden we overwegend CD8+ T-cellen, ook wel bekend 
als cytotoxische T-cellen, en slechts lage frequenties van CD4+ T-cellen, ook wel helper 
T-cellen genoemd. In laesies, NAWM en hersenvocht waren deze CD8+ T-cellen vrijwel 
uitsluitend geheugen T-cellen, terwijl we in bloed ook naïeve T-cellen detecteerden. 
Naïeve T-cellen ontwikkelen zich tot geheugen T-cellen wanneer ze het specifieke eiwit 
waardoor ze geactiveerd worden (antigeen) hebben herkend met hun T-cel receptor. 
De CD8+ T-cellen uit laesies vertoonde kenmerken van chronisch antigeen-specifieke 
stimulatie en cytotoxiciteit. Daarnaast vonden we een verrijking van een beperkte set 
van T-cel receptoren op CD8+ T-cellen (klonale verrijking) in laesies. Het repertoire aan 
T-cel receptoren vertoonde een sterke gelijkenis bij verschillende laesies van dezelfde 
patiënten. Deze gelijkenis vonden we niet bij laesies en NAWM. Klonale verrijking kan 
ontstaan wanneer antigeen-specifiek geactiveerde T-cellen gaan delen. Mogelijk zorgt 
een gemeenschappelijk antigeen daarom voor de klonale verrijking van CD8+ T-cellen in 
verschillende laesies. Deze resultaten suggereren dat cytotoxische geheugen T-cellen een 
belangrijke rol spelen in de pathogenese van MS.
Voor onderzoek naar het ontstaan van MS laesies wordt met name gebruik gemaakt van 
experimentele auto-immuun encefalomyelitis (EAE) proefdiermodellen. De laesies van 
MS en EAE diermodellen lijken veel op elkaar. Bij EAE wordt door middel van immunisatie 
met myeline-, glia- of neuroneiwitten een auto-immuun T-cel reactie geïnduceerd die 
leidt tot hersenontstekingen en -schade. Hierdoor wordt verondersteld dat vergelijkbare 
auto-immuun T-cellen ook in MS een oorzakelijke rol spelen.
  In hoofdstuk 2 hebben we een nieuwe methode ontwikkeld en gevalideerd 
om herkenning van potentiële MS geassocieerde kandidaat antigenen (MSAg) door 
T-cellen uit te kunnen lezen. Hierbij hebben we gebruik gemaakt van EBV-geïnfecteerde 
B-cel lijnen (BLCL) die MSAg produceren en presenteren aan T-cellen. Al kan antigeen 
stimulatie verschillen tussen BLCL en het nog niet gedefinieerde verantwoordelijke 
celtype in het CZS, biedt dit systeem een meer natuurgetrouwe stimulatie dan de eerder 
gebruikte T-cel stimulatie methodes. In hoofdstuk 2 hebben we dit systeem toegepast 
op uit hersenvocht gekweekte T-cellen van MS patiënten met een kort ziektebeloop en 
in hoofdstuk 7 op T-cellen gekweekt uit hersenvocht, laesie en NAWM monsters van 
overleden MS patiënten met een lang ziektebeloop. We hebben een panel aan myeline-, 
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glia- en neuron-specifieke MSAg getest maar vonden geen noemenswaardige herkenning 
van MSAg. De veronderstelde rol van MSAg-specifieke T-cellen in de pathogenese van MS 
wordt door onze resultaten niet ondersteund. 
Door de specifieke eigenschappen van HHV wordt verondersteld dat MS het gevolg is 
van een CZS infectie met deze virussen. In hoofdstuk 3 hebben we de aanwezigheid van 
alle tot nu toe bekende herpesvirussen onderzocht in hersenvocht van MS patiënten met 
een zeer kort ziekte beloop (minder dan 2 weken) en als controle patiënten met andere 
neurologische aandoeningen met een onbekende oorzaak (ANA). Doordat latente 
herpesvirussen zich in cellen bevinden is het lastig om hun aanwezigheid in hersenvocht, 
waarin zich slechts weinig cellen bevinden, vast te stellen. Om de pakkans te vergroten 
hebben we uit hersenvocht de cellen geïsoleerd voor analyse. Ondanks de verrijking voor 
latent virus en het gebruik van zeer gevoelige en specifieke polymerase ketting reactie-
gebaseerde meetmethode hebben we geen HHV-specifiek DNA gedetecteerd in cellen 
geïsoleerd uit hersenvocht van MS patiënten. De veronderstelde betrokkenheid van 
intrathecale herpesvirus infectie in een vroeg stadium van MS wordt door onze resultaten 
niet ondersteund.
Ondanks dat we geen herpesvirus infectie van het CSZ van MS patiënten hebben 
aangetoond is er overtuigend bewijs voor een rol van EBV in MS pathogenese. Op basis 
van epidemiologisch onderzoek wordt verondersteld dat infectie met EBV voorafgaand 
aan het ontwikkelen van MS vereist is. EBV is latent in B-cellen. Er zijn EBV positieve 
B-cellen aangetoond in laesies en de naburige hersenvliezen van MS patiënten, maar 
andere studies hebben dit niet kunnen bevestigen. In afwezigheid van aantoonbaar EBV-
specifiek DNA kan een EBV infectie van het CZS mogelijk worden aangetoond aan de 
hand van lokale productie van EBV-specifieke antistoffen IgG. De antistof-gemedieerde 
afweer, met name immuunglobuline G (IgG), tegen EBV-specifieke eiwitten is zowel in 
bloed als hersenvocht verhoogd bij MS patiënten ten opzichte van gezonde controles. 
Als een bepaald EBV-specifieke IgG betrokken is bij MS pathogenese worden deze ook 
mogelijk intrathecaal geproduceerd.
  In hoofdstuk 4 hebben we aangetoond dat er geen noemenswaardige verschillen 
zijn in het repertoire van EBV-specifieke antigenen welke herkend worden door IgG 
in hersenvocht tussen MS patiënten en patiënten met ANA. De IgG waarden gericht 
tegen Epstein-Barr nucleair antigeen 1 (EBNA-1) waren het meest sterk verhoogd bij MS 
patiënten. Binnen het EBNA-1 eiwit bleek een klein stukje van aminozuur 394 tot 451 
(EBNA-1394-451) het sterkst herkend te worden door IgG en in zowel serum als hersenvocht 
van MS patiënten. Na correctie voor de totale hoeveelheid IgG of albumine eiwit in het 
hersenvocht was het EBNA-1394-451 IgG niveau echter gelijk bij MS en ANA patiënten. 
Hieruit concluderen wij dat er geen lokale productie is van EBNA-1394-451 IgG, maar dat 
het verhoogde niveau in het hersenvocht van MS patiënten het gevolg is van lekkage uit 
serum door de bloed-brein-barrière van MS patiënten. Een mogelijke intrathecale infectie 
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met EBV wordt niet ondersteund door onze resultaten. Of EBNA-1394-451 IgG betrokken is 
bij de immuun pathogenese voor MS is echter niet duidelijk. Mogelijk zijn EBNA-1394-451 
IgG betrokken bij beschadiging van de bloed-brein-barrière in MS patiënten.
  Het risico op het ontwikkelen van MS is deels genetisch bepaald. In tegenstelling 
tot klassieke overerfbare genetische aandoeningen is er niet één enkele mutatie bekend 
die afdoende of vereist is voor het ontwikkelen van MS. Wel is momenteel van ongeveer 
230 natuurlijk voorkomende genetische varianten ('single nucleotide polymorphisms': 
SNPs) aangetoond dat deze vaker voorkomen bij MS patiënten dan bij gezonde controles. 
Deze MS-geassocieerde varianten (MS-SNPs) zijn hoofdzakelijk gerelateerd aan genen die 
betrokken zijn bij immuniteit, wat de rol van het immuunsysteem bij MS pathogenese 
onderschrijft. Een groot deel van deze genen zijn actief in geactiveerde B-cellen. Van het 
dominante MS risico gen HLA-DRB1*1501 is aangetoond dat dit voorspellend is voor een 
verhoogd EBNA-1 IgG niveau in bloed van gezonde EBV dragers.
  Mogelijk zijn andere MS-SNPs ook voorspellend voor EBV-specifieke IgG niveaus in 
MS patiënten. In hoofdstuk 5 hebben we van 78 SNP bekeken of deze associëren met 
specifieke IgG niveaus voor het latent EBNA-1 en reactiverend EBV 'early antigen-D' (EA-
D) in bloed van MS patiënten en gezonde EBV-geïnfecteerde individuen. Ter controle 
hebben we IgG specifiek voor het niet-MS-geassocieerd VZV, geanalyseerd. In onze studie 
hebben we de HLA-DRB1*1501 associatie bevestigd in MS patiënten. Verder vonden wij 
dat HLA-DRB1*1501 ook geassocieerd is met verhoogd EA-D IgG, maar niet met VZV IgG. 
Tevens vonden we een aantal SNP, of combinaties van SNP, die geassocieerd waren met 
EBNA-1 IgG, en niet met EA-D of VZV IgG waarden in serum. Het merendeel van deze 
MS-SNPs zijn geassocieerd met genen die betrokken zijn bij migratie van B-cellen (VCAM-
1), bij remming van gecontroleerde celdood (PRDX5/BAD, MYB/NHI1 en CARD11) en bij 
antigeen presentatie aan CD4+ T-cellen (CLEC16A, CIITA en HLA-DRB1*1501). Ook de 
SOX8-geassocieerde MS-SNP was met EBNA-1 IgG waarden geassocieerd maar de functie 
hiervan is onbekend. De regulatie van de EBNA-1 en EA-D IgG-geassocieerde genen 
wordt sterk beïnvloedt door EBV-specifieke eiwitten in B-cellen wat deze associaties 
onderschrijft. De genetische achtergrond voor MS is dus deels bepalend voor de antistof-
gemedieerde afweer tegen EBV.
In afwezigheid van een detecteerbare EBV infectie en specifieke intrathecale antistof 
productie kan een lokale rol voor EBV mogelijk gedetecteerd worden door de 
aanwezigheid van lokale EBV-specifieke T-cellen. EBV-specifieke T-cellen zijn potentieel 
betrokken bij de ziekteontwikkeling van MS. EBV-specifieke T-cellen herkennen mogelijk 
ook lichaamseigen antigenen doordat de eiwitten op elkaar lijken, dat wil zeggen door 
middel van kruisreactie. Anderzijds kunnen BLCL-specifieke T-cellen lichaamseigen 
eiwitten herkennen die door EBV infectie geproduceerd worden door BLCL, zoals het door 
EBV geïnduceerde lichaamseigen eiwit αB-crystalline. De frequentie van EBV-specifieke 
T-cellen in bloed is verhoogd ten opzichte van gezonde virus dragers, met name in een 
vroeg stadium van de ziekteontwikkeling. In hoofdstuk 6 hebben we daarom de frequentie 
van T-cellen die patiënt-eigen BLCL (autoBLCL) herkennen in het hersenvocht bepaald bij 
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MS patiënten in een vroeg stadium van ziekteontwikkeling en ANA. De frequentie van 
CD4+ T-cellen, en met name van CD8+ T-cellen, gericht tegen autoBLCL was verhoogd 
bij MS patiënten. De frequenties van deze CD4+ en CD8+ T-cellen waren gecorreleerd, 
hetgeen duidt op een gecoördineerde T-cel reactie. Deze CD8+ T-cellen herkende selectief 
EBV antigenen gerelateerd aan reactiverend EBV, en niet met latent EBV of αB-crystalline. 
Omdat CD8+ T-cellen in gezonde EBV-geïnfecteerde individuen juist hoofdzakelijk latente 
eiwitten herkennen, suggereert dit dat de T-cellen in MS patiënten hoofdzakelijk reageren 
met eiwitten die later tot expressie komen na EBV-reactivatie.
  Om te bepalen of BLCL-specifieke T-cellen betrokken zijn bij de vorming of 
continuering van laesies hebben we in hoofdstuk 7 gekeken of er een verrijking is van 
deze T-cellen in laesies ten opzichte van NAWM van dezelfde MS patiënt. In tegenstelling 
tot inactieve laesies en NAWM vonden we in actieve laesies veel autoBLCL-specifieke 
CD8+ T-cellen. In twee actieve laesies van één MS patiënt zagen we dat de autoBLCL-
specifieke CD8+ T-cel  respons slechts bestond uit enkele klonen: de dominante kloon 
werd in beide laesies gevonden. Om te bepalen of deze CD8+ T-cel kloon betrokken was 
bij de ontstekingsreactie hebben we deze cellen gelokaliseerd in een ingevroren deel van 
het laesieweefsel waaruit de desbetreffende T-cellen geïsoleerd waren. Al hebben we niet 
kunnen aantonen of het exact dezelfde kloon betrof, bevonden deze T-cellen zich zowel in 
de perivasculaire ruimte als in het parenchym van beide laesies. Het merendeel van deze 
T-cellen in het parenchym hadden gepolariseerde expressie van CD8 en de T-cel receptor 
wat suggereert dat ze hun antigeen herkende. Waarschijnlijk was dezelfde autoBLCL-
specifieke T-cel kloon betrokken bij het ontstekingsproces in beide laesies.
  Om te bepalen of autoBLCL-specifieke CD8+ T-cellen lokaal EBV herkennen hebben 
we in een restant van de cel-pellets van alle laesies waar deze T-cellen uit gekweekt 
zijn de aanwezigheid van EBV-specifieke transcripten onderzocht. In geen enkele 
laesie detecteerden we EBV transcripten, wat impliceert dat deze T-cellen mogelijk 
lichaamseigen antigeen herkennen die geproduceerd worden door autoBLCL. Dit kan 
bijvoorbeeld onstaan door moleculaire gelijkenis van EBV en lichaamseigen antigenen.
  Deze resultaten tonen een prominente rol voor autoBLCL-specifieke CD8+ T-cellen 
in laesies van MS patiënten aan, waarvan het antigeen nog niet bekend is. Identificatie 
van het oorzakelijke antigeen maakt het mogelijk MS patiënten hier specifiek tolerant 
voor te maken. Een dergelijke hoogst specifieke behandeling heeft mogelijk veel 
minder bijwerkingen dan de huidige breedspectrum immuun regulerende therapieën. 
Anderzijds, kan het induceren of versterken van een immuunrespons tegen latente EBV 
antigenen mogelijk voordelig zijn voor MS patiënten om de immuun controle van latent 
EBV te versterken, bijvoorbeeld door vaccinatie. Hiervoor moet uitgesloten worden dat 
deze EBV latente antigenen een rol spelen in de immunopathogenese van MS om een 
kruis-reactieve auto-immuun respons te voorkomen. 
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In dit proefschrift hebben we specifieke kenmerken van de T-cellen die betrokken zijn 
bij de ontwikkeling van MS laesies aangetoond (Hoofdstuk 7). We hebben geen bewijs 
gevonden voor betrokkenheid van T-cellen gericht tegen een panel aan MSAg in 
het hersenvocht vroeg in de ziekteontwikkeling (Hoofdstuk 2) en in laesies laat in de 
ziekteontwikkeling (Hoofdstuk 7). Ook hebben we geen bewijs voor een EBV infectie 
(Hoofdstuk 3) of EBV-specifieke antistof productie in het hersenvocht van MS patiënten 
gevonden (Hoofdstuk 4). De verhoogde EBV-specifieke antistofproductie bleek deels te 
verklaren aan de hand van de genetische aanleg voor het ontwikkelen van MS (Hoofdstuk 
5). De T-cel gemedieerde afweer tegen EBV in het hersenvocht van MS patiënten was 
verhoogd en gericht tegen lytische EBV Wen (Hoofdstuk 6). Eveneens hebben we een 
belangrijke rol voor CD8+ T-cellen gericht tegen EBV-geïnfecteerde B-cellen in actieve 
laesies aangetoond (Hoofdstuk 7).
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Lieve mensen,
Het voelt als een klein wonder dat dit proefschrift tot een goed eind is gekomen, 
aangezien ik aan het begin van het traject geen benul had van afweercellen, laat staan 
van hun rol bij MS immunopathogenese. De totstandkoming van dit proefschrift was dan 
ook alleen mogelijk met de begeleiding, ondersteuning en hulp van velen. Bij deze wil ik 
iedereen die bijgedragen heeft aan dit proefschrift hartelijk bedanken voor hun inzet en 
de leuke en vruchtvolle samenwerking. Al zijn er uit dit onderzoek genoeg interessante 
leads voortgekomen die nader onderzoek verdienen, omwille van deze thesis is het tijd 
om er een punt achter te zetten,
MS is een rotziekte voor zowel de patiënten als hun naasten. Voor het onderzoek 
beschreven in deze thesis hebben veel patiënten, tijdens de onzekere tijd rond het stellen 
van de diagnose, bloed en hersenvocht gedoneerd. Anderen hebben toestemming 
gegeven voor het gebruik van hun hersenen kort na overlijden. Dit getuigt van een, 
door mij gedeelde, sterke wil om MS de wereld uit te helpen. Het gedoneerde materiaal 
is van doorslaggevend belang geweest voor mijn onderzoek. De patiënten, hun familie, 
vrienden en eventuele nabestaanden welke tijdens deze emotionele tijden mee hebben 
gewerkt aan dit onderzoek wil ik daarvoor hartelijk bedanken.
Mijn promotoren Rogier en Georges, jullie gaven 
me het vertrouwen dat ik de overstap van virale 
gentherapie naar MS onderzoek kon maken. Naast 
inzicht in de complexe materie van herpes virologie 
en neuro-immunologie was het jullie visie en 
vastberadenheid die het mogelijk hebben gemaakt 
om naar dit mooie resultaat toe te werken. Jullie 
zeer uiteenlopende manieren van overleggen, 
problemen oplossen en schrijven van manuscripten heeft mij geleerd dat er meerdere 
wegen zijn die naar Rome leiden. Ik heb ongelooflijk veel van jullie geleerd. Daarnaast heb 
ik genoten van alle gezelligheid bij congressen, feestjes en “meetings” in huiselijke kring. 
Ik zou bijna vergeten dat het een beetje awkward is om trots lid van een herpesclub te 
zijn, want wat een fantastische club is het om onderzoek bij te doen. Monique, de manier 
waarop je me bij de eerste MS donor (en enige die tijdens “kantooruren” opgewerkt is) 
hebt gered is tekenend voor de rest van onze samenwerking. Altijd stond je voor me klaar 
met persoonlijk en wetenschappelijk advies of gewoon voor de gezelligheid. Bedankt 
voor je geduld bij mijn eindeloze stroom aan vragen over neuro-immunologie. Werner, 
je tomeloze energie en gedrevenheid (tot 22:00 uur) is ongekend. Ik heb genoten van de 
wetenschappelijke discussies over drie onderwerpen tegelijk zonder het geven van enige 
context. Mede dankzij jouw snelle schakelen, overzicht en inzicht in details is deze thesis 
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tot een goed einde gekomen. Freek, ouwe lab-reus. Je hebt me geleerd dat megaproeven 
altijd groter kunnen. Nu nog hoe je deze op tijd af hebt. Sarah, ik heb genoten van hoe je 
alles tot op het bot analyseert. Ik mis je 'six-o-clock questions'. Eef, kort maar krachtig. Suuz, 
leuk om even je kamergenoot geweest te zijn. Shirley, zorg jij er voor dat de herpesclub 
zijn mojo behoud? Je gaat er vast, net als ik, een hoop plezier beleven.
In het bijzonder dank ik mijn paranimfen Johanna en Samira. Johanna, je startte precies 
op het goede moment om de boel weer op de rit te krijgen. Vanaf de eerste dag ging je 
meteen vol gas en je was niet te stoppen, op één “stoooopid” vaccinatie na ;o). Meteen 
had je een klik met iedereen en dat zegt veel over jou; je bent een leuk mens. Samira, in 
korte tijd ging je van wat terughoudend en verlegen naar eigengereid, standvastig en 
zelfverzekerd. En terecht. De mooiste plaatjes van dit proefschrift hebben we aan jouw 
skills te danken. We hebben bergen moeten verzetten om het Acta stuk succesvol af te 
ronden en zonder jouw tomeloze inzet was dat nooit gelukt. Ik ben vereerd dat jullie 
beiden mij als paranimf willen ondersteunen. Allen bedankt voor de leuke tijd tijdens lab-
stamp-sessies, congressen, feestjes, uitjes, koffietjes, etentjes, borrels, …
Iedereen van het ErasMS bij de afdeling Neurologie, veel van jullie zag ik vrijwel alleen 
tijdens meetings, congressen, sportieve uitstapjes en feestjes. Toch is het een hechte 
groep en was iedere bijeenkomst gezellig en memorabel. Naghmeh, het onderzoek wat 
we samen deden was niet eenvoudig maar dankzij je doorzettingsvermogen en goed 
getimede koffie ’s-avonds, hebben we onze “negatieve” bevindingen tot een mooi positief 
en goed geciteerd verhaal gemaakt. Dorine, ik weet niet of ik het destijds helemaal over 
heb kunnen brengen, maar ik ben je zeer dankbaar voor hoe je voor Jacqueline en mij 
klaar stond in lastige tijden. Tessel, Daniëlle, Julia, Roos, Yuyi, Dorine, Rinze, Kim2, Immy, 
jullie enthousiasme is aanstekelijk. Bedankt voor alle hulp, discussies en gezelligheid. 
Laten we een drank doen.
Iedereen van het ErasMS bij de afdeling Immunologie, fijn dat ik altijd kon komen 
aanwaaien om te sparren of voor gebruik van apparatuur en leuke labspeeltjes. Jon, al 
ben je al enige tijd verbonden aan de RUG, bedankt voor je begeleiding, de uitnodigingen 
om te mogen spreken op symposia en afdelingsmeetings en de maatwerk cursus neuro-
immunologie aan het begin van het traject. Marvin, bedankt voor alle discussies, je 
inzet en kritische blik tijdens het schrijven van ons Acta stuk. Karim, onze ogenschijnlijk 
eenvoudige studie bleek nogal een rollercoaster. Zonder jouw rotsvaste vertrouwen in 
eigen data en kritische blik op het werk van derden was het nooit gelukt om deze studie 
te publiceren. Malou, promoveren kan een (z)ware beproeving zijn. Ik wens je alle succes 
en vertrouw erop dat je het B-cel project tot een goed einde brengt. Marie-José, Annet, 
Jamie, Liza, bedankt voor jullie hulp op het lab en input bij alle meetings. Hopelijk kruisen 
onze paden in de toekomst vaker.
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Alle (ex-)collega’s van de afdeling Viroscience, de afdeling heeft naast wetenschappelijk 
ook “quasi-wetenschappelijk” een reputatie hoog te houden. Sinterkerst, de vele borrels en 
het congres in Dakar, Senegal, zijn slechts enkele van de hoogtepunten waarvan ik blij ben 
dat ik die met jullie heb meegemaakt. Ik wil iedereen bedanken die heeft bijgedragen aan 
de unieke sfeer op de afdeling. Een aantal wil ik hier nog extra benoemen, zonder anderen 
tekort te doen. Ab, bedankt dat ik bij je op de afdeling terecht kon voor dit onderzoek, ook 
al bleef het woord “virus” in mijn presentaties op de afdeling soms onbenoemd. Rik, als 
mede vriezerachterwacht ben je de redder van vele onderzoeken, promoties en carrières, 
inclusief die van mij. Bedankt dat je altijd tijd voor me hebt gemaakt onder het mom 
van: “Ik heb nooit tijd, dus ik heb altijd tijd”. Daarnaast mijn lab- en kamergenoten (My 
lab- and office-roomies): Rory, Tien, Selma, Joyce, Alwin, Selma, Bri, Petra, Mart, Patrick, 
Stella2, Maarten, Marine, Henk-Jan, Fatiha, Selma, David, Arno, Stalin, Claudia, Debby 
S, Mart, and (provided the availability of calories) Do. Bedankt voor de samenwerking, 
(on)zinvolle discussies en gezelligheid. Virologieband “the Spikes”: Maarten, Carel, Sabine, 
dr. Martin, Monique, Stefan, Björn, Rob, Marleen, Esther. Zonder vals over te komen; we 
rocked! Simone, Maria, Loubna, Anouk, Wim, Robert, Dennis, Peter, bedankt voor al het 
geregel. Marion, bedankt voor de kans en steun om aansluitend aan deze promotie het 
B-cel platform uit te kunnen rollen op de afdeling. Ik heb er zin an. Barry, Byron, Ron, Petra, 
Noreen, Stella en Nella, we maken er wat moois van.
Natuurlijk wil ik ook mijn familie en vrienden bedanken voor de broodnodige relativering en 
het bieden van een uitlaatklep wanneer in het lab de werkelijkheid zich niet naar de theorie 
wilde voegen. Martijn, Jean, Pjotr, Jelly en Tthijs, bedankt voor de bijeen gesprokkelde 
Rock & Roll punten. Pa, ma en broers Jasper en Bas, bedankt voor de onvoorwaardelijke 
steun, interesse en geduld. Mijn schoonouders Simon en Jarka, jullie zijn misschien wel de 
belangrijkste reden geweest om de switch te maken naar MS onderzoek. Het feit dat jullie 
ondanks tegenslagen nooit bij de pakken hebben neergezeten is inspirerend.
En dan diegenen waar het mij allemaal om te doen is: mijn drie meisjes. Het is moeilijk 
in woorden te vatten wat jullie allemaal voor me betekenen. Allereerst mijn grote liefde 
en rotsvaste pijler, Jacqueline. Door de vele 'Het-wordt-wat-later-vandaag'-appjes is er 
onbedoeld veel op jouw schouders terecht gekomen. Ik bewonder hoe je desondanks 
altijd alles onder controle hebt. Ik ben ongelooflijk gelukkig met jou. Mijn kleine lieve 
meisjes: Mila en Lenka. Jullie maken me onbedoeld haarfijn duidelijk wat echt belangrijk 
is in het leven. Ik geniet elke dag van jullie open blik, van wat jullie allemaal kunnen en wat 
jullie ongetwijfeld nog gaan bereiken. Ik hou van jullie!
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Multiple sclerosis (MS) is a 
chronic inflammatory disease
of the central nervous system. 
Symptoms of MS include
cognitive, motoric, sensory and visual 
impairment, pain and fatigue. The genetic 
background of the host and infection with
the herpesvirus family member Epstein-Barr 
virus (EBV) are risk factors for developing MS 
but the pathogenic mechanisms are 
unknown. In this thesis we set out to
clarify the putative role of EBV in MS by 
analyzing the intrathecal viral prevalence,
breadth and magnitude of humoral and 
cellular EBV-specific immune responses
and autoimmune responses in MS patients.
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